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 Tissue engineered skeletal muscle has great potential to successfully treat volumetric 
muscle loss (VML), a condition with no ideal clinical treatment option. A broad range of 
engineered muscle constructs have been evaluated in preclinical models of VML with a few 
cases of clinical use as well. Despite improvements to muscle function following treatment, 
histological regeneration of the muscle tissue has varied broadly with the method of treatment. In 
addition, few studies have attempted to restore the damaged connection between muscle and 
nerve and robust neuromuscular regeneration following VML injury has yet to be achieved. To 
enable functional and histological muscle regeneration post-VML, a broad range of factors must 
be considered including a biomimetic and biocompatible scaffold design, selection of a 
translatable cell source, and modification of the regenerating environment to promote 
neuromuscular regeneration. The objective of this thesis was to develop a translatable 
engineered muscle construct with the ability to promote neuromuscular regeneration of murine 
VML defects.  
 This body of work describes a multistep approach towards the fulfillment of the above 
objective. First, an electrospun fibrin scaffold was developed that mimics the native stiffness and 
alignment of skeletal muscle and when combined with mouse myoblasts, enables the formation 
of an implantable skeletal muscle construct and robust muscle regeneration post-VML. The next 
two chapters describe the myogenic potential of two translatable cell sources on electrospun 
scaffolds: adipose derived stem cells (ASCs) and human pluripotent stem cells (hPSCs). While 
ASCs resulted in limited in vitro myogenesis on electrospun fibers and provided a minimal 
regenerative benefit, hPSC-derived myoblasts purified for a Pax7 myogenic subpopulation 
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demonstrated robust in vitro myogenesis in 3D constructs. While the regenerative potential of 
hPSC-derived myoblast constructs in muscle defects was limited, the results are a promising step 
towards the use of these cells to treat VML. Lastly, engineered muscle constructs were pre-
treated to promote acetylcholine receptor (AChR) clustering and neuromuscular regeneration 
through the delivery of agrin, a heparan sulfate proteoglycan, by either chemically tethering 
agrin to the scaffold or providing it in solution. Following implantation in VML defects for four 
weeks, the agrin pre-treated muscle constructs resulted in increased neuromuscular junctions, 
regenerating myofibers, vascular infiltration, neural infiltration, and nuclear yes-associated 
protein within the defect region. In addition, sustained local agrin delivery by the tethered agrin 
constructs resulted in higher densities of neurofilament and regenerating myofibers than soluble 
agrin constructs. This investigation revealed the remarkable potential of agrin-modified 
engineered muscle constructs for neuromuscular regeneration post-VML. Taken together, these 
findings have significant implications for the development of tissue engineered skeletal muscle 
and enabling the functional and histological regeneration of skeletal muscle following VML. 
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Chapter 1 Introduction 
 
1.1 Volumetric Muscle Loss 
Incidence and Major Causes of Volumetric Muscle Loss  
 Skeletal muscle comprises around 40% of total human body mass and is the most abundant 
tissue in the human body[1]. It has a high regenerative capacity following traumatic injury except 
in cases of volumetric muscle loss. Volumetric muscle loss (VML) is a defect where the muscle’s 
natural repair mechanisms are overwhelmed leading to chronic functional deficits in the affected 
muscle[2–5]. Causes of VML include combat injury, trauma (e.g. car accidents), tumor ablation, 
bone fracture fixation, and degenerative disease[3,6]. The incidence of VML in the general US 
population and the associated economic burden are difficult to estimate since there are no surgical 
or billing codes specifically dedicated to VML[7]. Estimates obtained from referencing surgical 
therapies (e.g. free functional muscle transfer), physical and occupational therapies (e.g. gait 
training and strength exercises), and advanced wound care are little more than educated guesses 
and may be highly inaccurate. However, some analyses have been performed for military 
personnel with extremity battlefield wounds. Among medically-retired military service-members, 
VML is a major cause of service-disqualifying disability, contributing to over 90% of muscle 
conditions leading to long-term disability and resulting in a projected lifetime disability cost of 
$341,300 per individual[3]. Of US servicemembers with extremity battlefield wounds from 2001-
2005, 53% involved penetrating soft-tissue wounds and 26% were bone fractures, the majority of 
which (82%) were open fractures with severe soft tissue damage[8]. These results were similar to 
those of previous wars[8,9]. Among the military patient population, 67% of total cases of VML were 
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in the lower limb (Figure 1.1a) and 58% of patients also had a bone fracture, 14% had a nerve 
injury, and 5% had a vascular injury in the limb with the VML[3]. 
 
Biology of VML  
VML is characterized by a persistent functional deficit and unlike other causes of muscle 
injury such as freeze injury, crush, toxin, ischemia reperfusion, and eccentric contractions which 
fully recover their function after 1-2 months, untreated VML injuries do not regain their full 
functional capacity[7]. The native regenerative potential of skeletal muscle through its resident 
satellite stem cell population has been extensively reviewed elsewhere[10,11]. In brief, muscle 
follows a predictable timeline in its response to injury, progressing through phases of degeneration 
and inflammation, regeneration, and fibrosis[4,11]. The degeneration and inflammation phase begins 
within minutes of muscle injury and extends 1-2 weeks post-injury. In this phase, injury-induced 
Figure 1.1. Incidence and biology of VML. a) Distribution of VML location in the body 
among medically retired military servicemembers. b) Differences between native skeletal 
muscle regeneration (left) and deposition of scar tissue following VML (right). c) Percent 
strength deficit post-VML in various pre-clinical models. Models include rat, mouse, and pig 
defects of the quadricep, TA, LD, EDL, and gastrocnemius muscles. Actual values are 
significantly higher than theoretical predictions based on mass loss alone.  
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disruption of the sarcolemma and basal lamina allow for the influx of extracellular calcium which 
causes autodigestion and necrosis of myofibers followed by immune cell invasion. Approximately 
1 week post-injury, muscle regeneration begins and peaks at around 2 weeks post-injury. In small 
injuries like contusions or sprains, the regeneration phase is characterized by satellite cell 
differentiation to myoblasts and fusion with other myoblasts or the remaining mature myofibers. 
In tandem, low-level fibrosis deposited by fibroblasts bridges the gap between still-functional 
myofibers in order to transmit force along the muscle as well as guide the regenerating myoblasts 
along the injury site. The fibrosis and scarring phase begins around 2 weeks post-injury and 
increases for up to 4 weeks post-injury and is characterized by increased fibroblast-mediated 
collagen deposition. There have been numerous prior reviews describing the disruptions to this 
regenerative pathway caused by VML injuries (Figure 1.1b)[4,5,7,12–15]. After the large-scale loss 
of tissue typified by VML, fibroblasts deposit a large volume of scar tissue faster than the rate of 
myoblast fusion and regeneration, ultimately preventing muscle regeneration within the defect 
site[4]. This results in a significant functional deficit to the damaged muscle that persists over time. 
Changes to gene expression within a muscle post-VML also have a significant impact on 
regenerative potential. Aguilar et. al. utilized RNA-sequencing to investigate molecular changes 
within untreated VML-injured muscle and those treated with a minced muscle graft. In untreated 
controls they found that inflammation-related genes and genes associated with ECM deposition 
and fibrotic remodeling remained upregulated up to 28 days post-injury[16]. Interestingly, despite 
finding significant improvements in both muscle strength and histological regeneration of the 
defect within the treated muscles, they found no difference in gene expression compared to 
untreated controls. Persistent upregulation of genes associated with fibrosis (collagen 3, MMP2, 
TGFβ1, PDGFRα, PDPN) and negative regulation of myogenesis (Id2, MSC, Snai1, MSTN, 
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BMP1) was present in both the treated and untreated groups at similar levels. This indicates that 
histologic and functional regeneration of VML-injured muscle is not sufficient to alter the pro-
fibrotic gene expression profile of the muscle at 28 days post-injury. Further research is required 
on the potential for continued remodeling of the muscle tissue and associated changes in gene 
expression at later time points. 
Understanding Functional Deficits in VML: A Multifaceted Injury 
 The exact causes of the significant functional deficits observed after VML remain 
somewhat obscure. Aside from the frank loss of muscle tissue and associated contractile proteins 
typified by VML, there are a variety of detrimental impacts to the remaining muscle body that lead 
to sub-optimal strength output by the muscle. In an analysis of 15 preclinical studies, Corona, 
Wenke, and Ward identified a trend describing the relationship between the strength deficit of 
VML-injured muscles and the extent of initial injury[7]. Using regression analysis of VML-induced 
strength deficits compared to initial percent VML, they found that a VML-injured muscle’s force 
output was significantly lower than what would be expected from the loss of muscle mass alone 
(Figure 1.1c). Specifically, the observed strength deficits were 60% higher per percent VML than 
would be predicted by muscle tissue loss alone. This observation was maintained across various 
preclinical animal models of VML and at a range of time points up to 4 months post-injury. It was 
hypothesized that the increased functional deficits were due to persistent detrimental impacts to 
remaining muscle including denervation, disorganization of myofiber architecture, and impaired 
force transmission to the tendon. 
Further elucidating this trend, Corona et. al. assessed strength deficits and the extent of 
motoneuron axotomy in a rat tibialis anterior (TA) VML model with an initial 20% TA mass 
loss[17]. In addition to confirming that the 20% mass loss yielded higher strength deficits ranging 
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from 45-90%, by labeling motoneurons innervating the entire TA prior to and immediately 
following the VML injury they found that there was no motoneuron death within the spinal cord 
due to VML but 57-79% of motoneurons had undergone significant axotomy and lost interaction 
with the TA muscle. Notably, this loss of motoneuron interaction with the muscle was present as 
early as 3 days post-injury and remained constant up to 21 days post-injury. Cross-sections of the 
injured TA revealed an increase in the number of myofibers in the healing muscle over time, which 
combined with the constant level of motoneuron axotomy suggests the occurrence of motor unit 
reorganization and expansion with each motoneuron innervating multiple myofibers. Further 
research is required on the impact of VML-induced motoneuron axotomy and motor unit 
expansion and the capability to engineer functional muscle-nerve interactions post-VML. Tissue 
engineered muscle constructs that incorporate methods to encourage neural infiltration and the 
formation of functional neuromuscular junctions post-VML are a promising avenue to restore 
interaction between the muscle and nerve post-VML. 
Preclinical Models of VML 
 Tissue engineered muscle grafts have been implanted in a broad range of preclinical models 
of VML spanning many muscle types within mice, rats, rabbits, dogs, and pigs (Figure 1.2)[18]. 
Variability of preclinical models occurs both within a species, where for example VML defects in 
mice have been evaluated in at least six different muscles, as well as across species as the defect 
size scales larger to approach that of VML defects in humans. These VML models have been 
extremely useful for understanding the biology of injury as well as for testing therapeutic 
strategies. Experiments in mice and rats provide for the highest throughput and facilitate the study 
of cell survival, histoarchitecture of the regenerated muscle, vascular and neural ingrowth, and 
functional regeneration. Scaling-up biomaterial-based interventions from defects where the 
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average mass of lost tissue is < 20 mg in mice or < 160 mg in rats to clinically relevant scenarios, 
which may easily be 3 or 4 orders of magnitude larger, is non-trivial. Biomaterial-based treatments 
of VML in larger preclinical (e.g. dog, pig) and even clinical models have generally resulted in 
functional improvements although histologic assessments have shown remarkably modest muscle 
regeneration.  
The actual size of the VML defect may not be the only factor driving inconsistencies in 
reporting therapeutic benefits. The lack of standardization in muscle type and location may also 
be a factor. For example, biomaterial strategies are agnostic to muscle types, which range from 
fusiform to bipennate. When comparing studies with differing results it is important to keep in 
mind the differences in anatomy presented by varying muscles within a single animal as well as 
anatomical differences between species. Differences between species become particularly relevant 
when studying regeneration of the neuromuscular junction (NMJ). Striking differences in NMJ 
morphology and size exist between vertebrate species with an increase in postsynaptic folding and 
focusing of the NMJ at a single site on the myofiber as one progresses from fish to mammals[19]. 
Human nerve terminals and NMJs are among the smallest among vertebrates and contain 
significantly higher levels of postsynaptic membrane folding which in humans increases the 
synaptic area by 8 times.  
 Although a broad range of preclinical models of varied VML defect sizes have been 
investigated along with the associated damage to vasculature and innervation, there is still no 
universal consensus on the definition of a critical sized defect in skeletal muscle, which might be 
utilized as a benchmark control and means of standardization in study design. A recent study by 
Anderson et. al. was the first to define a critical sized skeletal muscle defect within the mouse 
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quadriceps and characterized changes to fibrosis, macrophage infiltration, myofiber formation, 
vasculature, and innervation across a range of defect sizes[20].  
 When muscle is resected longitudinally (as opposed to use of a biopsy punch) or defects 
are partial-thickness it is difficult to maintain consistency in the defect size. Approaches to 
maintain reproducibility have included tattooing a region of fixed dimensions prior to removal[21], 
measuring the weight of muscle removed incrementally during surgery[22,23], measuring the 
functional deficit as muscle is removed incrementally during surgery[24], and recording the total 
removed muscle weight per animal[25]. To reproducibly assess differences in muscle damage and 
regeneration at different VML defect sizes, Anderson et. al. utilized biopsy punches with diameters 
ranging from 2 to 4 millimeters (corresponding to approximately 4-32% of the quadriceps wet 
weight) to create full-thickness defects in the mid-belly of the quadriceps with the leg in an 
extended position. They assessed tissue damage up to 28 days post-injury[20]. Fibrosis, persistence 
of CD68+ macrophages, and presence of myofibers with relatively small cross-sectional area 
increased over time with increasing defect size. By 28 days post-injury, the 2 mm size defects 
exhibited lower amounts of amounts of fibrosis and had similar levels of centrally-nucleated 
myofibers to uninjured controls demonstrating its status as a sub-critical sized defect with healing 
potential.  
Defects of 3 mm diameters were further investigated for neural and vascular regeneration. 
Transgenic Thy1-YFP mice, whose motor neurons express yellow fluorescent protein (YFP), were 
used to visualize innervation within the defect site up to 28 days post-injury. Although motor 
neurons were visible in uninjured muscle tissue, significant autofluorescence in VML defects 
prevented visualization of neurons within the injured muscle. Postsynaptic acetylcholine receptor 
clusters demonstrated marked differences in morphology between control and injured muscle and 
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were classified into three categories: normal pretzel, abnormal fragmented, and newly-formed. No 
clusters with a normal pretzel morphology were visible within the defect site at either 14 or 28 
days post-injury. Cluster morphology within the defect remodeled over time with significantly 
more clusters demonstrating a fragmented morphology at 14 days post-injury, decreasing over 
time to contain more of the newly formed clusters 28 days post-injury. Of the clusters present at 
28 days, 44.3% had an abnormal fragmented morphology and 55.7% appeared to be newly formed 
clusters. Despite remodeling in cluster morphology over time, no clusters were associated with a 
regenerated motor neuron. Total vascular volume within the defect site was quantified 28 days 
post-injury using Microfil and micro CT and demonstrated that injured muscle had a larger 
vascular volume as well as perfused vessels with a larger diameter compared to uninjured controls. 
 Although significant in its definition and characterization of a skeletal muscle critical sized 
defect, the previous study did not measure force deficits due to injury, which is a defining feature 
of VML and standard for the field. They also utilized adult female mice between 3 and 9 months 
of age and assessed VML injury to the quadriceps muscle alone. When translating the 3 mm critical 
size defect model to future studies, potential differences in anatomy and regeneration between 
various different muscle types as well as differences due to species, age, and sex must be 
considered. Larger animals generally have different muscle fiber type compositions than smaller 
animals, with a higher prevalence of slow twitch myofibers[26]. Young rodents have a higher 
density of satellite cells[27] with differences in remodeling post-VML[23] and may therefore require 
a larger critical sized defect than older animals. Differences in muscle anatomy and regeneration 
due to sex must also be considered as it has been shown that over 3,000 genes are differentially 
regulated between male and female muscle[28]. Fiber type composition, myofiber cross-sectional 
area, fatigue recovery, and endurance testing differ greatly between men and women in various 
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muscles and sex-based differences in skeletal muscle composition are present across species[26]. 
Male myofibers generally have a lower type I composition, a larger cross-sectional area, and are 
more fatigable than those in females, and women typically exhibit longer endurance and faster 
recovery from muscle exhaustion than men which may have implications for sex-based differences 
in regeneration following injury. Future studies on the applicability of the 3 mm critical sized 
defect to alternative preclinical models and potential differences due to muscle type, age, sex, and 
species would be of great benefit to the field.  
Significant advancements have been made in the use of pre-vascularized constructs within 
VML-injured muscle, including successes in characterization of in vitro vascular development, 
anastomosis with host vasculature post-implantation, and the development of several useful 
methodologies for in vivo vascular quantification. The majority of those studies have utilized a 
mouse abdominal defect model[29–35], however, and it is unclear if either the constructs implanted 
or the success of vascular regeneration would translate to muscles with a different anatomy or 
larger animal models with a higher vascular demand post-injury. As described below, different 
muscles within the body have varying degrees of heterogeneity in capillary density throughout the 
tissue and constructs that successfully anastomose with host vasculature within one defect model 
may not perform as well elsewhere in the body or in the process of scaling up to treat a human 
VML defect. Further research on the versatility of pre-vascularized constructs under development 
as well as their feasibility for use in large animal models is required. These differences between 
species in muscle anatomy, vascularization, and innervation must be considered when comparing 
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preclinical models to each other and when developing a tissue engineered muscle graft for VML 
treatment in humans. 
 
Current Clinical Treatment of VML 
 Optimal VML treatment depends on the location and size of a specific VML defect. The 
functional deficits associated with a small VML defect may be ameliorated by hypertrophy of 
surrounding muscles via physical therapy while muscles with larger VML defects do not respond 
to physical therapy[16]. Current treatment options for large-scale VML are limited and include 
transfer of an autologous free muscle flap[2,36], muscle transposition[2,3], or amputation and power 
bracing[36], all of which have major limitations. Donor site morbidity, lack of donor tissue, and 
the need for a highly skilled surgical team complicate VML treatment and decrease positive 
patient outcomes[6,36]. In battlefield injuries, free or rotational muscle flaps are often utilized as 
soft tissue coverage in the treatment of severe type III open tibia fractures but do not recover the 
strength deficit of the injured muscle surrounding the fracture[3]. Tissue engineering strategies 
aim to fill the muscle tissue volume and enable dense regeneration of vascularized and 
Figure 1.2. Preclinical models of VML.Various models of VML have been developed in mice, 
rats, rabbits, dogs, and pigs at a range of anatomical locations across species and with differences 
in muscle anatomy and pennation.  
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innervated muscle as well as to recover the full function of VML-injured muscle. An 
understanding of skeletal muscle vascular biology, neural biology and the impediments to 
regeneration caused by VML is vital to successful tissue engineered treatments. 
1.2 Tissue Engineering Strategies to Regenerate Skeletal Muscle  
 A range of approaches for the development of tissue engineered skeletal muscle have been 
reported with previous excellent reviews summarizing the current state of the field[18,37–44]. Tissue 
engineered skeletal muscle approaches fall into four main categories: acellular scaffolds, cells-
only rolled monolayers, minced muscle grafts, and tissue engineered muscle grafts (Figure 1.3)[45]. 
Each of these may be combined with growth factors or other pro-regenerative molecules or 
peptides to improve the regenerative response. There are benefits and drawbacks to both the 
acellular or cell-based approaches to skeletal muscle tissue engineering, with acellular scaffolds 
providing a lower regulatory hurdle and faster translation to the clinic[45] while cell-based 
approaches often result in significantly more histological muscle regeneration post-VML 
compared to acellular counterparts[25,46]. Minced muscle grafts have excellent engraftment 
potential but require in vitro expansion or the use of large volumes of host muscle tissue. The 





Cell sources for skeletal muscle tissue engineering have been reviewed elsewhere[45,47,48] 
and include satellite cells or other muscle-derived precursor cells, perivascular stem cells, bone 
marrow-derived mesenchymal stem cells, umbilical cord mesenchymal stem cells, adipose-
derived stem cells, induced pluripotent stem cells, and embryonic stem cells. Major considerations 
when selecting a myogenic cell source include expansion capacity, immunogenicity, 
translatability, differentiation potential, and engraftment potential in vivo. Muscle precursor cells 
are frequently combined with a material scaffold to provide mechanical support and assist in cell 
retention within the defect, or acellular scaffolds are implanted that are designed to promote 
endogenous muscle repair.  
The cells-only approach traditionally involves the injection of a muscle cell suspension 
with or without a hydrogel carrier[45,49]. However, this strategy, which does not provide significant 
structural support, is not particularly suitable for the treatment of VML defects. Instead, 
Figure 1.3. Tissue engineered skeletal muscle techniques are either acellular or cell-based. 
Four general approaches exist for engineered skeletal muscle: acellular scaffolds, rolled cell 
monolayers, minced muscle grafts, and cell-seeded scaffolds (here termed Tissue Engineered 
Muscle Grafts; TEMGs).  
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implantable cells-only 3D constructs have been developed by culturing muscle-derived cells in 
monolayer until confluence and subsequent delamination and formation of a cylindrical 3D 
construct[50,51]. One study cultured primary mouse muscle cells in monolayer for approximately 8 
days and implanted the delaminated monolayer as a 3D construct in a mouse VML model of the 
extensor digitorum longus muscle[51]. Muscle and vasculature were present within the explanted 
graft after 15 days in vivo. In a second study, rat primary muscle precursor cells were cultured as 
monolayers that were then delaminated and rolled into cylindrical constructs with bone marrow 
cell-derived bone anchors at each end[50]. The constructs were then implanted in a rat 30% VML 
model of the tibialis anterior and assessed after 28 days, at which they exhibited the formation of 
small myofibers and the presence of associated vasculature and nerves. The above cells-only 
approaches benefit from a high cell density within the constructs and promising results within 
small VML defects in vivo, but may be limited in their ability to scale-up to clinically relevant 
sizes and can be difficult to surgically manipulate due to the lack of a scaffold. 
Acellular Scaffolds 
There has been much discussion on the ideal biomaterial for skeletal muscle tissue 
engineering scaffolds, which has been the focus of several previous reviews[18,39,44,52]. The two 
main biomaterial categories are natural versus synthetic materials with hybrid materials as a third 
smaller category. Natural materials used for skeletal muscle tissue engineering include 
decellularized extracellular matrix (dECM) from various organ and donor sources as well as ECM 
components and other naturally-derived materials such as fibrin, hyaluronic acid, laminin, 
collagen, chitosan, silk fibroin, alginate, agarose, keratin, and gelatin. Synthetic materials used for 
skeletal muscle tissue engineering include polypropylene, poly-(lactic acid), poly-(glycolic acid), 
poly-lactic-co-glycolic acid, poly(ε-caprolactone), polyurethane, and polyethylene glycol. Natural 
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materials are bioactive, may contain pro-myogenic growth factors, and are biocompatible but have 
limitations in batch-to-batch variability, immunogenicity, and a lack of precise design control. 
Synthetic materials offer improvements in the tunability of mechanical cues and nanoscale 
topography as well as consistency between batches but may be limited in their biocompatibility, 
cell adhesion, and need for functionalization due to limited bioactivity. Hybrid materials are 
combinations of natural and synthetic biomaterials and are promising options for combining the 
bioactivity of natural materials with the precision of synthetic materials, but they may also retain 
the limitations of both categories. Biomaterials in all categories can be utilized with a broad range 
of fabrication methods that each provides different mechanical properties, degradation timeline, 
topographical cues to cultured cells, and in vivo engraftment potential. Generally, naturally derived 
biomaterials have resulted in improved muscle, vascular, and neural regeneration with significant 
emphasis placed on the method of fabrication and presence of alignment cues, native growth 
factors, myogenic stiffness, biocompatibility, and degradation timeline. 
There are currently conflicting reports on the ability of acellular scaffolds to consistently 
promote muscle regeneration and functional recovery post-VML. Acellular scaffolds are more 
clinically translatable with a lower regulatory burden and acellular decellularized ECM (dECM) 
scaffolds have the potential to modulate the immune response and macrophage polarization to 
promote muscle regeneration[53]. Despite these benefits, acellular scaffolds used to treat VML 
defects often lack histological evidence of muscle regeneration. There has been a broad range of 
preclinical studies comparing the efficacy of acellular or cell-seeded dECM[21,46,54–59] with mixed 
results. There have also been two recent clinical trials evaluating the regenerative potential of 
acellular dECM within human VML defects[58,60–62]. In an effort to address significant variability 
in reported results, the efficacy of using acellular dECM to treat VML injuries was systematically 
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evaluated in a large 2015 study with 120 rats (8 rats/group)[46]. Acellular dECM was implanted 
into two different defect models, a musculotendinous junction (MTJ) model and a VML model, 
and compared to untreated or autograft-treated controls at a range of time points up to four months 
post-treatment.  In the MTJ model, the implanted ECM scaffold completely resorbed without 
muscle tissue remodeling. In the VML model, the implanted ECM scaffold improved muscle 
function by 17% but remodeled into fibrous tissue lacking significant de novo myofiber formation 
and muscle regeneration (Figure 1.4c). Physical rehabilitation via voluntary cage wheel running 
did not improve the regenerative response of the decellularized ECM treatment. The ability of the 
implanted scaffold to improve contractile properties of the muscle without correlated muscle fiber 
regeneration within the defect area may be explained by scaffold mediated functional fibrosis and 
has been demonstrated repeatedly[22,25,46,63–65]. The implanted scaffold likely functions as a 
mechanical bridge between intact muscle fibers, transmitting the contractile force across the defect 
and subsequently resulting in a higher measured functional outcome. This is in contrast to force 
production by regenerating myofibers within the defect, which is the ultimate goal of a tissue 
engineered treatment for VML.  
The first use of a tissue engineered construct for VML treatment in humans was 2010 case 
report where a single patient with a blast-induced VML injury to the thigh was treated with 
acellular decellularized porcine ECM. The patient demonstrated improved isokinetic performance 
four months post-treatment and evidence of muscle formation in CT imaging nine months post-
treatment with no histology shown[58]. Following initial testing in mouse quadriceps VML defects 
with moderate regeneration following 6 months of dECM treatment[54], a recent study assessed 13 
human patients with VML injuries at a range of anatomical locations with an average muscle tissue 
deficit of 66.2% and evaluated the efficacy of an acellular scaffold composed of porcine dECM to 
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promote muscle regeneration[54,60]. Measurements of force production, improvements in functional 
task performance, and electromyographical assessments up to six months post-operatively 
demonstrated that patients showed an average of 37.3% improvement in muscle strength, 27.1% 
improvement in range of motion, and some electrophysiological improvements compared to pre-
operative values[60]. Regeneration and remodeling of the muscle tissue within the defect site was 
demonstrated through histology of muscle biopsies and CT or MRI imaging (Figure 1.4a). 
Disconnected islands of muscle tissue were present within the defect site in addition to vasculature, 
mobilization of perivascular stem cells, and some neurofilament (Figure 1.4b). Although the study 
incorporates robust functional testing and CT data there was limited histological analysis shown. 
Since muscle tissue engineering data in humans is scarce, the field would benefit from a more 
detailed quantification of the histological data including muscle, vascular, and nerve density across 




Minced Muscle Grafts (MMGs) 
A third category investigated pre-clinically for VML treatment is the use of minced muscle 
grafts. In this approach, autologous or allogeneic muscle is removed via biopsy, minced into small 
pieces and often expanded in vitro, and placed in the VML defect[16,22,66–68]. Minced muscle grafts 
Figure 1.4. Acellular decellularized ECM treatment in VML defects may promote 
regeneration with some variability. a,b) Minimal regeneration over time in a rat TA VML 
model following treatment with acellular decellularized ECM (urinary bladder matrix). c) 
Desmin (top) and MHC (bottom) positive muscle cells within mouse quadriceps VML defects 
following treatment with acellular decellularized ECM (urinary bladder matrix). Inset: center of 
the ECM implantation site. d,e) Computerized axial tomography images of human quadriceps 
VML defect pre-implantation (top) and 8 months following treatment with acellular 
decellularized ECM demonstrating the presence of new tissue within the defect region. f-h) 
Histological analysis over time of muscle biopsies from human VML patients treated with 
acellular decellularized ECM. MF20: pan-isoform myosin; MHC: myosin heavy chain.  
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can be easily generated from the patient’s own muscle and result in excellent muscle regeneration 
but require in vitro expansion or the use of large volumes of host muscle tissue. Due to the need 
to limit the volume of biopsied muscle removed from the patient, the minced muscle must be 
expanded for this approach to be feasible for the treatment of large defects. To maximize the 
regenerative potential of small muscle biopsies, the potential to decrease the percent composition 
of minced muscle by mixing it with pro-regenerative hydrogels and growth factors is an area of 
active investigation. Expansion capacity of autologous minced muscle within a collagen hydrogel 
at a range of muscle compositions was investigated and compared to grafts composed of 100% 
autologous minced muscle (Figure 1.5a,b)[66]. It was found that reducing the percent of muscle by 
50% retained its ability to promote functional improvement post-VML but the regenerating defects 
treated with 50% minced muscle contained less de novo myofiber regeneration than the 100% 
grafts and regenerating myofibers had smaller cross-sectional areas. The potential for improving 
outcomes of VML treatment with 50% minced muscle grafts via incorporation of laminin-111, a 
muscle extracellular matrix protein, within a hyaluronic acid hydrogel has also been investigated 
(Figure 1.5c)[67]. The 50% minced graft with laminin-111 and hyaluronic acid resulted in 
improved function compared to untreated controls but was not significantly different from 
treatment with 50% minced grafts lacking laminin-111 or lacking hyaluronic acid. De novo muscle 
regeneration remained less than that observed in injuries treated with 100% minced grafts, 
indicating a need for further research in the expansion and treatment potential of minced muscle 
grafts composed of less than 100% muscle. In addition, it was recently shown that VML-injured 
muscles treated with a 100% autologous minced muscle graft have no difference in gene 
expression compared to untreated controls, with upregulation of pro-fibrotic and inflammation-
related genes 28 days post-injury (Figure 1.5d)[16]. Although a promising option, more research is 
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required on efficient in vitro expansion methodologies of minced muscle grafts and overall scale-
up potential prior to clinical translation. 
 
Tissue Engineered Muscle Grafts (TEMGs) 
Tissue engineered muscle grafts (TEMGs) leverage the benefits of acellular and cells-only 
approaches through the combination of a translatable pro-myogenic cell source with a biomaterial 
scaffold. Despite their significant regenerative potential, TEMGs may be limited, however, by long 
in vitro pre-culture times, issues with cell distribution within the scaffold, and limited expandable 
myogenic cell sources. There has been extensive research on the use of various TEMGs to treat 
Figure 1.5. Minced muscle grafts of varied composition within VML defects enable 
histological regeneration but have a persistent pro-inflammatory gene expression profile.  
a,b) Collagen hydrogel containing 0-100% MMG within a rat VML defect for 8 weeks and 
quantification of myofiber number and diameter. (c) Histological analysis of a rat VML defect 
treated with a hyaluronic acid (HA) hydrogel supplemented with laminin-111 (LMN-111) with 
or without 50% minced muscle graft at 8 weeks post-implantation. d) Heatmap of differentially 
expressed genes comparing rat TA VML defects with no repair to those treated with 100% 
MMG up to 28 days post-injury demonstrating persistent similarities in transcriptional response 




VML defects in a range of preclinical models. Similar to the cells-only approach, there has been a 
broad range of cell sources incorporated into TEMGs including satellite cells or other muscle-
derived precursor cells[21,33,56,69–73], mesenchymal stem cells[74,75], adipose-derived stem cells[76–78], 
and human pluripotent stem cells[79–81] (Figure 1.6). Scaffold materials used in the development 
of TEMGs include dECM[21,55,56,74,82], collagen[83,84], hyaluronic acid[67,85], fibrin[24,25,49,70,77], 
poly(lactic acid)/poly(lactic-co-glycolic acid)[32,86], silk fibroin[87], keratin[71,72], gelatin[88,89], and 
methacrylated gelatin[90]. Regenerative potential of TEMGs following implantation within VML 
defects has varied widely and comparison between studies is complicated by the broad range of 
cells and scaffold materials as well as differences in in vitro pre-culture time, construct size, and 
the preclinical VML defect model used. Although TEMGs are limited by the regulatory hurdle and 
biological variability inherent to cell-based constructs, the combination of pro-myogenic cells with 
a biomaterial scaffold present has demonstrated increased histological regeneration of VML-
damaged muscle compared to acellular constructs in addition to improving muscle contractile 
function. Additionally, the incorporation of a biomaterial scaffold enhances construct durability 
and ease of surgical manipulation compared to cells-only constructs. Overall, TEMGs are a 





 VML is characterized by persistent loss of function over time and functional testing 
following treatment of VML injuries is a standard assessment. Different studies have tested 
functional output at a range of time points post-VML from 2 weeks[67] to 6 months post-injury[65]. 
Functional measurements primarily involve electrical stimulation of a nerve near the graft and 
subsequent measurement of the muscle’s twitch force, maximum isometric force, maximum 
specific force, and/or the force frequency relationship. Measurement of the force frequency 
Figure 1.6. Tissue engineered muscle grafts developed for VML 
treatment have incorporated a broad range of cell sources. a) 
Primary human muscle progenitor cells within fibrin and Matrigel. b,c) 
Human induced pluripotent stem cell-derived myoblasts within fibrin 
and Matrigel. d) C2C12 mouse myoblasts within electrospun fibrin. e) 
Primary rat satellite cells and muscle progenitors within fibrin and 
Matrigel. MF20: pan-isoform myosin; Lam: laminin; BTX: α-
bungarotoxin; SAA: sarcomeric α-actinin; MHC: myosin heavy chain. 
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relationship enables quantification of the muscle’s ED50, the frequency of stimulation that elicits 
its half-maximal contraction amplitude. Often, contralateral uninjured muscles are used as a 
comparison and forces may be presented as a percent of the contralateral. Ex vivo force 
measurement is also used to measure muscle contractility independent of innervation, whereby 
explanted muscle is tethered on both ends and directly stimulated[21,65]. In some cases, there were 
no differences between treatment groups following neural stimulation but ex vivo force 
measurement did show differences[21]. An alternative measure of muscle function that is less often 
utilized in tissue engineering approaches post-VML is the use of electromyography (EMG) and 
compound motor action potential (CMAP)[59,61,86,91]. In EMG, surface or needle electrodes are 
placed above or within the muscle and measure motor neuron electrical signals and electrical 
activity within the muscle in response to nerve activity. Due to the importance of neural 
regeneration post-VML to ultimate graft integration and function, EMG is a useful tool for muscle 
tissue engineers and should be more widely utilized to measure functional recovery post-VML. 
The vast majority of studies quantifying functional outcomes post-VML in preclinical 
models have analyzed muscle function at the muscle’s optimal length (L0) and measured standard 
functional outcomes such as maximum isometric contraction, specific force, twitch force, and 
force-frequency curves. As mentioned previously, there has been recent discussion on the 
discrepancy between improved functional outcomes post-implantation despite low and variable de 
novo myofiber regeneration, in particular with respect to implantation of acellular dECM 
scaffolds[22,25,46,63–65] calling into question the utility of these measurements to determine the extent 
of regeneration. It has been postulated that functional improvements due to acellular dECM 
implantation may be due to scaffold mediated functional fibrosis[46,64] . A significant recent study 
by Passipieri et. al. tested this hypothesis by utilizing a novel computational model to investigate 
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the biomechanical mechanisms underlying improved functional outcomes despite limited 
histological regeneration following implantation of acellular and cell-seeded dECM scaffolds in a 
rat latissimus dorsi (LD) model[65]. They found that increased contractile force measurements of 
the treated LD (acellular and cell-seeded) compared to non-repaired controls 2 months post-injury 
were primarily due to increased volume of tissue in the defect region and subsequent improved 
passive force generating ability. Despite improvements in de novo myofiber regeneration near the 
implant/host interface by cell-seeded grafts and an ~87% recovery of maximum isometric force, 
96% of the total measured force recovery was due to passive force generation and differences in 
measured contractility between acellular and cell-seeded grafts were likely due to graft thickness 
alone. The model also highlights the contribution of lateral force transmission to contractility of 
non-repaired VML-injured muscle, which should be a consideration by future studies on VML. In 
a substantial result, simulated forces predicted by the model demonstrate a significant decrease in 
the contribution of passive force generation to total measured contractile force when measurements 
are taken at 80% of the muscle’s optimal length. When measured at a suboptimal length, implanted 
grafts would require active force generation by myofibers within the defect in order to show 
marked improvements in overall muscle contractility. They also demonstrated decreases in the 
contribution of passive force generation with increased defect size. The predicted results must be 
validated experimentally but if true could improve measurement of graft function post-VML 
through the use of suboptimal muscle length and more accurately reflect histological results.  
 
1.3 Engineering Vascularized Skeletal Muscle 
Anatomy of Muscle Vasculature 
24 
 
 Due to the high metabolic demands of skeletal muscle, tissue engineering techniques for 
skeletal muscle regeneration must consider the design constraints imposed by the limits of oxygen 
diffusion. Previous studies with pancreatic islet cells and lung-derived fibroblasts have shown that 
the limiting oxygen diffusion distance in order to prevent necrotic cores in cultured tissues is 150-
200 μm[92–94]. Native muscle myofibers have diameters ranging from approximately 30-100 
μm[5,95], which, when combined with the diffusion distance of oxygen, demonstrate the need for 
perfusable vasculature within the large-scale regenerating muscle environment post-VML. The 
dense and organized structure of vasculature within native skeletal muscle is optimized for 
efficient nutrient transfer throughout the entire tissue and must be considered in tissue engineered 
constructs. Blood vessels within skeletal muscle are highly organized to provide optimal nutrient 
and gas diffusion to myofibers with arterioles and venules branching into terminal arterioles and 
terminal venules that are perpendicular to the skeletal muscle myofibers (Figure 1.7a)[96]. These 
terminal arterioles and venules are interspersed and alternate with one terminal venule present 
between two terminal arterioles, and a terminal arteriole is present approximately every 1 
millimeter down the length of each myofiber. The terminal arterioles and venules then branch into 
tortuous capillaries that run parallel to the myofibers and form organized networks called 
microvascular units[97]. To further the efficiency of gas transfer from blood vessels to muscle cells, 
capillaries are embedded within grooves in the myofiber sarcolemma and mitochondria within the 
myofiber interior congregate around these grooves, minimizing the required distance of gas and 
fatty acid diffusion[96].  
 Microvascular units (MVUs) are the smallest unit of control for vascular perfusion in 
skeletal muscle tissue and consist of a terminal arteriole and the group of 20-30 capillaries that it 
supplies[98] (Figure 1.7b). Each MVU covers approximately 1 millimeter of the myofiber length 
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after which a new MVU supplied by a different terminal arteriole begins. The width of a MVU is 
approximately 500 μm and it extends around 100 μm deep into the muscle, and there are 
approximately 20 MVUs per milligram of skeletal muscle tissue[98]. Capillaries within an MVU 
are 4-10 μm in diameter and have a tortuous architecture along the myofibers which functions to 
increase the capillary to myofiber surface area and maximize oxygen diffusion to the muscle[97,99]. 
Skeletal muscle is a highly plastic tissue with the capacity to adapt to increased oxygen and nutrient 
demands[99]. In resting muscle, the skeletal muscle microvasculature and MVUs are intermittently 
and unequally perfused. The skeletal muscle vasculature dilates in response to exercise with 
changes in oxygen demand sensed by muscle microcirculation and transmitted upstream to larger 
vessels inducing vasodilation and vasomotion, rhythmic oscillations in blood vessel diameter that 
impact blood flow. In addition, muscle vasculature and blood flow is modified in response to 
exercise by local factors released by the muscle as well as neurovascular changes to increase vessel 
perfusion[96,100]. When regenerating a large volume of skeletal muscle tissue after injuries such as 
VML, the microvascular architecture and capacity of the muscle vasculature to adapt to changing 
environmental and exercise demands should be considered. 
 A variety of mechanisms to quantify the extent of vascularization are utilized in the 
analysis of skeletal muscle biology. These may also be applied to the quantification of vasculature 
in engineered muscle constructs and regenerated muscle post-VML. For an excellent review of 
quantification methods of skeletal muscle vascularity see Olfert and Baum et al[100]. Capillary 
density (CD) is perhaps most frequently used and is defined as the number of capillaries per 
millimeter squared when counted in cross-section. Increases in skeletal muscle CD have been 
linked to increased muscle functional performance, mitochondrial volume density, and maximal 
aerobic capacity and decreased skeletal muscle CD is associated with poor prognoses for a variety 
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of diseases including peripheral arterial disease, diabetes, cachexia, and chronic obstructive 
pulmonary disease[100]. Despite the utility of CD to measure muscle vascularity, it does not account 
for changes in the capillary to myofiber surface area caused by differences in capillary vessel 
tortuosity or myofiber diameter. Capillary length density, the length of capillaries per unit volume 
of muscle fibers, incorporates vessel tortuosity but requires more technically challenging 
longitudinal sectioning and quantification methods. The capillary to fiber ratio (C/F ratio) is 
counted in cross section similar to CD but more accurately represents differences in capillary 
surface area and overall vascular density due to changes in myofiber area. Use of CD alone does 
not capture the impact of changes to myofiber cross-sectional area which can adapt in response to 
exercise and tissue remodeling after injury[100].  A final consideration when assessing muscle 
vascularity is the heterogeneity of vascular density throughout the depth of the native muscle 
tissue. Different muscles within the body have varying degrees of heterogeneity in both the muscle 
fiber type as well as capillary density throughout the tissue (Figure 1.7c)[100]. Tissue engineered 
constructs for skeletal muscle regeneration post-VML should consider the native capillary density 
and C/F ratio pattern for the specific muscle being treated, and analysis of regenerating muscle 
should consider differences in capillary density across a section of the native tissue. Engineered 
constructs with tunable vascular density or incorporation of a vascular density gradient depending 




Strategies to Enhance Vascularization of TEMGs 
Approaches to engineer vascularized skeletal muscle with the use of implantable 3D 
constructs fall into two main categories: muscle constructs relying on host vessel infiltration and 
constructs that are pre-vascularized in vitro prior to implantation with or without an incorporated 
myoblast cell source (Figure 1.8). Scaffold material may encourage host vascular infiltration, and 
constructs designed to promote vascularization post-VML have included fibrin, decellularized 
ECM, collagen, and combinations of poly-(lactic acid) and poly-lactic-co-glycolic acid. Fibrin in 
Figure 1.7. Tissue engineered muscle grafts 
developed for VML treatment have incorporated 
a broad range of cell sources. a) Primary human 
muscle progenitor cells within fibrin and Matrigel. 
b,c) Human induced pluripotent stem cell-derived 
myoblasts within fibrin and Matrigel. d) C2C12 
mouse myoblasts within electrospun fibrin. e) 
Primary rat satellite cells and muscle progenitors 
within fibrin and Matrigel. MF20: pan-isoform 
myosin; Lam: laminin; BTX: α-bungarotoxin; SAA: 
sarcomeric α-actinin; MHC: myosin heavy chain. 
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particular has a demonstrated pro-angiogenic potential[101] and has been utilized in combination 
with other biomaterials to promote vascularization in vivo. Defect size is also a critical determining 
factor in the feasibility and practicality of host vessel infiltration. While host vessel infiltration 
may be sufficient for the survival of implanted grafts within smaller defects in mice and rats, larger 
animal models of VML and human patients would likely require an implanted vascular source for 
graft survival over time[102]. Significant work has been done with both approaches to engineer 
vascularized muscle yielding promising results with the potential for clinical translation. 
 
Host Vessel Infiltration 
 Infiltration of the host blood vessels into an implanted construct is impacted by a variety 
of factors including ischemia within the defect site, paracrine signaling by regenerating muscle 
cells, pro-angiogenic biomaterial scaffolds, and mobilization of immune cells. Approaches to 
encourage host vessel infiltration often utilize microsurgical techniques to graft portions of major 
host vessels onto implanted muscle constructs or the implantation of muscle constructs adjacent to 
a major vessel. Early studies utilizing host vessel infiltration were mainly concerned with 
Figure 1.8. Engineering Vascularized Skeletal Muscle. Strategies to vascularize tissue 
engineered constructs include host vessel infiltration (left) and implantation of pre-vascularized 
constructs (middle and right). 
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supporting the survival of implanted muscle tissue and focused on graft survival over time while 
later studies prioritized analysis of the infiltrating vasculature itself and developed advanced 
quantitative techniques to do so. A variety of skeletal muscle tissue engineering studies that rely 
on host vessel infiltration post-VML have been summarized in Table 1.1. There are also numerous 
studies investigating host vessel infiltration following muscle injuries other than VML (ischemia, 
myotoxin, etc) that are outside the scope of this review. 
Table 1.1. Tissue engineering studies utilizing host vessel infiltration to vascularize 
implanted muscle constructs post-VML. 
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The feasibility of encouraging host vasculature to infiltrate an implanted muscle construct 
was initially assessed with a microsurgical arteriovenous (AV) loop implantation model. In one 
study, rat or human muscle was implanted within the groin in a semi-sealed chamber connected to 
host AV vessels. Gross examination of the tissue demonstrated survival of vascularized muscle 
tissue 6 weeks post-implantation[103]. A second study further elucidated the potential of the AV 
loop and examined the potential of host vessels to vascularize an implanted acellular fibrin 
scaffold. After vascularizing the scaffold in vivo for 2 weeks, they then injected fluorescent 
primary rat myoblasts into the scaffold site to test its ability to support muscle growth in vivo over 
time[104]. Myoblasts implanted into vascularized scaffolds were visible up to 8 weeks post-
implantation while control myoblasts implanted into the contralateral groin lacking an AV loop 
were not detectable. Yet another study utilized a different technique to promote vascularization of 
an implanted muscle construct by creating a fibrin scaffold seeded with primary rat myoblasts and 
implanting it within a cylindrical silicone chamber surrounding the host femoral artery and 
vein[102].  Three weeks post-implantation, host vessels had infiltrated the muscle construct and the 
explanted construct contained desmin positive muscle cells and was contractile when electrically 
stimulated.  
 Other studies have attempted to encourage host vessel infiltration by transecting a major 
blood vessel and attaching the transected end to the implanted construct. To vascularize and 
innervate a construct composed of primary rat myoblasts, Williams et. al. implanted the construct 
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along the biceps femoris muscle of rats and attached transected ends of the sural nerve and blood 
vessel to the implant[105]. After just one week post-implantation they saw host vessels within the 
graft. In a unique animal model enabling intravital imaging of blood vessel infiltration, Juhas et. 
al. implanted engineered muscle bundles composed of primary rat satellite cells in fibrin into a 
mouse dorsal skinfold window model after two weeks of in vitro pre-cultivation (Figure 
1.9a,b)[73]. The dorsal skinfold model enabled direct visualization of constructs and blood vessels 
through a glass coverslip in the live animal and a broad range of quantification techniques. Host 
blood vessels rapidly infiltrated the implanted constructs with pre-differentiated constructs that 
contained more mature muscle cells inducing a higher blood vessel density over time than 
undifferentiated constructs that contained an immature satellite cell-like phenotype.  Additionally, 
the infiltrating blood vessels were perfused by host blood flow after just one week in vivo, which 
is visible via video. To further quantify the blood vessel maturity, they also quantified the cross-
sectional lumen density of the blood vessels and found that constructs containing more mature 
muscle cells had an overall higher lumen density. The average lumen diameter increased over time 
to reach 7 μm, similar to native hindlimb muscle, and the average rate of vessel ingrowth in pre-
differentiated constructs was 18.9 ± 2.1 vessels·mm-2·day-1. Although their muscle constructs were 
not implanted in a VML model, the dorsal skinfold window model is an important advancement 
for the field due to its ability to enable live intravital imaging and detailed analysis of host vessel 
infiltration into implanted muscle constructs. 
 Another interesting approach to encourage host vessel infiltration is the use of gene therapy 
to encourage vessel growth. Zhou et. al. utilized primary rat myoblasts transfected to overexpress 
human vascular endothelial growth factor 165 (VEGF-165) or human stromal cell-derived factor 
1 (SDF-1) on a calf skin-derived collagen sponge to encourage vessel growth after implantation in 
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a back muscle defect[106] (Figure 1.9c). They implanted four groups of cells pre-cultured on the 
collagen sponge: non-transfected myoblasts, VEGF-165 transfected myoblasts, SDF-1 transfected 
myoblasts, and a 1:1 ratio of VEGF-165 and SDF-1 transfected myoblasts. After up to 8 weeks 
post-implantation they found that the while the VEGF-165 and SDF-1 transfection groups had 
more vessels than non-transfected controls they contained varied degrees of vascular infiltration 
to the graft. The combined co-culture of VEGF-165 and SDF-1 myoblasts, however, had enhanced 
vascular infiltration than either growth factor group alone as well as larger vascular lumens. Upon 
analysis of microvascular density they found that capillary density in all three transfection groups 
decreased slightly over time as the tissue remodeled, with each group displaying different temporal 
changes in capillary density over the eight week regenerative period.  
 Host vessel infiltration serves as a useful tool to demonstrate viability and regenerative 
potential of tissue engineered muscle constructs during initial testing within small VML defects. 
Reliance on host vasculature for graft survival when scaling to large, clinically-relevant defect 
sizes is not feasible and alternative methods of promoting construct vascularization are vital to 
clinical translation. Despite this eventual need, studies that utilize host vessel infiltration in small 
defect sizes are relatively high throughput and provide useful and important information on early-
stage muscle regenerative potential of an engineered construct. Additionally, critical vascular 
quantification metrics have been developed through the use of host vessel infiltration that can 





Pre-vascularized constructs for skeletal muscle tissue engineering include both constructs 
containing vessels alone and co-cultures of vessels and muscle cells. Major skeletal muscle tissue 
engineering studies that rely on pre-vascularized scaffolds for VML treatment have been 
summarized in Table 1.2. Early successes in vascularized skeletal muscle tissue engineering 
Figure 1.9. Host vessel infiltration to various implanted engineered muscle constructs. a,b) 
Dorsal skinfold window containing constructs composed of primary rat satellite cells in fibrin. 
Vessels are visible in real time infiltrating constructs. c)  Angiogenic gene-modified primary rat 
myoblasts in collagen implanted within VML defect. i) control; ii) VEGF+ myoblasts; iii) 
SDF+ myoblasts; iv) VEGF+SDF+ myoblasts. d) Mouse myoblasts on electrospun fibrin 
scaffold implanted in VML defecte) Acellular aligned collagen scaffolds implanted in VML 
defect followed by exercise. MHC: myosin heavy chain.  
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included the development of a 3D tri-culture system containing cell sources for the three major 
components of vascularized muscle: skeletal muscle cells, human endothelial cells, and pericytes 
to support the developing vascular network[29]. Mouse embryonic fibroblasts were used as a 
pericyte cell source and it was found that inclusion of fibroblasts in the 3D construct significantly 
improved vascular maturity over time and that fibroblasts differentiated to express smooth muscle 
actin and were located around endothelial cells as a support for vessels. Constructs implanted in a 
mouse abdominal wall VML defect model contained perfusable human vessels after 2 weeks as 
well as desmin and myogenin positive muscle, with tri-culture constructs resulting in greater 
vascular perfusion in both lectin perfusion and luciferase injection assays (Figure 1.10d). 
Table 1.2. Tissue engineering studies that utilize pre-vascularized constructs to vascularize 
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Further work on the tri-culture system utilizing C2C12 myoblasts, GFP-positive human 
umbilical vein endothelial cells (HUVECs), and human foreskin fibroblasts (HFFs) investigated 
the impact of in vitro culture time on vascular maturity and integration following implantation in 
an abdominal wall defect model[31]. Tri-culture scaffolds were compared to empty scaffolds or 
those containing just C2C12s and all implanted constructs were evaluated after 2 weeks in vivo. 
Grafts implanted after different pre-culture times displayed differences in vessel alignment and 
maturity 2 weeks post-implantation with increased incubation time in vitro causing more mature 
morphology post-implantation. The three-week pre-culture group exhibited the most mature 
morphology with parallel, aligned myofibers and vessels, similar in morphology to native 
abdominal muscle. Functionality of the implanted vessels was assessed through tail-vein injection 
of fluorescent dextran and tri-culture constructs resulted in improved blood flow through 
implanted grafts compared to acellular or myoblast-only constructs. Blood flow, blood vessel 
37 
 
density, C/F ratio, and smooth muscle actin density increased with in vitro pre-culture time among 
the tri-culture groups. Interestingly, the signal of implanted GFP-HUVECs decreased in the three-
week pre-culture group despite the increase in overall blood flow, indicating remodeling of the 
more mature implanted vasculature and replacement by the host. 
To further investigate vascular network formation within 3D constructs, Lesman et. al. 
directly compared vascular morphogenesis of HUVEC:HFF co-cultures versus 
HUVEC:HFF:C2C12 tri-cultures in 3D constructs of varied scaffold composition (50% 
PLLA:PLGA, fibrin and thrombin at different concentrations, composite of PLLA:PLGA + 
fibrin)[30]. Quantification of vascular network maturity via live cell imaging of fluorescent vessels 
over 7 days of in vitro culture was performed through a maturity scoring system that classified the 
extent of network connectivity into four categories (Figure 1.10a,b). In an interesting result, they 
found that the incorporation of myoblasts slightly impeded in vitro vascular network maturity over 
time compared to the co-culture lacking myoblasts. They evaluated integration of the co-culture 
constructs with host vasculature in vivo by implanting co-cultures on a range of scaffold 
compositions in an abdominal wall defect for 10 days and determined that while both fibrin and 
composite scaffolds with cells resulted in some anastomosis with host vessels, the composite 
scaffolds containing both PLLA:PLGA and fibrin resulted in the highest amount of perfused host 
vessels within the graft regardless of whether or not cells were included. Although significant 
perfusion of infiltrating host vessels was visible along with some mosaic vessels composed of 
mouse and human cells, few of the implanted RFP+ human vessels were perfused with dextran at 
10 days (Figure 1.10e). 
To avoid the lengthy in vitro cultivation times of pre-vascularized constructs and develop 
a more clinically translatable VML treatment, Pilia et. al. assessed the vascular regenerative 
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potential of freshly isolated microvascular fragments (MVFs) versus adipose derived stem cells 
(ASCs) in a collagen scaffold implanted in a rat VML model of the TA muscle for 1 or 2 weeks[78]. 
MVFs and ASCs were isolated from rat epididymal fat pads and while MVFs were freshly isolated 
prior to implantation, ASCs were cultured and utilized at passage 2. VML defects treated with 
MVFs contained vessels earlier with a higher vessel density than those treated with ASCs or 
acellular controls but all treatment groups had a vessel density that remained lower than control 
native skeletal muscle. Vascular perfusion measured via DiI systemic injection was present as 
early as 7 days in the MVF group and after 14 days in the ASC group, although total vascular 
perfusion was low and unevenly distributed throughout the defect. MVFs isolated from GFP+ rats 
were then used to determine whether perfusable vessels within the defect were derived from 
implanted MVFs or host vessel ingrowth and the majority of vessels within the defect area were 
GFP-positive. Although overall vascular perfusion was low in this study, it is noteworthy that 
MVFs freshly isolated on the day of surgery enabled significant vascularization of implanted 
constructs and is a step toward a more clinically translatable treatment. 
The vascular potential of MVFs in 3D muscle constructs was further investigated by a 
recent study that utilized co-culture of freshly isolated primary rat MVFs and in vitro expanded 
primary rat myoblasts in a collagen gel for regeneration of a large VML defect to the rat biceps 
femoris muscle[109]. Constructs containing MVFs with or without myoblasts were pre-cultured for 
4 days in vitro before implantation and compared to muscle autografts or the empty defect. 
Interestingly, the in vitro constructs containing both MVFs and myoblasts had increased vascular 
network formation with a higher number of branches and total vessel length compared to MVF-
only constructs (Figure 1.10c). This is in contrast to previous research comparing 3D tri-culture 
to co-culture systems where the inclusion of myoblasts slightly impeded vascular network 
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formation[30]. After 2 weeks post-implantation, micro-CT angiography demonstrated that all 
treatment groups had equal vascular volumes, primarily composed of small vessels. Defects treated 
with constructs containing MVFs had a higher proportion of small vessels compared to empty or 
autograft groups. Both MVF treatment groups contained high levels of fibrosis, adipose 
infiltration, low levels of muscle regeneration, and poor maintenance of tissue volume within the 
defects demonstrating a need for further research on the capability of muscle constructs pre-
vascularized with MVFs to improve regeneration post-VML. 
Utilizing a unique host vessel infiltration technique, Shandalov et. al. investigated the 
potential to promote increased perfusion and anastomosis of their pre-vascularized constructs by 
following a two step implantation protocol[32]. The construct was cultured in vitro for 10 days then 
first implanted around the mouse femoral artery and vein for 1-2 weeks, after which it was 
transferred as a vascularized axial flap to an abdominal wall VML defect site. The study used a 
50% PLLA:PLGA scaffold and tested differences between acellular constructs and those 
containing C2C12s alone, co-culture of HUVECs and human dermal fibroblasts, or a tri-culture of 
C2C12s, HUVECs, and fibroblasts. In the cohort of constructs that had been implanted around 
femoral vessels for 1 week, tri-culture constructs had the highest capillary density and functional 
vessel density (FVD) while among those that had been implanted for 2 weeks, both tri-culture and 
C2C12 monoculture constructs had high CDs and FVDs. Interestingly, for both implantation 
timelines the HUVEC-fibroblast co-culture and acellular constructs resulted in comparatively low 
CD and FVD. The perfusion rate and perfused vascular volume in implanted grafts were quantified 
through the use of ultrasound imaging following injection of a microbubble contrast agent. One 
week of implantation increased both the perfusion rate and perfused vascular volume of tri-culture 
constructs compared to other groups while 2 weeks of implantation caused both tri-culture and 
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C2C12 monoculture constructs to have highly perfused vascular volumes with no difference in 
perfusion rate among all three groups. Overall, earlier vascular network maturity was seen in 
implanted tri-culture constructs with monoculture muscle constructs following close behind given 
an extra week of implantation around femoral vessels. This indicates that implanted myoblasts 
promote vasculogenesis by femoral vessels compared to co-culture constructs containing vessels 
alone. Despite differences between groups after incubation around femoral vessels, fewer 
differences were seen following transfer to an abdominal wall VML defect. Tri-culture constructs 
that had incubated around femoral vessels for 1 week had the highest CD and vessel size but no 
difference was seen between groups for constructs that had incubated around femoral vessels for 
2 weeks. Overall, these results indicate that tri-culture constructs have more rapid integration with 
host vessels when transplanted as a vascularized flap pre-incubated in vivo. Constructs containing 
myoblasts or pre-cultured vessels alone have the potential for equal vascular integration post VML 
when the initial incubation time around host femoral vessels is increased. 
The impact of vessel alignment on engraftment within VML-injured muscle as well as 
methods to tune that alignment were investigated by Rosenfeld et. al[34]. 3D co-cultures of 
HUVECs and neonatal human dermal fibroblasts on gelatin-based scaffolds were cultured for 4 
days then subjected to cyclic strain (10% strain, 1 Hz) for an additional 4 days of culture, resulting 
in vessels aligned diagonal to the direction of strain. Static strain was applied to other constructs 
prior to cell seeding and maintained for the entire 8-day culture period, resulting in vessels aligned 
parallel to the direction of strain. After implantation for 2 weeks in an abdominal wall VML defect 
model, statically-strained constructs preserved their pre-implantation vessel alignment and vessels 
were on average 2.5 times longer than vessels in implanted unstrained control constructs. 
Furthermore, by comparing statically-strained constructs implanted with vessels either aligned 
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with or perpendicular to host musculature, they demonstrated that vessel alignment with host 
muscle cells provides improvements in integration and mechanical durability upon implantation. 
Native skeletal muscle is a highly organized tissue with myofiber and vascular alignment and this 
study provides strong evidence for the importance of promoting blood vessel alignment in 
engineered muscle constructs implanted in VML defects. 
Our group recently demonstrated that electrospun fibrin hydrogel scaffolds induce 
alignment of a vascular network formed by 1:1 HUVEC:ASC co-culture after 11 days in vitro[112]. 
When cultured with C2C12 myoblasts, the electrospun scaffolds promoted dense muscle and 
vascular regeneration in a mouse VML defect of the TA muscle. To enable scale-up to larger defect 
sizes, we tested the ability of pre-vascularized scaffolds lacking myoblasts to anastomose with host 
vessels after a 10-day implantation within the mouse TA VML defect. Implanted human vessels 
anastomosed with host vessels and mosaic vessels were visible that were partially of human and 
partially of mouse origin (Figure 1.10f). In addition, implanted human vessels that were perfused 
with mouse red blood cells were visible within the defect. Despite integration with host 
vasculature, the implanted pre-vascularized scaffolds were ringed with a collagen boundary that 
prevented full integration with the host musculature. Upon further investigation we determined 
that significant collagen was deposited by the ASCs during in vitro culture prior to implantation. 
Previous work utilizing adipose-derived MVFs in a large VML defect reported similar high levels 
of collagen in MVF treatment groups[109], indicating a need for further research into the 
regenerative potential of adipose-derived MVFs and ASCs within the highly fibrotic VML 
environment. 
 In a step forward for clinical translation of pre-vascularized constructs, tri-culture 
constructs containing primary human adult venous endothelial cells (ECs), smooth muscle cells, 
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and myoblasts have been developed and tested in an abdominal wall VML defect model[33,35]. In a 
direct comparison to HUVECs as an endothelial cell source, it was found that the constructs 
containing adult human ECs with adult supporting cells had a higher vessel network complexity 
in both co-culture and tri-culture than those with HUVECs[35]. Upon implantation in an abdominal 
wall defect for 9 days, human vessels at the implanted graft perimeter were mainly replaced by 
host vessels that had vascularized more than 80% of the implants.  The host vessels had infiltrated 
an average of 2 mm into the grafts with no difference based on EC source. Genetic modification 
of primary human adult venous endothelial cells and primary human adult venous smooth muscle 
cells transduced to express angiopoietin 1 (ANGPT1) and vascular endothelial growth factor 
(VEGF), respectively, resulted in increased vessel elongation and maturation in 3D constructs in 
vitro compared to constructs containing non-transduced cells[33] (Figure 1.10g-j). An abdominal 
imaging window was developed to facilitate intravital imaging of vessel growth within the defect 
over time and is a beneficial tool for further research in the vascularization of implanted constructs 
post-VML. Constructs with genetically modified cells also resulted in faster host vessel infiltration 
and increased total vessel length within the defect up to 7 days post-implantation. Interestingly, 
the implanted endothelial cells decreased within the graft area over time and this occurred more 
rapidly with genetically modified cells than controls.  
 There has been significant recent success in the development and characterization of pre-
vascularized muscle constructs both in vitro and in vivo. As stated above, due to the high metabolic 
demands of skeletal muscle tissue, any large-scale VML defect will likely need an implanted 
vascular source to sustain the regenerating muscle tissue. Previous work described above has 
characterized differences in vascularization and muscle regenerative potential related to cell 
sources, in vitro pre-cultivation time, scaffold composition, the application of mechanical strain, 
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and pre-incubation around major host vessels in vivo. A broad range of quantification metrics have 
been developed including the use of trackable fluorescent endothelial cells, vascular perfusion, 
intravital imaging techniques, analysis of blood flow rate, and micro-CT angiography, among 
others. Despite the broad successes in the field thus far, the majority of studies evaluating pre-
vascularized constructs in vivo post-VML have been limited to a rodent abdominal wall defect 
model and it is as yet unclear if similar results would be generated in other muscle types that may 
have significant variations in anatomy. In addition, there is a strong need to evaluate the above 






1.4 Engineering Innervated Skeletal Muscle 
Biology of the Neuromuscular Junction 
 The neuromuscular junction (NMJ) is the site of contact between motor neurons and the 
myofibers within skeletal muscle that they innervate. Motor neuron axons travel from the central 
nervous system to skeletal muscles primarily unbranched and upon reaching the target muscle they 
branch extensively to contact individual myofibers at the NMJ[19]. The primary purpose of the 
NMJ is to convert motor neuron action potentials into muscle contraction. In response to motor 
neuron action potentials and subsequent release of acetylcholine, myofibers undergo membrane 
depolarization, the opening of voltage-gated calcium channels, and an increase in intracellular 
calcium concentration to trigger activation of the contractile apparatus[113]. Postsynaptic 
Figure 1.10. Pre-vascularized constructs for VML treatment composed of varying cell 
populations and demonstrating a variety of in vitro and in vivo quantification methods. a) 
Classification of in vitro network maturity from single endothelial cells to a fully-developed 
vascular network. b) Differences in in vitro vascular morphology between endothelial cell + 
fibroblast co-culture compared to myoblast+ endothelial cell + fibroblast tri-culture. Dense desmin+ 
myotubes are visible in tri-culture. c) Comparison of vascular network morphology in in vitro 
constructs containing GS1-Lectin + freshly-isolated MVFs (i) in combination with GFP+ primary 
rat myoblasts or (ii) MVFs alone. d) Comparison of perfusable vessels within abdominal wall VML 
defects via lectin (i) and luciferin (ii) perfusion. VML treatments contained either myoblast 
monoculture, myoblast + endothelial cell co-culture, or myoblast + endothelial cell + fibroblast tri-
culture. e) Co-culture of RFP+ HUVECs and HFFs implanted in abdominal wall VML defect. 
Perfusion with FITC-dextran demonstrates anastomosis of host and implanted vessels. f) 
Immunohistochemistry demonstrating anastomosis of a human vessel (Hu-CD31) from pre-
vascularized electrospun scaffolds (ASCs + HUVECs) with a host vessel (Ms-CD31) within a TA 
VML defect. g) Abdominal imaging window (AIW) provides novel method for intravital confocal 
imaging of vascular infiltration into an abdominal wall VML defect. h) Visualization of host vessels 
(blue; Ms CD31), perfused vessels (red; dextran), and implanted human endothelial cells (green; 
Hu ECs) below the abdominal imaging window. Implanted tri-culture constructs contained human 
endothelial cells, smooth muscle cells, and myoblasts and were compared to those angiopoietin 1- 
and VEGF-expressing tri-cultures. Host vessel perfusion with TRITC-dextran (i) enables 
quantification of functional host vasculature (j) when compared to total Ms CD31+ host vessels. 
HUVEC: human umbilical vein endothelial cell; GFP: green fluorescent protein; αSMA: α-smooth 





acetylcholine receptors (AChR) are organized into dense clusters optimized to intercept the 
acetylcholine signal from the nerve terminal. The highly specialized NMJ structure ensures the 
efficiency of signal transfer across the synapse between a motor neuron and skeletal myofiber and 
effective muscle contraction. 
Pre- and Postnatal Development of the Neuromuscular Junction 
 During prenatal development of skeletal muscle tissue, primitive clusters of acetylcholine 
receptors form in the center regions of developing myofibers prior to innervation and independent 
of neuronal signals in a process termed pre-patterning[114,115]. The density of acetylcholine 
receptors within pre-patterned myofibers during embryonic development is approximately 1000 
receptors/μm2. Pre-patterned cluster formation and stabilization is partially induced by the 
myofiber membrane-associated cytoplasmic protein rapsyn[114]. Rapsyn forms aggregates with 
acetylcholine receptors in the developing myofiber membrane, facilitating cluster formation, and 
mice lacking rapsyn do not form AChR clusters within their muscles. The muscle specific receptor 
tyrosine kinase, MuSK, is also vital to proper AChR clustering and NMJ formation and mice 
lacking MuSK also have no clusters of AChR. As motor neuron axons grow into the developing 
muscle, AChR clusters at synaptic sites contacted by a nerve are stabilized and enlarged while 
AChR clusters not contacted by the infiltrating nerve axons disperse over time (Figure 1.11). At 
this stage in development the AChR clusters are each poly-innervated by two or more axons. 
Agrin, a large heparan sulfate proteoglycan, is secreted by the nerve terminal and is vital for AChR 
cluster stabilization and prevention of AChR dispersal[114]. In fact, mice lacking agrin die in utero 
or at birth due to NMJ dysfunction[116]. The AChR density at synaptic sites increases dramatically 
as the muscle develops to approximately 10,000 receptors/μm2 and in adult muscle can reach 
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20,000 receptors/μm2 at the NMJ[117]. Non-synaptic AChR, by contrast, are present at a low density 
of <10 receptors/μm2.  
During postnatal development, neurons are pruned to single contact at each synaptic site 
and as the muscle matures, around half of the motor neurons innervating the developing muscle 
degenerate[114]. The AChR clusters mature and undergo a morphological change from an immature 
oval-shaped plaque morphology to a more mature pretzel shape[117]. This transition is caused by 
folding of the postsynaptic membrane and localization of dense AChR clusters at the fold 
crests[114]. Additionally, as the muscle matures, locations along the nerve terminal outside of the 
synaptic cleft are covered by a synaptic non-myelinating Schwann cell. Interestingly, ECM 
proteins within the neuromuscular synapse differ from the general basal lamina surrounding 
myofibers outside of the synapse. The two major basal lamina proteins, collagen IV and laminin, 
have different isoforms within the synaptic region. Differences between synaptic and extrasynaptic 
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ECM proteins has been reviewed elsewhere[117] and synaptic ECM proteins have been shown to 
play a vital role in NMJ development. 
Mature Neuromuscular Junctions in Adult Muscle 
The adult vertebrate NMJ exhibits a complex pretzel morphology due to folds within the 
postsynaptic membrane that correlate with the spatial location of nerve terminal boutons to enable 
a high efficiency of signal propagation[19]. The folds penetrate approximately 1 μm into the 
Figure 1.11. Pre- and Post-Natal Development of the Neuromuscular Junction. During 
embryonic development the immature muscle is pre-patterned with immature plaque-shaped 
AChR clusters prior to nerve contact. Following polyinnervation, nerve-secreted agrin stabilizes 
contacted AChR clusters while extrasynaptic clusters disperse. During postnatal development, 
neurons are pruned to single contact with myofibers and agrin helps to refine AChR clusters 
morphology. Adult skeletal muscle is highly organized with one neuron innervating each 
myofiber at the NMJ, which exhibits a mature, pretzel morphology with direct overlap between 
the presynaptic nerve terminal bouton and the postsynaptic AChR clusters. 
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cytoplasm of the muscle cell and significantly increase the area of the postsynaptic membrane. 
Each terminal bouton is 1-5 μm wide and upon activation releases numerous 50 nm diameter 
membrane-bound synaptic vesicles containing acetylcholine to be received by the highly dense 
postsynaptic AChR clusters. The synaptic cleft, the space between the presynaptic nerve terminal 
and postsynaptic myofiber membrane, is approximately 50 nm wide and filled with large 
molecules that ensure NMJ ultrastructural organization and efficient signal propagation from nerve 
to muscle[115]. In adults, each myofiber is innervated at its NMJ by a single axon from a motor 
neuron[115]. Motor neurons branch within the muscle tissue to innervate multiple myofibers, termed 
its motor unit, and myofibers within a motor unit are generally distributed throughout the muscle 
to ensure uniform contraction.  
 Native neuromuscular regeneration and repair of NMJs can occur following peripheral 
nerve lesions depending on the severity of injury[115]. Nerve axons undergo Wallerian degeneration 
whereby the axon cell membrane degrades, axon cytoskeleton and organelles disintegrate, and 
terminal Schwann cells invade the NMJ synaptic cleft with the debris cleared by recruited and 
resident macrophages. Interestingly, it has been shown that despite severe disruptions to pre-
synaptic nerve axons following denervation, the number of acetylcholine receptors remains 
unchanged up to 20 days post-injury then drops by 50 and 70% at 30 and 60 days post-injury[118]. 
Despite this, after denervation the AChR become dispersed from their synaptic clusters and are 
present throughout the myofiber surface[119]. Regeneration begins at the axon proximal end and in 
small injuries, the regenerating axon grows following its previously occupied location to 
preferentially re-innervate original synaptic locations or axons may sprout from neighboring 
NMJs[120]. Following severe injury where the basal lamina is disrupted, regenerating nerves may 
innervate new locations along the myofiber with the potential for poly-innervation. As the 
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regenerated NMJ matures, reorganization occurs to ensure mono-innervation and AChR cluster 
arrangement. Concurrent muscle regeneration is vital for proper maintenance of regenerated NMJs 
and re-innervated NMJs on basal lamina ghosts lacking myofibers decline over time. In addition, 
satellite cell function has been connected to NMJ regeneration post-injury with reductions in 
postsynaptic morphology, loss of postsynaptic myonuclei, and deficits in NMJ reinnervation 
linked to satellite cell depletion[115].  
Strategies to Enhance Neural Ingrowth and Formation of NMJs in TEMGs 
 The formation of neuromuscular junctions in tissue engineered muscle constructs both in 
vitro and post-implantation is important for ultimate function of the engineered muscle. Significant 
research has been performed on NMJ biology, development, and regeneration using in vitro NMJ 
models and is described briefly below. In vivo formation of NMJs has included the incubation of 
3D skeletal muscle constructs along major nerves, neurotization, and the use of rehabilitative 
exercise. The following sections will provide an overview of in vitro engineered NMJs and focus 
on studies promoting NMJ formation in vivo within VML-injured muscles. Methods and 
biomaterials utilized to encourage neuromuscular regeneration post-VML are summarized in 
Table 1.3. 
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Engineered NMJs In Vitro 
 The development of in vitro NMJs has been the focus of previous reviews and has provided 
a vital tool for the analysis of NMJ development and function[122]. Co-culture of neurons and 
myoblasts both in monolayer or 3D constructs has enabled in vitro NMJ formation where 
electrically induced nerve stimuli result in measurable post-synaptic potentials and contractile 
activity in myofibers[123–125]. To demonstrate that this interaction functions via conventional NMJ 
interactions, nerve-induced myofiber activity can be prevented by application of the AChR blocker 
D-tubocurarine[126]. Dixon et. al. recently described the development of the first fully human 3D 
nerve and muscle co-culture system using human primary skeletal myoblasts and human induced 
neural stem cells within a collagen/Matrigel scaffold[127]. In a recent study by Vila et. al., the first 
human patient-specific tissue engineered in vitro NMJ system was developed using primary human 
skeletal muscle cells and muscle-derived hiPSCs differentiated into motoneurons within a 
collagen/Matrigel scaffold[128]. To monitor NMJ function, they utilized photosensitive 
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motoneurons to form light-sensitive NMJs and developed an optical stimulation platform to 
quantify NMJ activity and muscle contraction. The significant advancements in the development 
of human NMJs within 3D in vitro constructs in recent years have provided useful tools for patient 
disease monitoring and drug screening and could provide significant benefit to studies assessing 
neuromuscular regeneration following VML. 
 In vitro AChR clusters are a vital postsynaptic component of the NMJ and have been 
induced in both monolayer and 3D culture of myoblasts through the use of various pharmacologic 
agents (including agrin and laminin) as well as via electrical stimulation[129]. Agrin is present in 
the developing and adult NMJ responsible for stabilizing AChR clusters and has been extensively 
researched for its ability to induce AChR clustering and promote NMJ formation in cultured 
myotubes[130–138]. Laminin is an extracellular matrix protein present in skeletal muscle with various 
isoforms present at different stages of development as well as within the neuromuscular synapse 
versus extrasynaptically[117]. Significant variability exists in protocols of agrin application with 
concentrations ranging from 10 ng/ml to 10 μg/ml and inconsistencies in time point and duration 
of application. Despite variability in application, it remains clear that agrin application provides a 
significant stimulus to cultured myotubes to cause clustering of AChRs. Interestingly, this differs 
from the native biological function of agrin during embryonic development, which as described 
above does not induce AChR clustering itself but rather stabilizes the pre-formed clusters in the 
developing muscle. Additionally, the morphology of agrin-induced clusters appears limited to an 
immature plaque shape as opposed to developing into a mature cluster pretzel morphology as 
demonstrated by an interesting study by Bruneau et. al[137]. In that study, cluster formation induced 
by both agrin and laminin was evaluated with AChR fluorescence tracked over time. Significant 
differences in cluster morphology were present when induced with the two agents and it was 
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demonstrated that agrin application following an initial laminin application stimulated 
acetylcholine receptors to transfer from a pretzel-shaped laminin-induced cluster to the more 
immature agrin-induced cluster. This effect was seen after just one hour of agrin application and 
resulted in the complete disappearance of the larger laminin-induced clusters after just 24 hours. 
Other studies have found that the combined application of agrin and laminin induced significantly 
more AChR clustering than agrin or laminin alone[131,138]. The potential of agrin pre-treated 
constructs to promote innervation post-implantation was assessed using a fibrin gel containing 
C2C12 myoblasts and 1 μg/ml agrin[130]. Following subcutaneous implantation near the peroneal 
nerve for up to 8 weeks, implanted constructs that had been pre-treated with agrin exhibited 
significantly more nerve infiltration in vivo. While this study is a promising first step, further 
investigation is required on the potential for agrin or other pharmacologic agents to encourage 
neuromuscular regeneration within the severely damaged VML environment. 
Neurotization Post-VML 
Neurotization is the process of surgically re-innervating muscle fibers by insertion of a 
donor nerve within the muscle tissue[119]. Clinical use of neurotization to repair peripheral nerve 
injuries is limited as it is considered an inefficient method to repair innervation at the motor 
endplate[119]. Despite this, neurotization continues to be a useful experimental tool to study 
innervation of implanted engineered tissues including skeletal muscle. Few studies have directly 
investigated neurotization as a method to innervate an implanted 3D construct in VML-injured 
muscle. Most studies assessing the benefits of neurotization for muscle tissue engineering have 
utilized non-VML models such as denervation of host muscle via nerve transection[139], 
subcutaneous implantation[140], and other non-muscle defect models[141]. Due to differences in 
neural infiltration and NMJ recovery between small muscle injuries versus after VML with its 
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associated gross loss of the basal lamina, further investigation is necessary on the innervation 
potential of neurotization within the extensively damaged VML environment. 
The potential regenerative benefits of neurotization were characterized post-VML and 
compared to non-neurotized controls in a notable recent study. Kaufman et. al[86] implanted a pre-
vascularized 3D muscle construct within a mouse abdominal wall VML defect model and nerve 
infiltration was encouraged via neurotization of the femoral nerve within the femoral bundle, 
which was transferred to the implanted construct. In control constructs, the femoral vessels were 
transferred to the implant without the femoral nerve. After 6 weeks spontaneous electrical activity, 
a marker of poor muscle innervation, was measured via EMG within the implant region. 
Neurotized grafts had no spontaneous activity while 5 out of 7 control non-neurotized grafts 
presented with spontaneous activity. Compound motor action potential (CMAP) was measured 
following stimulation of the transferred portion of the femoral nerve and compared to uninjured 
muscle as well as non-neurotized controls. CMAP amplitude for neurotized samples reached 0.6 
mV whereas control samples had no measurable CMAP. Both neurotized grafts and controls 
contained β3-tubulin-positive neurofilament with significantly more area coverage in neurotized 
grafts. Longitudinal sections enabled visualization of NMJ size and morphology and although 
smaller than within uninjured muscle, NMJs with overlapping neurofilament or synaptophysin and 
acetylcholine receptor clusters were visible within the implanted constructs in both groups (Figure 
1.12). The promotion of increased innervation within implanted 3D muscle constructs post-VML 
is significant and NMJs were visualized longitudinally, allowing for proper assessment of NMJ 
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size and morphology. Despite this, no quantification of NMJ size, morphology, or extent of neural 
and acetylcholine receptor cluster overlap was reported and would be of benefit to the field.  
Rehabilitative Exercise Post-VML 
 Physical rehabilitation is often considered to be beneficial for muscle healing and 
accelerates the repair of small, acute muscle injuries via immune modulation, promotion of 
vascularization, release of pro-myogenic growth factors, and reduction of fibrosis[142–144]. 
Following VML, physical rehabilitation has been used clinically in an attempt to promote 
increased muscle strength in the remaining muscle and synergist muscles in order to offset the 
funtional deficit cause by the injury but results have been limited and physical therapy has not 
resulted in clinically meaninful improvements in range of motion, limb function, or muscle 
strength post-VML[15,16]. The emerging field of regenerative and rehabilitative medicine aims to 
Figure 1.12. Improved functional outcomes and NMJs within VML-injured muscle 
following neurotization. a) Abdominal wall defects treated with a neurotized pre-vascularized 
construct. b,c) Compound muscle action potential (CMAP) of native muscle, neurotized graft, 
and non-neurotized control. CMAP amplitude of neurotized grafts was significantly higher than 
non-neurotized control. d) Longitudinal view of NMJ morphology present within the defect 
site. TUB: tubulin; ACHR: acetylcholine receptors; SYN: synaptophysin.  
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combine the rehabilitative effects of physical exercise with regenerative outcomes and de novo 
tissue formation. Application of this aproach to VML injured muscle has been recently 
reviewed[15,145].  
To investigate the potential of physical rehabilitation to enhance regeneration of the lost 
muscle tissue, Aurora et. al. utilized a rat VML defect of the TA muscle and assessed the 
regenerative impact of 1 or 7 weeks of voluntary caged wheel exercise on the injured muscle 
beginning 1 week post-injury[142]. After 7 weeks of exercise, maximal torque output of TA muscles 
in exercised rats was 17% higher than in sedentary rats. Despite improved function, muscles in 
exercised rats contained signficantly more fibrosis within the defect region compared to those of 
sedentary rats and had upregulated pro-fibrotic genes. Exercise also resulted in double the amount 
of centrally-nucleated myofibers within the remaining muscle compared to sedentary controls, an 
indication of chronic injury and remodeling. Clinical use of physical rehabilitation following ECM 
treatment of VML-injured muscle has also resulted in improved functional outcomes[60,62] and may 
be a useful tool for encouraging neural infiltration post-VML. 
Quarta et. al. recently directly assessed the impact of exercise on neural regeneration 
following a VML defect in mice of the TA muscle through the use of either voluntary caged wheel 
running or higher intensity treadmill running[21]. Using caged wheel exercise, it was determined 
that mice regained their pre-injury daily running habits 1 week post-injury. To further validate this, 
forced treadmill exercise within the first week post-injury resulted in delayed muscle regeneration 
and increased fibrosis while exercise delayed by one week post-injury resulted in accelerated 
myogenesis and decreased fibrosis. Following treatment with 3D constructs composed of primary 
mouse satellite cells and muscle resident cells on a decellularized ECM scaffold and one week of 
recovery post-injury, mice were exercised on treadmills for one hour per day over a period of 3 
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weeks. Exercised mice demonstrated a 20% improvement in gait analysis and significant 
improvements in neural-stimulated and ex vivo force output compared to sedentary controls. In 
addition, exercised mice had increased levels of AChR clusters and NMJs within the defect 
compared to muscles in sedentary mice (Figure 1.13a-c). Interestingly, differences between 
groups was more pronounced in the distal portion of the muscle, perhaps due to variability in NMJ 
location and motor endplate patterning of the native muscle tissue. While significant in its detailed 
analysis of functional output and NMJ formation following exercise, this study would benefit from 
further analysis of the morphology and maturity of regenerating NMJs through the use of 
longitudinal sectioning and image analysis of the entire NMJ structure. 
 The impact of voluntary caged wheel exercise on muscle regeneration post-VML was 
further investigated by Nakayama et. al., who implanted either topographically aligned or 
randomly-oriented collagen scaffolds within a mouse VML defect of the TA muscle and began 
voluntary exercise 1 week post-injury for a period of 2 weeks[84]. The presence of AChR clusters 
and NMJs was quantified in muscle within 500 μm or 1000 μm of the implanted scaffold (Figure 
1.13d,e).  Aligned scaffolds with exercise resulted in increased levels of AChR clusters and NMJs 
in muscle within a 500 μm distance from the scaffold. Randomly-oriented scaffolds with exercise 
demonstrated increases in AChR clusters and NMJ formation when the analysis was expanded to 
include muscle within a 1000 μm distance from the scaffold. Although it is signficant that exercise 
increased neural regeneration within muscle at varying distances surrounding the defect, it would 
be more informative to quantify neural regeneration within the defect and the implanted scaffold 
itself. In addition, analysis of nerve-evoked muscle function would further demonstrate any 
improvements to neural regeneration and muscle function due to exercise. Future studies on the 
regenerative potential of rehabilitative exercise should include a broad array of quantitive 
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measures including both muscle function and histological regeneration as well as neurally-
stimulated force output and/or EMG with CMAP. To robustly assess neural regeneration post-
VML and provide further understanding of this complex injury environment, studies should also 
quantify nerve infiltration to the defect site, the presence of NMJs (with overlapping AChR cluster 
and nerve stains), and 3D NMJ morphology and size. 
 
1.5 Conclusion and Future Directions 
 In this review we have summarized the current state of the field of skeletal muscle tissue 
engineering for VML treatment with a focus on engineering vascularized and innervated muscle. 
Significant variability exists in the composition of engineered muscle constructs, preclinical VML 
Figure 1.13. Improved functional outcomes and NMJs within VML-injured muscle 
following rehabilitative exercise. a-c) Primary mouse satellite cells and muscle resident cells in 
TA VML defects had improved force output and NMJ formation following treadmill exercise. 
d,e) Acellular aligned collagen scaffolds implanted in TA VML defects had increased NMJ 
formation in muscle surrounding the defect area following voluntary caged wheel exercise. 
SynPh: synaptophysin; NFL: neurofilament; αBTX: α-bungarotoxin. 
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defect models, and measured outcomes following implantation. In order to effectively compare 
results between studies, the field would benefit from increased standardization of defect models 
and outcome measures. Native skeletal muscle has highly organized vascular and neural networks 
which must be considered when engineering skeletal muscle constructs and analyzing in vivo data.  
Host vessel infiltration or pre-vascularization of constructs prior to implantation are 
reliable methods to promote vascularization of implanted constructs. Significant progress has been 
made in the field of vascularized skeletal muscle tissue engineering but continued research on pre-
vascularized construct translatability to varied muscle types and within large animal VML defect 
models is required. Promoting neural regeneration post-VML is a relatively early area of research 
and primary methods to encourage innervation of regenerating muscle post-VML are neurotization 
and rehabilitative exercise. Although both methods have resulted in moderate successes, there is a 
need for further research on innervation post-VML and for the incorporation of improved 
quantification techniques to measure nerve ingrowth and NMJ morphology and maturity within 
the defect site. Intravital imaging has recently enabled real-time monitoring of vascular infiltration 
post-VML and would be an exciting and beneficial method for assessing nerve ingrowth as well. 
Additionally, growth factor release from implanted constructs within VML defects has been 
investigated for its pro-angiogenic potential. Growth factor release is an obvious choice to promote 
neural regeneration as well.  Based on current publications, there is no evidence that it has been 
investigated in the VML environment to date. Future studies should focus on the development of 
novel technologies to encourage robust vascular and neural regeneration following VML as well 
as useful quantification metrics. Future studies should also incorporate robust quantification of 
immature, developing vasculature and nerves and enable a correlation between the regeneration 
state of the tissue and any improvements in functional outcome in order to delineate minimum 
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requirements for functional regeneration post-VML (Figure 1.14). Further investigation into the 
presence of potential synergistic effects of regenerating vasculature and nerves in the post-VML 
environment may also improve the design of engineered treatments. 
Figure 1.14. Integration of implanted pre-vascularized and neurotized engineered skeletal 
muscle construct into host musculature. VML treatment with an in vitro pre-vascularized 
muscle construct results in anastomosis with host vasculature and dense perfusable vessels. 
Neurotization enables host neural infiltration to the implanted construct with regenerating 
neuromuscular junctions. Vasculature and nerves within the construct region show a mid-stage 
regenerating phenotype post-VML, with lower vascular density and organization, poly-
innervation, and immature plaque-shaped neuromuscular junctions. 
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Future studies developing treatments for VML should also consider differences in 
regenerative potential between acute and chronic VML defects. Most prior studies have evaluated 
engineered skeletal muscle constructs within acute VML defects, where the VML injury was 
created immediately before construct implantation. In the clinical reality, however, chronic VML 
is much more common whereby a VML injury is sustained and treatment is only available months 
or even years later. Few studies have directly compared the regenerative potential of an engineered 
muscle construct in acute versus chronic VML[21] and significant differences in regeneration are 
likely due to variation in the muscle regeneration timeline. In addition to incorporating 
consideration of variability due to the age, sex, and anatomical location of preclinical models, 
future studies should also consider treatments that would translate well to a chronic VML 
environment. 
 
1.6 Specific Aims 
 The overall goal of this thesis was to develop an implantable 3D muscle construct to 
regenerate volumetric muscle loss defects. To accomplish this goal, initial studies focused on 
scaffold design and regenerative capabilities when cultured with C2C12 myoblasts. Next, the 
myogenic potential of two translatable human cell sources was evaluated in vitro on electrospun 
scaffolds and in vivo in a range of critical and sub-critical muscle defects. Lastly, scaffolds were 
chemically modified to promote neuromuscular regeneration through the delivery of a 
proteoglycan to cultured myoblasts in vitro and within the regenerating VML environment 
following implantation. These studies are summarized by three Specific Aims: 
Aim 1: Develop a 3D engineered muscle construct with C2C12s on electrospun fibrin 
and successfully treat a murine VML defect (Chapter 2) 
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Aim 2: Investigate the myogenic potential of translatable cell sources on electrospun 
scaffold in vitro and in vivo (Chapters 3-4) 
Aim 3: Enhance neuromuscular regeneration in VML defect via in vitro pre-treatment of 





Chapter 2 Development of a 3D Engineered Muscle 




Volumetric muscle loss (VML) is a defect impacting greater than 20% of an individual 
muscle volume overwhelming muscle’s natural repair mechanisms and leading to chronic 
functional deficits [146]. Current treatments are limited and include transfer of an autologous free 
muscle flap [36], muscle transposition [146], or amputation and power bracing [36], all of which have 
major limitations. Donor site morbidity, lack of donor tissue, and the need for a highly skilled 
surgical team complicate VML treatment and decrease positive patient outcomes [36]. Tissue 
engineered grafts have great potential to create clinical treatment options for regeneration of VML. 
Decellularized extracellular matrix (dECM), both acellular and cell-seeded, has been extensively 
investigated as a scaffold to treat VML and evaluated in preclinical [6,21,46,55–57] and clinical [58,60,61] 
models with varied results. Despite some improvements to muscle function, results with acellular 
dECM lack significant myofiber formation, while cell-seeded dECM is limited by batch-to-batch 
variability, poor mechanical durability, and potential immunogenicity. Other scaffold materials 
used in preclinical models to treat VML include collagen [83], hyaluronic acid [85], fibrin [24,49,70], 
poly(lactic acid)/poly(lactic-co-glycolic acid) [32], keratin [71,72], gelatin [88,89], and methacrylated 
gelatin [90]. Despite improvements to muscle function, formation of regenerating myofibers, and 
vascular infiltration, there has yet to be a scaffold system that enables the formation and long-term 
survival of dense myofibers and vasculature to mimic that of native skeletal muscle.  
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Our group has recently demonstrated the capacity to enhance the bioactivity and 
biocompatibility of naturally occurring fibrin by electrospinning it into microfiber bundles with 
alignment topography, tunable substrate stiffness, and controllable porous architecture [147]. Fibrin 
is an ideal scaffold material because it is FDA-approved, biodegradable, has tunable chemical and 
mechanical properties, and has been used previously for tissue engineered skeletal muscle with 
promising results [24,49,70]. Alignment cues enhance stem cell myogenic differentiation as well as 
myocyte fusion [148,149] and substrate stiffness impacts stem cell differentiation and myogenesis 
[150,151]. The electrospun hydrogels are also suturable and can be bundled to offer scale-up 
capabilities. Here we developed axially aligned fibrin hydrogel microfiber bundles with an elastic 
modulus similar to native muscle and evaluated their ability to support the development of mature, 
contractile skeletal muscle constructs using C2C12 myoblasts. Moreover, we assessed the ability 
of the electrospun hydrogels with and without C2C12s to treat VML in a murine model in which 
30-50% of the tibialis anterior (TA) muscle was removed. We tested the hypothesis that the 
combination of C2C12s on electrospun hydrogels promotes muscle regeneration and functional 
recovery compared to scaffold alone or no repair. In addition, we tested the ability of pre-
vascularized electrospun hydrogels to provide an implanted vascular source and enable eventual 
scale-up to larger injury models. 
 
2.2 Materials and Methods 
Electrospinning Fibrin Scaffolds 
Scaffolds were fabricated as described previously [147]. Briefly, 1% fibrinogen (Sigma) or 
sodium alginate (Sigma) were extruded in parallel with 3-5 kV applied to form hydrogel microfiber 
bundles. Fibrinogen remained constant at 4 ml/hr while alginate concentrations and extrusion rates 
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were varied to alter scaffold properties (Fig. 3.2E). Scaffolds with 15% alginate were utilized for 
experiments. Additional details are described in 3.5 Supplemental Methods. 
Characterization of Scaffold Pore Size, Porosity, and Stiffness  
Scaffolds frozen in OCT (Tissue Tek) were sectioned with a cryostat (10 μm; Leica). 
Porosity was quantified using Hematoxylin & Eosin (H&E, Sigma) stained sections with ImageJ 
(NIH) and defined as the pore areas divided by total scaffold area (n=2–6). Scaffolds were also 
loaded into a custom bioreactor and stiffness analyzed as described previously [152]. Briefly, 
scaffolds were adjusted to zero strain then stretched to 10% strain at 1% strain/s as force sensors 
generated a stress-strain curve. Stress data was filtered using the Savitzky-Golay filter to remove 
cyclic noise from the motor. 
Cell Culture and Seeding on Scaffolds 
C2C12s (ATCC) were used at passage 8. A seeding volume of 40 μl at 7,500 cells/μl was 
pipetted onto scaffolds in 5 μl droplets and incubated for 1 hour at 37°C, after which C2C12 
Growth Medium with 30 μg/ml aprotinin (Affymetrix) was added. Samples were differentiated on 
day 3 of culture. Pre-vascularized scaffolds were seeded with a 1:1 ratio of human umbilical vein 
endothelial cells (HUVECs; Lonza) and passage 3 primary human adipose-derived stem cells 
(ASCs) isolated as previously described [153] for a total seeding density of 300,000 cells/scaffold.  
Whole Mount Immunostaining 
Samples fixed in methanol at -20°C overnight were washed with PBS then blocked and 
permeabilized for 3 hours at 4°C. Scaffolds were incubated with primary antibodies overnight at 
4°C (135 rpm) followed by three 1-hour washes. Scaffolds were then incubated with DyLight 488-
conjugated goat anti-mouse or DyLight 649-conjugated goat anti-rabbit (1:400; Jackson 
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ImmunoResearch) overnight at 4°C (135 rpm) followed by three 1 hour washes with DAPI in the 
second wash (1:2000; Sigma). Samples were imaged with a confocal microscope (Zeiss).  
In Vitro Force Measurement 
Day 7 C2C12-seeded scaffolds were loaded into a custom bioreactor described previously 
[152] with one end clamped to a force sensor. Field stimulation was applied with platinum electrodes 
every 5 seconds at 5-7 V and 50-100 Hz and the resulting force of contraction was measured with 
the force sensor. 
VML Defect Model 
Animal and surgical procedures were approved by the Institutional Animal Care and Use 
Committee at Johns Hopkins University School of Medicine. Bilateral VML defects in female 
NOD-scid IL2Rgnull (NSG) immunodeficient mice (Jackson Lab) were used for all experiments. 
Treatment groups per experiment are detailed in SI. Mice were anesthetized with isofluorane, the 
TA muscle was exposed, and approximately 30-50% of the muscle removed. After bleeding 
ceased, scaffolds were placed in the defect site and ligated on both ends to the remaining TA 
muscle with non-absorbable sutures (6-0 Nylon, Express Medical Supplies) (Fig. 2). Surgical glue 
(Histoacryl, B. Braun) and Reflex wound clips (CellPoint Scientific) were used to close the skin. 
Rimadyl was injected subcutaneously post-surgery for pain management (5 mg/kg). Mice were 
sacrificed by isoflurane overdose and cervical dislocation. Upon harvest, implanted scaffolds and 
surrounding TA muscle tissue were removed and cryopreserved.  
Histology 
Harvested TA muscles were weighed and flash-frozen in OCT with 2-methylbutane 
(Sigma). Samples were sectioned with a cryostat (10 μm) and rehydrated in DI water before 
staining with H&E or Masson’s Trichrome (MT; Sigma). For immunohistochemistry, slides were 
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fixed in methanol or acetone at -20°C for 10 min, rinsed with PBS three times, then blocked for 1 
hour at RT. Slides were incubated with antigen-specific primary antibodies overnight at 4°C. After 
three 15 min washes with PBS, slides were incubated with secondary antibody for 1 hour at RT. 
Slides were washed then mounted with 50% glycerol and imaged on a fluorescence microscope 
(Zeiss). 
In Vivo Functional Testing 
In vivo assessment of mouse TA muscle contractility was performed at 2 and 4 weeks as 
previously described [154]. Briefly, mice were anesthetized with isoflurane and the leg was 
stabilized in a custom-made apparatus. The foot was taped to a foot plate connected to a torque 
sensor and stepper motor and the ankle was positioned at 20° of plantarflexion, which has been 
shown to be the optimum length to achieve maximum ankle dorsiflexor torque (in which the TA 
muscle accounts for the majority of ankle dorsiflexion). Electrodes were placed subcutaneously at 
the fibular head to stimulate the fibular nerve and induce dorsiflexion. Voltage and frequency were 
optimized for each leg during tetanic contractions (300 ms duration) and the maximal isometric 
torque was quantified per leg at each time point (n=7). To also assess resistance to fatigue, each 
TA was subjected to a series of 50 isometric tetanic contractions (one contraction every 2 seconds) 
and the resulting drop in maximal isometric torque and recovery after 2 and 5 minutes were 
quantified (n=7).  
Statistics 
Statistical analysis was performed using GraphPad Prism 5 software. Statistical 
significance for most experiments was determined by one-way ANOVA with Dunnet post-test 
utilizing the uninjured values as control. Statistical significance for myofiber and vascular densities 
67 
 
was determined by one-way ANOVA with Tukey’s post-test. Error bars represent standard error 
of the mean (SE). *: p < 0.05; **: p < 0.01; ***: p < 0.001; ǂ: not significant. 
 
2.3 Results 
Electrospun Scaffold Properties Tailored for Tissue Engineered Skeletal 
Muscle 
Electrospun fibrin scaffolds were designed to mimic the hierarchical structure and native 
characteristics of skeletal muscle (Fig. 3.1A). The optimized fibrin scaffolds contain intrinsic 
alignment on the micro-scale, have a porous interior, and are suturable (Fig. 3.1B-D). To control 
porosity and stiffness, fibrin scaffolds were electrospun containing various amounts of alginate, 
which served as a sacrificial polymer to induce porosity (Fig. 3.2). A 15% alginate composition 
was selected for subsequent studies due to its myomimetic stiffness similar to the 12 kPa stiffness 
of native skeletal muscle [151] (Fig. 3.1E) and high internal porosity. Topographical alignment cues 
enable alignment of a range of cell types (Fig. 3.3), a vital component of functional skeletal muscle 
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constructs that enables uniaxial contraction and has been shown to contribute to myogenesis 
[148,149]. 
Figure 2.1. Fabrication of electrospun fibrin scaffolds. A) Schematic of hierarchical 
structure of electrospun scaffolds. B) Scanning EM of microscopic scaffold structure and 
alignment. C) Longitudinal section of 15% alginate scaffolds stained with H&E demonstrating 
internal porosity. D) Scaffolds bundled and sutured into muscle defects. E) Representative 
stress-strain curve. F) (i) MHC (red) and DAPI (blue) staining of aligned, multinucleated 
myotubes on scaffolds at day 7 with (ii) sarcomeric striations. Inset: C2C12s on glass substrate. 




Figure 2.2. Electrospinning fibrin scaffolds and cell seeding. A) Schematic of scaffold 
fabrication via electrospinning, alginate removal, and subsequent cell seedin. B) Longitudinal 
sections of scaffolds stained with H&E at increasing alginate percentages to assess changes in 
porosity. C) Scaffold porosity and pore area distribution at a range of alginate percentages. D) 
Scaffold stiffness at a range of alginate percentages.  E) Concentrations and flow rates of alginate 






Myoblast-Seeded Scaffolds Form Mature Contractile Muscle Constructs In 
Vitro 
To test the suitability of electrospun fibrin scaffolds as a substrate for mature muscle 
constructs, C2C12 myoblasts were seeded and cultured for 7 days. C2C12s formed densely aligned 
myosin heavy chain positive (MHC+) myotubes along the scaffolds and exhibited multinucleation 
and sarcomeric striations, hallmarks of mature muscle (Fig. 2.1F). In comparison, C2C12s 
cultured on glass coverslips for 7 days formed disorganized myotubes lacking similar alignment 
Figure 2.3. Electrospun scaffolds induce alignment of 
various cell types. Scaffold alignment cues induce cellular 
alignment of C2C12 myoblasts, vasculature formed by 
human umbilical vein endothelial cells (HUVECs) and 
adipose-derived stem cells (ASCs), primary human 




and features. C2C12-seeded scaffolds also exhibited spontaneous contractions and contracted in 
response to electrical stimulation generating approximately 1 mN of force (Fig. 2.1G). To 
potentially increase cell uniformity, an alternate ‘spread’ scaffold structure was fabricated (Fig. 
2.4A,B) and its myogenic potential assessed. C2C12-seeded spread scaffolds exhibited a similar 
density of aligned, multinucleated myotubes compared to ‘bulk’ scaffolds (Fig. 2.4C-E) and 
spontaneous contractions.  
 
Figure 2.4. Altering electrospun scaffold morphology maintains alignment cues with C2C12 
cell density. (A) Dense alignment of MHC-positive C2C12 myotubes are present on both bulk and 
spread scaffolds at day 7. (B) DAPI (blue) and brightfield (gray) images of scaffold cross-sections 
demonstrating no significant difference in cell density between bulk and spread scaffolds at 7 days. 
(C) Quantification of C2C12 percent coverage between bulk and spread scaffolds demonstrated 
no significant difference in C2C12 density. ǂ: not significant 
 
Regeneration of Murine VML Defects with Myoblast-Seeded Electrospun 
Scaffolds 
An established murine VML defect model [21,46,50] was used to test the regenerative 
potential of C2C12-seeded electrospun scaffolds. Scaffolds were bundled and sutured into the 
defect (Fig. 2.5) for 2 or 4 weeks. Each mouse was treated with bulk scaffolds in the right leg and 
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spread scaffolds in the left leg (n=3). Both bulk and spread C2C12-seeded scaffolds resulted in 
significant levels of muscle regeneration at 2 weeks (Fig. 2.6C) with graft areas densely populated 
with centrally-nucleated MHC+ myofibers and a robust, dense capillary network. Myofiber 
density increased from 2 to 4 weeks for both groups, approaching that of native skeletal muscle, 
whereas vascular density remained high at both time points (Fig. 2.6D). Individual myofiber 
diameters in all groups averaged ~23 μm, which is roughly half the diameter of myofibers in native 
TA muscle (Fig. 2.6E). Treatment groups also exhibited significant volume recovery of the graft 
areas, with total TA cross-sectional areas in treatment groups mimicking that of native TA muscle 
(Fig 2.6F). As spread scaffolds did not confer any advantage in regenerative outcomes, bulk 




Figure 2.5. Murine VML defect and scaffold 
implantation model. Macroscopic depiction of VML 
defect creation via partial TA resection, an empty VML 
defect, scaffold implantation, and morphology of the 
scaffolds within the defect at 4 weeks post-implantation. 
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Myoblast-Seeded Scaffolds Enable Muscle Regeneration but Acellular 
Scaffolds Do Not  
We directly compared three experimental groups (n=7): (i) untreated defects; (ii) acellular 
scaffolds; or (iii) C2C12-seeded scaffolds in the VML model to assess the role of cells and 
scaffolds in regeneration. Approximately 11 ± 3 mg of muscle tissue was resected per defect and 
the contralateral leg remained as an uninjured control. Bundles of 4 acellular or C2C12-seeded 
scaffolds were sutured into the defect site in treatment groups and the defect remained empty for 
the untreated group. Constructs remained in vivo for 4 weeks.  
Figure 2.6. In vivo regeneration of VML defects. A, B) Bulk and spread scaffolds. C) MHC 
(green), CD31 (red), and DAPI (blue) staining of VML defects treated with C2C12-seeded 
scaffolds at 2 and 4 weeks. High densities of centrally-nucleated myofibers (arrows) and 
vasculature are present. Dotted line denotes approximate graft region. H: host muscle tissue. D) 
Myofiber and vascular densities at 2 and 4 weeks (n=18). Red: 2 weeks; Blue: 4 weeks; Green: 
native muscle. E) Myofiber diameters (n=24) and F) cross-sectional areas (n=11) following 
treatment. *: p < 0.05; **: p < 0.01; ***: p < 0.001; ǂ: not significant. Error bars are SE. 
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Figure 3.7. Evaluation of muscle morphology. A) MHC (green) and DAPI (blue) staining at 4 
weeks post-injury compared to uninjured muscle (f: acellular fibrin scaffold). Outlines denote 
approximate graft region. B) Masson’s Trichrome staining demonstrating low fibrosis and 
integration of C2C12 samples. C) H&E staining of cell morphology within the defects. 
Arrowheads denote centrally-nucleated myofibers.  
 
Untreated defects exhibited loss of muscle tissue at the defect site, lacked myofibers, and 
contained significant fibrotic tissue (Fig. 2.7A-C). Remnants of acellular scaffolds could be 
observed at 4 weeks, but exhibited varying levels of fibrosis and lacked the presence of any MHC. 
In stark contrast, defects treated with C2C12-seeded scaffolds exhibited significant volume 
recovery, muscle mass increase, lack of fibrosis, and high myofiber density (Fig. 2.8). In the 
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C2C12 treatment group, myofibers were primarily centrally-nucleated and began to approximate 
the structure of native uninjured TA muscle. 
Figure 3.8. Morphological Characteristics. A) Mouse body and TA weights at various time 
points. B) TAs containing C2C12 constructs weighed significantly more than other groups. Values 
are means ± SE (n=4-5). * p < 0.05. 
 
Defects treated with acellular scaffolds exhibited disorganized laminin deposition within 
the scaffold interior, but had no myofibers present at 2 weeks. In contrast, defects treated with 
C2C12s had organized circular myofibers with a laminin structure similar to uninjured muscle 
(Fig. 2.9A). Embryonic myosin, a transient marker of regenerating skeletal muscle, was evident 
in C2C12-treated defects at 2 weeks with expression decreasing by 4 weeks. Defects treated with 
acellular scaffolds did not express embryonic myosin at 2 weeks, suggesting that the regeneration 
seen in C2C12-treated groups was due to the implanted cells (Fig. 2.9B). Myofibers in C2C12 
treatment groups stained positively for the slow-twitch myofiber marker BA-D5 at 4 weeks (Fig. 
2.9C). Significantly, C2C12 treatment groups also exhibited host neurofilament within the graft 
area, suggesting the possibility of functional connectivity between the host nerve and implanted 
muscle constructs (Fig. 2.9D). 
To track implanted cells in C2C12-seeded scaffolds, a subset of C2C12s was transduced 
to express mCherry and luciferase and seeded onto scaffolds. Transduced C2C12s formed aligned 
MHC+ myotubes on the scaffold surface that had similar morphology to non-transduced samples 
and expressed mCherry and luciferase (Fig. 2.10B-E). Bundles of 4 scaffolds containing 
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transduced C2C12s were implanted into bilateral VML defects and luciferase expression was 
quantified. Implanted C2C12s were retained within the defect areas, remained viable, and 
proliferated in vivo up to 28 days (Fig. 2.10A). Vascular perfusion was observed in uninjured 
muscles (Fig. 2.10F) and C2C12-seeded scaffolds (Fig. 2.10G) via tail vein injection of FITC 
dextran and confocal imaging.  
Figure 3.9. Morphologic and functional characterization of regenerating muscle. A) Laminin 
(red) and DAPI (blue) staining demonstrates differences in myofiber size and morphology between 
groups. B) Embryonic myosin (red) and DAPI (blue) staining. C) Slow-twitch myosin (green; BA-
D5) and DAPI (blue) staining. D) Neurofilament ingrowth into the graft region of C2C12 samples 
at 4 weeks is visible with β-tubulin III (pink) and DAPI (blue) staining. Arrowheads show 
neurofilament within host muscle. Scale bars: 500 μm, inset- 50 μm. Outlines denote approximate 
graft region. E) Maximal isometric torque (n=7). (F) Percent fatigue (n=7). * p < 0.05; ǂ: not 




Figure 3.10. Luciferase-expressing C2C12s proliferate within VML defects and contain 
perfusable vasculature. A) Average total flux at each time point demonstrating that C2C12s 
proliferate up to 4 weeks post-transplantation (n=2). Inset: BLI of bilateral VML defects treated 
with scaffolds seeded with luciferase-expressing C2C12s. Signal was localized to the defect region 
indicating a lack of cell migration away from the defects. B) Bioluminescence imaging (BLI) of a 
scaffold seeded with C2C12s transduced to express luciferase (day 8). C) C2C12s expressing 
mCherry (red) in monolayer and D) seeded onto fibrin scaffolds at day 6. E) MHC (red) staining 
of transduced C2C12s at day 7 demonstrates that transduced C2C12s continue to form aligned 
myotubes on scaffolds. F) FITC-dextran (green) injection enables visualization of vascular 
perfusion within native TA muscle and G) defects treated with mCherry+ C2C12-seeded scaffolds 




Myoblast-Seeded and Acellular Scaffolds Both Enable Functional Recovery 
The effects of acellular and C2C12-seeded scaffolds on muscle contractile function were 
evaluated by measurement of maximal isometric torque of the ankle dorsiflexor muscles (Fig. 
3.11A). Muscles containing untreated defects demonstrated ~30% torque deficit compared to 
uninjured controls at 2 and 4 weeks post-injury (Fig. 3.9E). Interestingly, defects treated with both 
acellular and C2C12-seeded scaffolds demonstrated complete functional recovery at both 2 and 4 
weeks post-injury, with maximum isometric torque levels equal to uninjured controls (Fig. 3.9E). 
Muscle resistance to fatigue was also tested via the loss in maximal torque after 50 isometric 
contractions. No significant differences in percent fatigue were present between groups at both 
time points (Fig. 3.9F) although untreated muscles were slower to recover (3.11C).   
Figure 3.11. Fatigue testing between groups. A) Macroscopic depiction of setup for 
measurement of in vivo torque within mouse dorsiflexor muscles. The tibia is stabilized and the 
foot secured against a motor-driven plate, enabling stimulation of the ankle dorsiflexor muscles 
via the fibular nerve and force measurement. B) Representative graph from uninjured TA muscle 
depicting the drop in maximal isometric torque of the dorsiflexor muscles between the first and 
final repetitions of fatiguing isometric contractions enabling the calculation of percent fatigue. C) 
Average isometric torque for all groups was measured over time to quantify resistance to fatigue 




Pre-Vascularized Scaffolds Anastomose to Host Vessels 
Although C2C12-seeded scaffolds implanted in VML defects exhibited a high density of 
vascular infiltration and myoblast survival up to 4 weeks, scale-up to large animal models would 
likely require an implanted vessel source to meet the increased nutrient and oxygen demands of 
larger tissues. Therefore, we tested whether engineering scaffolds with pre-formed vascular 
networks would expedite blood flow throughout the grafts. Electrospun scaffolds were seeded with 
human umbilical vein endothelial cells (HUVECs) and human adipose-derived stem cells (ASCs) 
in a 1:1 ratio and cultured for 11 days to form aligned vessels along the scaffold length (Fig. 
3.12A). Bundles of 4 pre-vascularized scaffolds were implanted into VML defects and harvested 
after 10 days. Implanted human vessels successfully anastomosed with host vessels and exhibited 
perfusion by host red blood cells (Fig. 3.12B-C).  
Interestingly, the implanted pre-vascularized scaffolds exhibited low levels of degradation 
and were each surrounded by a thick collagen boundary (Fig. 3.12D). This is in contrast to C2C12-
seeded scaffolds implanted for a similar amount of time where scaffolds were completely replaced 
by dense myofibers and host vessels, lacking significant collagen deposition. In addition, although 
pre-vascularized scaffolds retained the implanted human vessels, there was little host vessel 
infiltration to the scaffold interior as well as a complete lack of myofibers within the scaffolds 
(Fig. 3.12E-F). Cross-sections of in vitro pre-vascularized and C2C12-seeded scaffolds stained 
with Masson’s Trichrome demonstrated a similar difference in collagen deposition on the scaffold 
surface by ASC:HUVEC co-cultures compared to C2C12s (Fig. 3.12G). To test our hypothesis 
that the collagen on the scaffold surface was deposited by ASCs and prevents integration with 
surrounding host tissue, scaffolds seeded with ASCs were implanted into VML defects for 2 
weeks. ASC-seeded scaffolds had dense collagen boundaries preventing scaffold degradation and 
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integration with host tissue (Fig. 3.13), similar to those seen in implanted pre-vascularized 
scaffolds.  
Figure 3.12. Pre-vascularized scaffolds in VML defect. A) CD31 (green) and DAPI (blue) 
staining of vasculature on scaffolds. B) Pre-vascularized scaffolds implanted in VML defects for 
10 days contained human vessels (green) that anastomosed with host mouse vessels (red; arrow). 
C) Implanted human vessels (green) were perfused with mouse red blood cells (red; arrows). D) 
Masson’s Trichrome staining demonstrating differences in muscle regeneration, collagen 
deposition, and scaffold degradation. E) Mouse (red) and human (green) CD31 staining. F) MHC 
(green) staining. G) Masson’s Trichrome staining of cross-sections from in vitro pre-vascularized 
scaffolds and C2C12-seeded scaffolds demonstrating differences in collagen deposition, scaffold 





Figure 3.13. ASC-seeded scaffolds implanted in VML defects form collagen boundaries. 
Scaffolds seeded with ASCs and implanted in murine VML defects for 2 weeks exhibit significant 
collagen deposition that prevents scaffold degradation and integration with the host. 
 
2.4 Discussion  
Electrospun fibrin scaffolds mimic the hierarchical structure and mechanical properties of 
muscle and provide a pro-regenerative environment for cells. The scaffolds also have the potential 
to be used off-the-shelf and can be stored long-term and rehydrated prior to cell seeding and 
implantation [147]. Prior reports indicate that treatment with acellular scaffolds relies on muscle 
stem/progenitor cell and vascular ingrowth from the remaining muscle tissue and provides 
demonstrable improvements to muscle contractile function, but muscle regeneration has been 
limited [46,54,60] and the need for inclusion of a myogenic cell source to regenerate muscle tissue 
following VML has been demonstrated [46,56,57,72]. Yet cell-seeded scaffolds have been typically 
impaired by fibrosis, an inability to fully recapitulate the myofiber and vascular density present in 
native skeletal muscle, and poor cell viability. This study demonstrates that the pro-regenerative 
environment created by electrospun scaffolds stimulates remarkable vascular and myogenic 
regeneration with little to no fibrosis at the graft-host interface.   
Fibrin has been used previously in skeletal muscle constructs to treat VML with mixed 
results. Murine TA VML defects treated with fibrin microthreads seeded with C2C12s enabled 
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some muscle regeneration, vascular infiltration, and functional recovery 60 days post-
implantation, but regenerated myofibers were bounded by significant collagen deposition and were 
disorganized despite microthread alignment cues [24]. Fibrin microthreads seeded with human 
muscle cells and used to treat murine TA VML defects resulted in high levels muscle regeneration 
and some collagen deposition within the defect at 10 weeks post-implantation, but no vascular 
regeneration was shown [70]. Another study assessed the efficacy of progressive injections of 
C2C12s or human muscle progenitor cells in fibrin to treat murine TA VML defects, which 
resulted in a variable density of vascularized myofiber formation at 4 weeks post-implantation 
with high interior myofiber density but a low density at the graft outskirts [49]. A recent study where 
dECM seeded with primary muscle cells was used to treat a murine TA VML defect resulted in 
high levels of vascularized muscle regeneration 30 days post-implantation where the number of 
total blood vessels per field mimicked native muscle. However, the number of vessels per myofiber 
was around 0.2 and was not compared with native skeletal muscle [21]. In addition, although 
myofiber density within the defect appeared to be high in histological images, the value was not 
compared to native skeletal muscle. In the current study, the electrospun fibrin scaffolds provided 
alignment cues and unique mechanical properties that overcame these limitations. 
 The extent of muscle and vascular regeneration following VML injury when treated with 
C2C12-seeded electrospun scaffolds seen here is a significant improvement over previous 
treatment modalities. Although regenerating myofibers had roughly half the diameter of native TA 
myofibers, the density of myofibers seen as well as the high prevalence of perfusable vasculature 
within the defect was substantial. Myofiber density within the grafts reached 68% coverage of the 
field of view with remaining areas composed of blood vessels and connective tissue, as 
demonstrated by CD31 and laminin staining. Myofibers within the defect contained thicker 
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laminin boundaries and smaller myofiber diameters than native skeletal muscle, which may 
explain the overall difference in myofiber densities. Vascular density in the grafts was higher than 
in native skeletal muscle with an average coverage of 5.3% of the field of view. The blood vessels 
in C2C12-treated defects were significantly larger in cross-sectional area than those seen in native 
muscle, increasing the total area of vessel coverage per field of view compared to native muscle. 
In vivo degradation of electrospun fibrin scaffolds varies depending on the cell type with which it 
is seeded. We have found that C2C12-seeded scaffolds completely degrade 2 weeks post-
implantation and are replaced with dense regenerating muscle and vasculature, while ASC-seeded 
and pre-vascularized scaffolds maintain much of their structure after 2 weeks in vivo and lack 
corresponding regeneration. Interestingly, cross-sections of in vitro C2C12-seeded scaffolds 
exhibit increased porosity and swelling compared to cross-sections of pre-vascularized scaffolds, 
which also contain a dense collagen boundary. It is thus likely that differences in cell-biomaterial 
interactions and subsequent scaffold swelling and degradation contribute to variations in 
regeneration, and that rapid scaffold degradation in response to C2C12s enables the robust muscle 
and vascular regeneration seen here.  
The recovery of volume in C2C12-treated versus acellular or untreated defects is likely due 
to beneficial cell-matrix interactions coupled with survival and growth of implanted cells. It is 
unlikely to be due to hypertrophy of the remaining host muscle in response to injury as this would 
have been present in defects that were untreated or treated with acellular scaffolds as well. ASC-
seeded scaffolds also demonstrate good volume recovery, but cell-scaffold interactions differed 
between ASCs and C2C12 myoblasts. C2C12-seeded scaffolds were completely degraded by 2 
weeks post-implantation, while pre-vascularized and ASC-seeded scaffolds were still present after 
2 weeks and acellular scaffolds were still present after 4 weeks in vivo. Cross-sections of in vitro 
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C2C12-seeded scaffolds exhibited large internal pores and increased swelling compared to cross-
sections of pre-vascularized scaffolds, demonstrating that scaffold remodeling exhibits marked 
differences depending on cell type. In fact, an interesting result of the study was the apparent 
“insulation” of scaffolds seeded with ASCs. The increased collagen deposition surrounding pre-
vascularized scaffolds is unlikely due to an immune response by the host, since immunodeficient 
animals were used and a similar response was not present when C2C12-seeded scaffolds were 
implanted. Our hypothesis that ASCs were the collagen source was supported by experiments with 
ASC-seeded scaffolds without HUVECs, which resulted in distinct collagen boundaries 
surrounding the scaffold as well as a complete lack of scaffold degradation or integration with the 
host. This result was unexpected, as ASCs have been utilized for their pro-regenerative paracrine 
signaling [155–157] and as a myogenic cell source both in vitro [158–161] and in vivo [162–164]. 
Nevertheless, in a study where pre-vascularized collagen scaffolds containing adipose-derived 
microvascular fragments and primary myoblasts were implanted in a full-thickness VML defect 
in the biceps femoris, there was no muscle regeneration and instead significant collagen deposition 
within the defect, supporting our results [109]. The integrative capacity of scaffolds with cultured 
ASCs and the contribution of ASCs to collagen deposition within muscle defects requires further 
investigation.  
Interestingly, both C2C12-seeded and acellular scaffolds recovered the contractile function 
of injured muscle at both 2 and 4 weeks despite the inability of acellular scaffolds to support 
muscle regeneration and the vast difference in myofiber formation between C2C12-seeded and 
acellular treatment groups. A possible explanation for this discrepancy could be the presence of 
scaffold mediated functional fibrosis that has been recently described [46], where the implanted 
scaffold provides a mechanical bridge to prevent prolonged overload injury to the remaining 
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muscle after injury. Implanted acellular scaffolds are thus able to transiently augment or repair 
contractile function without a corresponding presence of regenerating myofibers in the defect area 
[57]. 
 In conclusion, the current study provides a novel construct system containing electrospun 
fibrin scaffolds that, when combined with a myoblast cell source, enable unprecedented levels of 
functional muscle and vascular regeneration. The electrospun scaffolds mimic the stiffness of 
native muscle, contain intrinsic alignment cues, are suturable, biodegradable, mechanically robust, 
and are made from an FDA-approved biomaterial. Interestingly, VML defects treated with 
acellular electrospun scaffolds recovered the muscle’s contractile function similar to C2C12-
seeded scaffolds, despite their lack of corresponding regenerating myofibers. The electrospun 
scaffolds have scale-up potential to larger animal models and support the formation of implantable 
vasculature. 
 
2.5 Supplemental Methods 
Electrospinning Fibrin Scaffolds 
Fibrin scaffolds were electrospun in a sterile environment with sterile solutions. Parallel 
syringes containing solutions of fibrinogen (Sigma) or sodium alginate (Sigma) were connected 
via a y-syringe and extruded by syringe pumps with an applied voltage of 3-5 kV applied to a 27G 
needle tip to form hydrogel microfiber bundles with a range of alginate percentages. The 
fibrinogen solution remained constant at 1% fibrinogen with an extrusion rate of 4 ml/hr. Porosity 
and stiffness was varied by altering alginate solution concentrations and extrusion rates as listed 
in Fig. S1E. Polyethylene oxide (average MZ ~ 4 000 kDa, Sigma) was added to each solution at 
0.2 wt% to increase viscosity during electrospinning. The electrospun hydrogel solutions were 
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collected for 5.75 minutes on a rotating dish (~35rpm) containing 50 mM CaCl2 and 20 U/ml 
thrombin (Sigma) as crosslinking agents. Samples were allowed to crosslink and additional 3-5 
min after electrospinning and were then wrapped around a 1.5 × 3.0 cm acrylonitrile-butadiene-
styrene frame 4 times to yield a hydrogel microfiber bundle ~700 μm in diameter termed “bulk 
scaffolds”. To fabricate “spread scaffolds” the hydrogel was wrapped 8 times along the frame. 
Scaffolds were incubated overnight in 250 mM sodium citrate (Sigma) to dissolve the alginate and 
then transferred to DI water until cell seeding or implantation 
Cell Culture and Seeding on Scaffolds 
C2C12 myoblasts were expanded in C2C12 Growth Medium: high-glucose DMEM 
(Invitrogen), 10% fetal bovine serum (FBS; Atlanta Biologicals), and 1% penicillin/streptomycin 
(P/S; Invitrogen) and used for experiments at passage 8. In preparation for cell seeding, scaffolds 
were incubated in high glucose DMEM for 20 min at 37 °C. The scaffolds were then transferred 
to 6-well cell culture plates coated with 2% agarose type VII (Sigma) to minimize cell adhesion to 
the plate surface, which increases the seeding efficiency. For all experiments, a total seeding 
volume of 40 μl at 7,500 cells/μl was pipetted onto the scaffold surface in a series of 5 μl droplets 
(for a total seeding density of 300,000 cells/scaffold). Scaffolds with cells were incubated for 1 
hour at 37°C with hydration levels maintained by addition of 15 μl of C2C12 Growth Medium 
halfway through. After the 1 hour incubation, 3 ml of C2C12 Growth Medium containing 30 μg/ml 
aprotinin (Affymetrix) was added to each well and care was taken to ensure the scaffolds had been 
submerged in the media. On day 3 of culture myoblasts were transferred to C2C12 Induction 
Medium: high-glucose DMEM, 2% horse serum (ThermoFisher Scientific), 1% P/S, 1% insulin-
tranferrin-selenium (ITS; Corning Cellgro), and 30 μg/ml aprotinin and remained in C2C12 
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Induction Medium for the extent of in vitro culture. Media was changed every other day and 
C2C12-seeded scaffolds were used for experiments on day 7 of culture. 
 Scaffolds seeded with other cell types were seeded following the same protocol and seeding 
density. Pre-vascularized scaffolds were seeded with a 1:1 ratio of human umbilical vein 
endothelial cells (HUVECs; Lonza) to primary human adipose-derived stem cells (ASCs) isolated 
as previously described (41) and cultured in HUVEC Medium: 2% FBS (Lonza), 1% P/S, EGM2-
BulletKit (Lonza), and 30 μg/ml aprotinin. For in vivo experiments pre-vascularized scaffolds 
were implanted on day 11 of culture. Primary human ASCs were expanded in ASC Growth 
Medium: high-glucose DMEM, 10% FBS, 1% P/S, and 1 ng/ml FGF-2 (PeproTech) and seeded 
on scaffolds at passage 3.  
Whole Mount Immunostaining 
Methanol-fixed scaffolds were blocked and permeabilized (Block/Perm) for 3 hours with 
0.2% Triton X-100 and 5% normal goat serum (Sigma) in PBS with 0.1% Tween (PTw). Scaffolds 
were then incubated with primary antibodies diluted in blocking solution overnight at 4°C on a 
rocker at 135 rpm, followed by three 1-hour washes. Primary antibodies included mouse anti-
myosin heavy chain, fast (1:400; Sigma), mouse anti-CD31 (1:500; Sigma), and rabbit anti-desmin 
(1:50; Santa Cruz Biotechnology). Scaffolds were then incubated with DyLight 488-conjugated 
goat anti-mouse or DyLight 649-conjugated goat anti-rabbit (both 1:400; Jackson 
ImmunoResearch) diluted in blocking solution overnight at 4 °C on a rocker at 135 rpm, followed 
by three 1 hour washes. DAPI was incorporated in the second wash at a dilution of 1:2000. Samples 
were then imaged with a Zeiss LSM 510 confocal microscope. To visualize cell morphology of 
ASC constructs scaffolds were fixed with 3.7% formaldehyde at 4°C for 3 hours and then washed 
with PBS three times for 20 min each. Scaffolds were then incubated in Block/Perm for 3 hours at 
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4 °C. A staining solution containing Phalloidin-TRITC (12.5 μg/ml; Sigma Aldrich) and DAPI 
(1:2000) was diluted in 0.1% PTw and incubated with scaffolds for 1 hour at RT on a slow rocker. 
Scaffolds were washed three times for 20 min each in 0.1% PTw then imaged with a confocal 
microscope. 
VML Defect Model 
For initial in vivo testing of C2C12-seeded scaffolds and comparison of bulk versus spread 
scaffold structures, bilateral VML defects in 6 five-month-old female NOD-scid IL2Rgnull (NSG) 
immunodeficient mice (Jackson Lab) were treated with C2C12-seeded bulk or spread scaffolds. 
Each mouse received 4 bulk scaffolds in the right leg and 2 spread scaffolds in the left leg (n=3) 
to maintain equal total amounts of fibrin implanted per leg, as each bulk scaffold is half the volume 
of a spread scaffold. Mice were sacrificed at 2 and 4 weeks post-implantation and samples were 
cryopreserved by flash-freezing in 2-methylbutane (Sigma-Aldrich). For the subsequent C2C12 in 
vivo study 21 two-month-old female NSG mice (Jackson Lab) were used with the right leg 
receiving the VML defect and the left contralateral leg remaining as uninjured control. We 
compared three experimental groups (n=7): (i) untreated defects; (ii) acellular scaffolds; or (iii) 
C2C12-seeded scaffolds. In scaffold-treated groups, 4 scaffolds were bundled and placed in the 
defect site. Acellular scaffolds were incubated for 24 hours in C2C12 Induction Medium with 
aprotinin before implantation. For untreated defects, after muscle removal and cessation of 
bleeding the skin was closed over the empty defect. One mouse from the untreated group was 
euthanized 2 days post-surgery due to complications from the procedure and was excluded from 
analysis. Mice underwent in vivo functional testing at 2 and 4 weeks post-implantation and were 
sacrificed at 4 weeks as described above. The implanted scaffolds were removed along with 
surrounding native TA muscle, weighed, and cryopreserved for histology. For the analysis of 
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scaffolds seeded with mCherry+Luciferase+ C2C12s in vivo, 5 three-month-old female NSG mice 
(Jackson Lab) received bilateral VML defects following the same surgical protocol that were 
treated with bundles of 4 mCherry+Luciferase+ C2C12-seeded scaffolds (n=2), regular C2C12-
seeded scaffolds (n=4), or acellular scaffolds (n=2). Mice were sacrificed at 4 weeks post-
implantation as described above and their TA muscles harvested and cryopreserved. For the pre-
vascularized scaffold in vivo study 4 four-month-old female NSG mice (Jackson Lab) received 
bilateral VML defects following the same surgical protocol as above. Defects were treated with 
bundles of 4 pre-vascularized scaffolds or acellular scaffolds (n=3) or compared to uninjured 
controls. Acellular scaffolds were incubated for 24 hours in HUVEC Medium with aprotinin 
before implantation. Mice were sacrificed at 10 days post-implantation as described above and 
their TA muscles harvested and cryopreserved. For the comparison of ASC-seeded scaffolds in 
vivo, 5 two-month-old female NSG mice (Jackson Lab) received bilateral VML defects treated 
with ASC-seeded or acellular scaffolds (n=3) compared to untreated controls. Mice were sacrificed 
at 2 weeks post-implantation and their TA muscles harvested and cryopreserved.  
Histology 
H&E and Masson’s Trichrome stains were imaged on a Zeiss Axio Imager upright 
microscope. For immunohistochemistry, slides were fixed in ice-cold methanol for 10 min and 
rinsed with PBS three times for 15 min each, then blocked in 10% normal donkey or goat serum 
(Sigma) in PBS for 1 hour at RT. For CD31 staining, slides were fixed in ice-cold acetone for 10 
min instead of methanol, rinsed with PBS, then blocked in 10% normal goat serum (Sigma). Slides 
were incubated with antigen-specific primary antibodies in blocking solution overnight at 4°C. 
Primary antibodies included rabbit anti-laminin (1:100; Sigma Aldrich), mouse anti-embryonic 
myosin (4 μg/ml; DSHB), mouse anti-myosin heavy chain (fast-twitch) (1:400; Sigma Aldrich), 
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mouse anti-myosin (slow-twitch) (5 μg/ml; DSHB), rat anti-mouse CD31 (1:50; BD Biosciences), 
mouse anti-human CD31 (1:500; Sigma Aldrich), mouse anti-mouse TER-119 (1:50; BD 
Biosciences), and rabbit anti-β tubulin III (1:200; Sigma). After three 15 min washes with PBS, 
slides were incubated with Cy3-conjugated donkey anti-mouse, DyLight 488-conjugated goat anti-
mouse, Alexa Fluor 647-conjugated donkey anti-rabbit (all 1:400; Jackson ImmunoResearch), or 
Alexa Fluor 594-conjugated goat anti-rat (1:500; Invitrogen) and DAPI (1:2000) diluted in 
blocking solution for 1 hour at RT. Slides were washed three times for 15 min then mounted with 
50% glycerol and imaged on a Zeiss Axio Observer inverted fluorescence microscope. 
C2C12 Transduction and BLI Imaging 
Serial dilution of lentivirus was performed to determine the optimal multiplicity of 
infection (MOI) for transduction. C2C12s at passage 5 were seeded in a well plate in C2C12 
Growth Medium at a density of 4000 cell/cm2 and allowed to adhere for approximately 5 hours. 
Cells were then transduced with a CMV-mCherry-Luciferase lentivirus (MOI 25) in C2C12 
Growth Medium with 5 μg/ml polybrene. Cells were incubated with lentivirus for 48 hours, 
washed with PBS, and fed with C2C12 Growth Medium. After approximately 8 hours the 
transduced cells were passaged and expanded for further use. Transduced C2C12s were used at 
passage 8 for all experiments and seeded on scaffolds following the above standard protocol. 
Bioluminescence imaging (BLI) was performed on mice implanted with transduced C2C12s to 
assess cell retention. Mice were anesthetized using isoflurane and injected with 150 mg/kg of D-
Luciferin Potassium Salt (Gold Biotechnology, Inc.) 5 min prior to imaging. Images were acquired 
every 2-3 min using an IVIS Spectrum (PerkinElmer Inc.) with medium binning until peak 
luminescence signal was observed. Total proton flux of the region with the implanted scaffold was 
quantified using Living Image Software (Perkin Elmer Inc.). To image in vitro scaffolds seeded 
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with transduced C2C12s, D-Luciferin Potassium Salt was added to culture medium at 150 ug/mL 
30 minutes prior to imaging. Scaffolds were imaged and analyzed using an IVIS Spectrum and 
Living Image Software. 
Vascular Perfusion 
After anesthetizing mice with isoflurane, 100 μl of 10 mg/ml FITC-Dextran (Sigma 
Aldrich) was injected into the tail vein to enable systemic perfusion. Mice were immediately 
sacrificed via isoflurane overdose and cervical dislocation and the TA muscles were harvested and 
stored on ice. Samples suspended in cell culture medium in chamber slides were immediately 
imaged with a Zeiss LSM 510 confocal microscope. 
Quantification of Muscle Morphology 
In the bulk versus spread scaffold study, myofiber and vascular densities at 2 and 4 weeks 
were quantified via ImageJ analysis of areas staining positive for MHC or CD31 in 3 thresholded 
high magnification images within the graft region at 2 different locations per leg. Myofiber 
diameters were quantified using SMASH Matlab analysis (43) of laminin staining in 4 high 
magnification images within the graft region at 2 different locations per leg. TA cross-sectional 
areas were quantified using ImageJ software and manual outlining of whole-muscle section cross-






Chapter 3 Human Adipose-Derived Stem Cells: Assessment 
of Myogenic Potential In Vitro and In Vivo 
 
3.1 Introduction 
 Volumetric muscle loss (VML) occurs when a tissue defect exceeds 20% of an individual 
muscle volume, which overwhelms the natural repair mechanism and leads to chronic functional 
deficits in the affected muscle[146]. Limited treatment options for VML include transfer of an 
autologous free muscle flap[36], muscle transposition[146], amputation, and power bracing[36]. These 
treatments have low success rates in restoring muscle function and at best provide aesthetic 
benefits and prevent further necrosis[36,146]. They are also limited by donor site morbidity, lack of 
donor tissue, and the need for a highly skilled surgical team, which complicate VML treatment 
and lead to unsatisfactory patient outcomes[36]. Tissue engineered (TE) grafts offer a potentially 
more effective regenerative medicine treatment option for VML that may alleviate the varied 
limitations of current treatments and lead to improved functional outcomes. 
A range of materials have been utilized as scaffolds to treat VML with varied results, 
including decellularized extracellular matrix (ECM)[21,46,54–58,60], collagen[83], hyaluronic acid[85], 
fibrin[24,49,165], keratin[71,72], gelatin[88,89], and poly(lactic acid)/poly(lactic-co-glycolic acid) 
(PLA/PLGA)[32]. Our group has demonstrated the capacity to enhance the bioactivity and 
biocompatibility of fibrin by electrospinning it into microfiber bundles with alignment topography, 
tunable substrate stiffness, and controllable porous architecture[147]. Alignment cues have been 
shown to strongly enhance stem cell myogenic differentiation as well as myocyte fusion[148,149]. 
Electrospun hydrogels can be tuned to physiological stiffness to enhance myogenesis, as substrate 
stiffness has been reported to strongly affect stem cell differentiation and myogenesis[150,151]. We 
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have recently successfully treated a murine VML defect consisting of partial resection of the 
tibialis anterior muscle by combining the electrospun fibrin microfiber bundles and C2C12 
myoblasts[25].  
 Adipose-derived stem/stromal cells (ASCs) are clinically translatable and previous studies 
have shown them to be a promising cell source for applications in skeletal muscle 
regeneration[158,162,166–168]. While a number of groups have researched myoblasts[50], satellite 
cells[85], or mesangioblasts[169] for skeletal muscle tissue engineering, the practicality of using these 
cell types for clinical treatments is limited by their low accessibility, low yield, and difficulty in 
long-term culture and expansion[85]. In contrast, ASCs are isolated from lipoaspirate involving a 
more mild procedure and lipoaspirate has 100 times higher stem cell yields than bone marrow, 
another mesenchymal stem cell source with myogenic potential[170]. ASCs also have high stem cell 
proliferation rates[166], can differentiate down the myogenic pathway[158,162,166], provide a pro-
regenerative environment[171], and evade the host immune system[172]. Although many studies have 
assessed in vitro ASC myogenic potential[158,159,173,174,160–164,166,168,170], there have been few studies 
assessing in vivo muscle regeneration using ASCs. It has been shown that ASCs injected into the 
muscles of dystrophic mice could differentiate into dystrophin+ mature muscle cells[162] with a 
pool of replenished Pax7+ satellite cells[168], ASCs seeded onto PLGA microsphere carriers 
transplanted subcutaneously in nude mice formed new muscle tissue after 60 days[164], and NG2+ 
ASCs seeded onto hyaluronic acid scaffolds transplanted subcutaneously in nude mice expressed 
muscle markers after 30 days[175]. Another study assessed the regenerative potential of rat ASCs 
in collagen within a murine VML defect and did not see muscle regeneration, although implanting 
adipose-derived microvascular fragments did result in low levels of muscle regeneration[78]. The 
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ability of rat ASCs in a decellularized ECM matrix to regenerate a murine VML defect was also 
assessed and resulted in low levels of ASC contribution to regenerating myofibers[76].  
Here, we utilized axially aligned fibrin hydrogel microfiber bundles with an elastic 
modulus similar to that of native muscle tissues to evaluate the growth and myogenic 
differentiation of human ASCs seeded on electrospun fibrin microfiber bundles in vitro in the 
absence or presence of biochemical induction cues. Moreover, we assessed the ability of the 
microfiber bundles with and without ASCs to treat a robust murine VML model, in which the 
entire tibialis anterior (TA) and extensor digitorum longus (EDL) muscles were both removed. We 
tested the hypothesis that the combination of human ASCs on electrospun fibrin fibers promotes 
muscle regeneration and that ex vivo differentiation of ASCs down a myogenic lineage prior to 
transplantation would significantly enhance this response.  
 
3.2 Materials and Methods 
Electrospinning Fibrin Fiber Bundles 
Fibrin fibers were electrospun in a sterile environment with sterile solutions using a 
protocol that has been described previously[25,147]. Briefly, parallel syringes containing sterile 
solutions of fibrinogen (Sigma-Aldrich, St. Louis, MO, USA) or sodium alginate (Sigma-Aldrich, 
St. Louis, MO, USA) were connected via a y-syringe and extruded by syringe pumps with an 
applied voltage of 3-5 kV applied to a blunted 27G needle tip to form hydrogel microfiber bundles. 
Polyethylene oxide (average MZ ~ 4,000 kDa, Sigma-Aldrich, St. Louis, MO, USA) was added to 
each solution at 0.2 wt% to increase viscosity during electrospinning. The electrospun hydrogel 
solutions were collected for 5.75 minutes on a rotating dish (~35rpm) containing 50 mM CaCl2 
and 20 U/ml thrombin (Sigma-Aldrich, St. Louis, MO, USA) as crosslinking agents. Samples were 
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crosslinked an additional 3-5 min after electrospinning and were then wrapped around a 1.5 × 3.0 
cm mylar frame 3-4 times to yield a hydrogel fiber bundle ~1 mm in diameter. Fibers were 
incubated overnight in 250 mM sodium citrate (Sigma-Aldrich, St. Louis, MO, USA) to dissolve 
the alginate and then transferred to DI water until cell seeding or implantation. The resulting fibers 
have a tensile modulus of 11 kPa and are suturable and remain elastic when strained up to 50% of 
their length.  
Cell Culture 
ASCs were isolated from lipoaspirate tissue under an IRB approved protocol as previously 
described[153]. Two female donor sources were used: a 39-year old Caucasian and a 63-year old 
African American. In vitro studies utilized ASCs from both donors while in vivo studies utilized 
ASCs from the first donor. Briefly, tissue was digested with collagenase (1 mg/mL; Worthington 
Biochemical Corp., Lakewood, NJ, USA) to isolate the stromal vascular fraction of cells. These 
cells were plated onto tissue culture plastic and were termed “passage 0 ASC” when they reached 
80–90% confluence. ASCs were thawed and expanded for two passages in Growth Medium: high-
glucose DMEM (ThermoFisher Scientific, Waltham, MA, USA) with 10% fetal bovine serum 
(FBS; Atlanta Biologicals, Flowery Branch, GA, USA), 1% penicillin/streptomycin (P/S; 
ThermoFisher Scientific, Waltham, MA, USA), and 1ng/mL FGF-2 (PeproTech, Rocky Hill, NJ, 
USA). The ASCs were then trypsinized and used at passage 3 for all experiments. The phenotypic 
profile of the cells at this passage from both donors was examined via flow cytometry for 
mesenchymal (CD73, CD90, CD105) and vascular markers (CD31, CD34). Briefly, ASCs at 
passage 1 were thawed and expanded as described above. Passage 3 ASCs were then suspended 
in phosphate-buffered saline (PBS) containing 2% FBS and incubated with monoclonal antibodies 
conjugated to fluorescein isothiocyanate or phycoerythrin for 30 min at 4°C. Cells were then 
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analyzed with a flow cytometer (BD Accuri C6, BD Biosciences, San Jose, CA, USA). All 
antibodies were purchased from BD Biosciences. 
Cell Seeding and Growth on Fibers 
Fibers with 15% removed alginate were utilized for all experiments. In preparation for cell 
seeding, fibers were incubated in high glucose DMEM for 20 min at 37°C. The fibers were then 
transferred to cell culture plates coated with 2% agarose type VII (Sigma-Aldrich, St. Louis, MO, 
USA) to minimize cell adhesion to the plate surface and increase seeding efficiency onto the fibers. 
For the seeding density study a seeding volume of 15 μl at either 10,000, 20,000, or 40,000 cells/μl 
was pipetted onto the fiber surface. All subsequent in vitro and in vivo studies used 15 μl at 40,000 
cell/μl (for a total seeding density of 600 000 cells/fiber bundle). Fibers with cells were incubated 
for 1 hour at 37°C with hydration levels maintained by addition of 15 μl of Growth Medium 
halfway through. After the 1-hour incubation, Control Medium (high-glucose DMEM, 10% FBS, 
1% P/S, 30 μg/ml aprotinin (ThermoFisher Scientific, Waltham, MA, USA), and 1 ng/mL FGF-2) 
was added to fully submerge the fibers. Media was changed 24 hours post-seeding and then every 
other day until harvest. 
Myogenic Induction 
Induction of ASCs toward myogenesis was performed with an adapted protocol previously 
described[176]. After 7 days of growth in Control Medium fibers were transferred to Induction 
Medium: low glucose DMEM (ThermoFisher Scientific, Waltham, MA, USA) with 1% FBS, 5% 
horse serum (HS; ThermoFisher Scientific, Waltham, MA, USA), 1% P/S, 30 μg/ml aprotinin, and 
10 μM 5-Azacytidine (Aza; Sigma-Aldrich, St. Louis, MO, USA). After 24 hours the fibers were 




To compare cell viability and morphology a Live/Dead Viability/Cytotoxicity Kit 
(ThermoFisher Scientific, Waltham, MA, USA) was used at a range of seeding densities. Samples 
were incubated with calcein AM and ethidium homodimer-1 for 20 min then imaged with a 
confocal microscope (Zeiss LSM 510, Oberkochen, Germany).  
PicoGreen Assays 
DNA content of seeded cells on the fibers at various densities was quantified using a 
PicoGreen dsDNA quantitation kit (ThermoFisher Scientific, Waltham, MA, USA). Cells were 
lysed by placing whole fibers in 500 μl of digestion buffer (10mM Tris, 1mM EDTA, 0.1% Triton 
X-100, and 0.1 mg/mL proteinase K) before incubation with PicoGreen and reading with a 
fluorescent plate reader (BioTek, Winooski, VT, USA) at excitation 485 nm and emission 530 nm. 
Cellular infiltration into the fiber interior was assessed using 10 μm-thick cryosections and staining 
for 30 min with DAPI (Sigma-Aldrich, St. Louis, MO, USA).  
Whole Mount Immunostaining 
Samples were fixed in ice-cold methanol at -20°C overnight then rinsed three times for 20 
min each. Fibers were then cut from their frames and placed in 0.5 ml tubes for subsequent staining 
steps. Fibers were blocked and permeabilized (Block/Perm) for 3 hours with 0.2% Triton X-100 
and 5% normal goat serum (Sigma-Aldrich, St. Louis, MO, USA) in PBS with 0.1% Tween (PTw). 
Fibers were then incubated with primary antibodies diluted in blocking solution overnight at 4°C 
on a rocker at 135 rpm, followed by three 1-hour washes with PTw. Primary antibodies included 
mouse anti-myogenin (5 μg/ml; DSHB, Iowa City, IA, USA) and rabbit anti-desmin (2.7 μg/ml; 
Santa Cruz Biotechnology, Dallas, TX, USA). Fibers were then incubated with DyLight 488-
conjugated goat anti-mouse and DyLight 649-conjugated goat anti-rabbit (both 1:400; Jackson 
ImmunoResearch, West Grove, PA, USA) diluted in blocking solution overnight at 4°C on a rocker 
98 
 
at 135 rpm, followed by three 1 hour washes with PTw. DAPI was incorporated in the second wash 
at a dilution of 1:2,000. Samples were then imaged with a confocal microscope.  
To visualize cell morphology and multinucleation, fibers were fixed with 3.7% 
formaldehyde at 4°C for 3 hours and then washed with PBS three times for 20 min each. Fibers 
were then cut from their frames and incubated in Block/Perm for 3 hours at 4°C. A staining solution 
containing Phalloidin-TRITC (12.5 μg/ml; Sigma-Aldrich, St. Louis, MO, USA) and DAPI 
(1:2,000) was diluted in 0.1% PTw and incubated with fibers for 1 hour at RT on a slow rocker. 
Fibers were washed three times for 20 min each in 0.1% PTw then imaged with a confocal 
microscope. 
VML Defect Model 
Animal and surgical procedures were approved by the Institutional Animal Care and Use 
Committee at Johns Hopkins University School of Medicine. For the acellular scaffold study 10 
two-month old male NOD-Rag1null IL2rgnull (NRG) immunodeficient mice (Jackson Lab, Bar 
Harbor, ME, USA) were used and for the cell-seeded scaffold study 14 two-month old female 
NOD-scid IL2Rgnull (NSG) immunodeficient mice (Jackson Lab, Bar Harbor, ME, USA) were 
used. Two strains of immunodeficient mice were utilized due to mice availability at the time of 
the study. NRG and NSG mice are phenotypically very similar and both are highly 
immunodeficient with the only known phenotypic difference related to radiation/chemotherapy 
sensitivity which was not relevant to this study. Mice were anesthetized with isofluorane and the 
TA and EDL muscles were removed from the anterior tibial compartment in a bilateral defect on 
all mice, as described previously[177]. Care was taken to ensure bleeding had ceased before 1 or 3 
fiber bundles were placed in the empty defect site and ligated on both ends to the tendons of the 
peroneus longus muscle with non-absorbable sutures (6/0 POLYPRO, CP Medical, Norcross, GA, 
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USA). Surgical glue (Histoacryl, B. Braun Medical, Bethlehem, PA, USA) and stainless steel 
wound clips (Reflex Wound Clips, CellPoint Scientific, Gaithersburg, MD, USA) were used to 
close the skin. Rimadyl (Patterson Veterinary, Greeley, CO, USA) was given at 5 mg/kg 
subcutaneously post-surgery for pain management. For the cell-seeded study, acellular fibers were 
incubated for 24 hours in Control Medium before implantation. Upon harvest, fibers were removed 
along with the surrounding native muscle tissue. One mouse containing acellular and uninduced 
fibers died before the 3-month study ended and was excluded from data analysis. 
Histology 
Mice were sacrificed at 2 (male NRG, n=,) , 4, and 12 weeks; and the portion of their hind-
limb containing the scaffold and surrounding muscle tissue was harvested and frozen in OCT. 
Samples were cut into 10 μm sections on a cryostat, dried on Superfrost Plus slides, and rehydrated 
in DI water before staining with Masson’s Trichrome (Sigma-Aldrich, St. Louis, MO, USA) stain. 
Slides were imaged on an Axio Imager upright microscope (Zeiss, Oberkochen, Germany). 
Fibrosis was quantified with Image J software (NIH, Rockville, MD, USA) by measuring the 
collagen area and fiber cross-sectional area (n=15: 5 samples with 3 cryosections per sample). In 
both the acellular and cell-seeded in vivo studies, fibrosis was normalized to the cross-sectional 
area of the implanted fibrin fiber for each sample. In the cell-seeded in vivo experiment, relative 
cross-sectional area was determined by comparing the cross-sectional areas of cell-seeded samples 
to the average cross-sectional area of 2 week acellular controls (containing 3 fibers/defect). 
Immunohistochemistry 
Samples were cryosectioned as described above. Slides were fixed in ice-cold methanol 
for 10 min and rinsed with PBS three times for 15 min each, then blocked in 10% normal donkey 
serum (Sigma-Aldrich, St. Louis, MO, USA) in PBS for 1 hour at RT. For CD31 staining, slides 
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were fixed in ice-cold acetone for 10 min, rinsed with PBS, then blocked in 10% normal goat 
serum (Sigma-Aldrich, St. Louis, MO, USA). Slides were incubated with antigen-specific primary 
antibodies in blocking solution overnight at 4°C. Primary antibodies included rabbit anti-mouse 
CCR7 (2.6 μg/ml; Abcam, Cambridge, UK), rabbit anti-human LaminAC (1.1 μg/ml; Abcam, 
Cambridge, UK), mouse anti-human LaminAC (1:20; Abcam, Cambridge, UK), mouse anti-
embryonic myosin (4 μg/ml; DSHB, Iowa City, IA, USA), mouse anti-myosin heavy chain (24.3 
μg/ml; Sigma-Aldrich, St. Louis, MO, USA), rabbit anti-laminin (4.5 μg/ml; Sigma-Aldrich, St. 
Louis, MO, USA), and rat anti-mouse CD31 (0.3 μg/ml; BD Biosciences, San Jose, CA, USA). 
The embryonic myosin, myosin heavy chain, and laminin antibodies have reactivity for both 
mouse and human proteins. After three 15 min washes with PBS, slides were incubated with Cy3-
conjugated donkey anti-mouse, Alexa Fluor 647-conjugated donkey anti-rabbit (both 1:400; 
Jackson ImmunoResearch, West Grove, PA, USA), or Alexa Fluor 594-conjugated goat anti-rat 
(1:500; ThermoFisher Scientific, Waltham, MA, USA) and DAPI (1:1,000) diluted in blocking 
solution for 1 hour at RT. Slides were washed three times for 15 min then mounted with 50% 
glycerol and imaged on an Axio Observer inverted fluorescence microscope (Zeiss, Oberkochen, 
Germany). To quantify immunostaining, CCR7 area was measured with ImageJ and cells staining 
positive for eMHC and MHC were counted manually. 
Statistics 
Statistical analysis was performed using GraphPad Prism 5 software (GraphPad Software, 
La Jolla, CA, USA). Statistical significance for the DNA assay was determined by one-way 
ANOVA with Tukey’s post-test (n=3). In the first in vivo study assessing acellular scaffolds, 
statistical significance for fibrosis and CCR7 areas (n=14-16) was determined by unpaired two-
tailed t-test. For the second in vivo study assessing cell-seeded scaffolds, statistical significance 
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for fibrosis areas and immunostained samples (n=9-15) was determined with one-way ANOVA 
with Dunnet post-test. Statistical significance when assessing percent of ASCs in the defect (n=12-
15) was assessed with an unpaired two-tailed t-test. 
 
3.3 Results 
ASCs Align on Fiber Surface and Infiltrate into the Interior of Fiber Bundle 
ASCs at passage 3 from both donors highly expressed the mesenchymal markers CD73, 
CD90, and CD105 and had negligible to very low expression of the vascular markers CD31, CD34. 
ASCs were seeded onto the fibers and proliferated to cover the fiber surfaces, aligning with the 
major axis of the fibers with good cell viability at a range of seeding densities and time points (Fig. 
3.1A). There were no visible differences in cell morphology at the three seeding densities from 
days 7-21. ASCs became confluent on the fiber surface by day 7 and maintained their confluency 
through day 21. In addition to covering the fiber surface, ASCs also migrated into the porous fiber 
interior (Fig. 3.1B). DNA quantification was used to assess cell numbers at different times in 
culture. Differences in DNA content were statistically significant among the three seeding 
densities at day 0 and day 7 but not later time points (Fig. 3.1C). The maximum total DNA content 
was statistically similar among all groups on days 14 and 21. A seeding density of 40,000 cell/μl 





Figure 3.1. ASC growth and myogenesis on electrospun fibrin fibers. A) Live 
(green)/Dead (red) staining of cells seeded at 40 000 cells/μl at days 0 and 21. B) 
Histological cross-section stained with DAPI (blue) showing ASC infiltration to the 
fiber interior at day 21. C) Quantification of total DNA content of fibers seeded with 
ASCs at the three seeding densities at days 0, 7, 14, and 21. *p<0.05 D) Phalloidin 
(red) and DAPI (blue) staining illustrating some multinucleation of ASCs on fibers at 
2 months in both uninduced and induced groups. Arrows demonstrate aligned and 
elongated nuclei within potential myotubes. Inset: lower magnification image of 
phalloidin staining. Scale bar: 200 μm. E) Desmin (purple) and F) myogenin (green) 
staining ASCs grown on fibers in both uninduced and induced groups at 2 months. 
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ASCs Do Not Fully Replicate Myotube Characteristics at Two Months In Vitro 
After 2 months of in vitro culture, phalloidin staining of both uninduced and induced ASCs 
on the fibers revealed the presence of long tubes of cells in the fiber interior with elongated and 
aligned nuclei that paralleled the fiber’s major axis and mimicked the appearance of multinucleated 
myotubes (Fig. 3.1D). Although both uninduced and induced groups expressed high levels of 
desmin, a muscle structural protein (Fig. 3.1E), expression of the muscle transcription factor 
myogenin was low and non-nuclear (Fig. 3.1F). Interestingly, although ASCs cultured for 2 
months did not replicate myotube multinucleation and protein expression completely, there were 
no significant differences between uninduced and induced samples. This indicates that 5-
azacytidine did not provoke a significant pro-myogenic benefit and suggests that the fiber 
alignment and stiffness alone may encourage ASCs to begin mimicking myotube characteristics. 
Fiber Number Determines Fibrotic Response In Vivo 
When acellular fibers were implanted, native tissue surrounding the defect sites had a 
healthy appearance upon removal at 2 and 4 weeks with no visible scarring for both 1 and 3 
fibers/defect (Fig. 3.2B). There was less fibrosis at both time points when 3 fibers/defect were 
implanted than there was for 1 fiber/defect, as evident by collagen staining with Masson’s 
Trichrome stain (Fig. 3.2C). When quantifying total collagen area per sample, the mean values at 
2 weeks were 1.36 mm2 for 1 fiber/defect and 1.05 mm2 for 3 fibers/defect, and at 4 weeks were 
0.72 mm2 for 1 fiber/defect and 0.73 mm2 for 3 fibers/defect. Only the two 4-week groups had a 
significant difference with 1 fiber yielding significantly more collagen than 3 fibers although 
fibrosis in both groups did decrease over time (Fig. 3.2D). There were significant differences in 
normalized fibrosis (fibrotic area (mm2) /scaffold cross-sectional area (mm2)) between 1 fiber and 
3 fibers at both time points. When quantifying normalized fibrosis, the mean values at 2 weeks 
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were 5.28 (mm2/mm2) for 1 fiber/defect and 0.99 mm2/mm2 for 3 fibers/defect, and at 4 weeks 
were 5.43 mm2/mm2 for 1 fiber/defect and 1.19 mm2/mm2 for 3 fibers/defect. Differences between 
normalized fibrosis levels for 1 fiber/defect and 3 fibers/defect were statistically significant at both 
2 and 4 weeks. Samples were stained with the M1 macrophage marker CCR7 and areas stained 
within the fibers were quantified. There were no statistically significant differences in macrophage 





Figure 3.2. Fibrosis resulting from implantation of acellular fibers into VML 
defect. A)  Schematic illustrating fiber implantation into a murine VML defect model. 
B) Gross images of defects with 1 or 3 fibers/defect at Day 0 and 2 or 4 weeks post-
transplantation. Black arrows illustrate fiber location within defect site. C) Masson’s 
Trichrome staining demonstrates varying levels of fibrosis among groups. Dashed 
yellow lines denote fiber boundaries. D) Quantification of total collagen area and 
normalized collagen area over time for both groups (n=14-15). (E) Quantification of 
total CCR7 staining area (n=15). 
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Cell-Seeded Scaffolds Retain Fiber Cross-Sectional Area 
Bilateral murine VML defects were implanted with three fibers/defect that were acellular, 
uninduced, or induced and harvested after 1 or 3 months. The schematic in Fig. 3.3A demonstrates 
how fibers were distributed in the 14 mice used for this study. Upon removal at 1 month, there 
were distinct visible differences in the appearances of cell-seeded versus acellular fibers, where 
both cell-seeded groups had robust, opaque fibers visible between the sutures while the acellular 
fibers were translucent (Fig. 3.3B, top). These differences correlated with histology data and 
Masson’s Trichrome staining, where cell-seeded fibers had larger cross-sectional areas than those 
of acellular fibers (Fig. 3.3B, bottom). Masson’s Trichrome staining also demonstrated that all 
three groups had minimal fibrosis at both time points and there was no significant difference in 
normalized fibrosis between all three groups (Fig. 3.3C). When compared to the cross-sectional 
area of an early-stage implant, cell-seeded fibers had significantly higher retention of fiber cross-
sectional area than acellular fibers at both time points (Fig. 3.3D). The percentage of ASCs in the 
cell-seeded fibers was measured comparing the number of human-specific LaminAC+ nuclei to 
the number of other nuclei in the fiber cross-sections. Over 50% of cells in the fibers were ASCs 
for both groups at both time points and there were no statistically significant differences in the 




Figure 3.3. Analysis of cell-seeded fibers implanted in VML defects. A) Schematic illustrating 
the experimental plan. Two fibers were implanted per mouse and harvested at 1 or 3 months. 
Mouse #3 in the 3-month cohort died before the study ended. B) Differences in appearance were 
visible between acellular and cell-seeded groups immediately before harvest, with acellular groups 
appearing more translucent and cell-seeded groups more opaque (top). Black arrows illustrate fiber 
location within defect site. Masson’s Trichrome stain demonstrates minimal fibrosis in all three 
groups and the larger cross-sectional area present in cell-seeded groups (bottom). Dashed yellow 
lines denote fiber boundaries. C) Quantification of normalized fibrosis among all three groups at 
both time points showed that there were no significant differences between both cell-seeded groups 
and acellular fibers (n=9-15). D) Quantification of relative cross-sectional area for all three groups 
at both time points showed that cell-seeded samples had significantly higher retention of cross-
sectional area than acellular samples (n=9-15). E) Quantification of the percent of LaminAC+ 
nuclei in both cell-seeded groups showed high percentages of ASCs in the harvested scaffolds with 
no significant difference between groups (n=12-15).  
 
Limited Expression of Myogenic Markers In Vivo 
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Immunostaining with embryonic myosin (eMHC) was used to assess the presence of 
regenerating muscle within the defect site. A small number of eMHC+ cells were visible within 
the fiber interior in both ASC groups as well as LaminAC+ nuclei distributed throughout the fibers 
(Fig. 3.4A). In a few cases there were eMHC+ cells whose nuclei were LaminAC+, indicating that 
those ASCs had differentiated to myogenic cells or had fused with a native regenerating muscle 
fiber (Fig. 3.4A, right). Myosin heavy chain (MHC), a mature muscle marker, was found at low 
levels within the fiber interiors as well (Fig. 3.4B). Both induced and uninduced samples contained 
laminin+ cells with human nuclei, further suggesting that some implanted ASCs had fused with or 
differentiated into regenerating myofibers within the defect (Fig. 3.4C). At 1 month, there were 
significantly more eMHC+ cells in fibers with uninduced ASCs than there were in acellular fibers, 
although there was no significant difference for fibers with induced ASCs. At 3 months, all three 
groups had similar numbers of eMHC+ cells (Fig. 3.4D). At 1 month, 67.7 ± 27.0 percent of 
eMHC+ cells in fibers with uninduced ASCs and 42.4 ± 34.2 percent of eMHC+ cells in fibers 
with induced ASCs had a LaminAC+ nucleus immediately adjacent. At 3 months, 43.0 ± 23.0 
percent of eMHC+ cells in fibers with uninduced ASCs and 49.2 ± 28.8 percent of eMHC+ cells 
in fibers with induced ASCs had a LaminAC+ nucleus immediately adjacent. At both 1-month and 
3-month time points, there were significantly more MHC+ cells in fibers with uninduced ASCs 
than there were in acellular fibers. Fibers with induced ASCs, however, had similar numbers of 
MHC+ cells to those in acellular fibers at both time points. At 1 month, 41.8 ± 32.6 percent of 
MHC+ cells in fibers with uninduced ASCs and 27.5 ± 28.2 percent of MHC+ cells in fibers with 
induced ASCs had a LaminAC+ nucleus immediately adjacent. At 3 months, 61.6 ± 33.0 percent 
of MHC+ cells in fibers with uninduced ASCs and 43.8 ± 35.6 percent of MHC+ cells in fibers 
with induced ASCs had a LaminAC+ nucleus immediately adjacent. When cross-sections of the 
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excised defect site at 12 weeks were stained for mouse CD31, host vascular infiltration was 










 There are limited therapeutic options available for the treatment of VML. ASCs are 
potentially advantageous for tissue engineered muscle because of their ease of isolation, higher 
stem cell yields and proliferation rates, and reported myogenic potential[158,159,170,173,174,160–164,166–
168]. Their biological relevance arises from the fact that adipocytes and myoblasts share a common 
Myf5+ precursor[178] and brown preadipocytes express high levels of myogenic genes[179]. Even 
so, the ability of ASCs to directly differentiate into myoblasts is limited[150]. In addition to their 
differentiation capabilities, ASCs have the potential to promote muscle regeneration by providing 
a pro-regenerative environment and modulating the immune system[171,172]. ASCs have also been 
shown to be pro-angiogenic and the ASC secretome includes the angiogenic factors VEGF, HGF, 
and IGF-1[180]. The current study assessed the in vitro and in vivo myogenic potential of both 
uninduced and induced ASCs on a myomimetic electrospun fibrin scaffold. 
Figure 3.4. Immunostaining of embryonic myosin, myosin heavy chain, and LaminAC+ 
nuclei in the fiber interior. A) Sections of the excised defect site were stained with 
embryonic myosin (eMHC; red), human-specific LaminAC (cyan), and DAPI (blue). Inset 
(left): concentrations of eMHC were found in the center of the implanted fibers. Dotted line 
denotes fiber boundary. Inset (right): Example of colocalizing eMHC+ and human 
LaminAC+ cell in fibers with induced ASCs.  Images depict fibers at 4 weeks. B) Sections 
of the excised defect site were stained with myosin heavy chain (MHC; red), human-specific 
LaminAC (cyan), and DAPI (blue). Inset: concentrations of MHC were found in the center 
of the implanted fibers. Dotted line denotes fiber boundary. Images depict fibers at 12 weeks. 
C) Sections of the excised defect site were stained with laminin (red), human-specific 
LaminAC (cyan), and DAPI (blue). Inset: concentrations of laminin+ cells with human nuclei 
were found in the center of the implanted fibers. Dotted line denotes fiber boundary. Image 
depicts uninduced fibers at 4 weeks. D) Quantification of the number of eMHC+ and MHC+ 
cells inside fibers among the three groups (n=9-15). There were significantly more eMHC+ 
cells at 1 month in fibers with uninduced ASCs than in acellular fibers. There was no 
significant difference in eMHC expression among groups at 3 months. There were 
significantly more MHC+ cells at both 1 month and 3 months in fibers with uninduced ASCs 
than in acellular fibers. E) Sections of the excised defect site were stained for mouse CD31 
(CD31; red) and DAPI (blue). Inset: host vascular infiltration was found in the interior of the 
implanted fibers in all groups at 3 months. Dotted line denotes fiber boundary. 
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The scaffold utilized in this study is highly suited for muscle regeneration and has 
successfully treated VML when combined with C2C12 myoblasts[25]. Fibrin is a naturally 
occurring biocompatible and biodegradable material generated during the blood clotting process. 
As a scaffold material, it can be degraded gradually in vivo in the presence of plasmin. It is a vital 
component of the native coagulation cascade and thus is present in the native wound healing 
environment. As a surgical adhesive, in-situ gelled fibrin hydrogel has been widely used in the 
clinic with an excellent safety profile[181]. Electrospinning fibrinogen onto a rotating collection 
dish where it rapidly crosslinks with thrombin under tension enables internal alignment capture of 
the hydrogel fiber[147] that mimics the alignment of fibers in native muscle. Cellular alignment is 
a prerequisite for the uniaxial contraction of functional muscle and construct alignment has been 
shown to enhance myoblast fusion and stem cell myogenesis[148,149]. The electrospun fibers also 
mimic the macroscopic structure of muscle, where groups of muscle fibers are bundled to form 
fascicles, which in turn are bundled to form the muscle tissue. Each fibrin fiber is a collection of 
bundled microfibers, mimicking the native fascicle, and assembling multiple fibrin fibers is 
scalable to replace an entire muscle. Substrates that mirror the stiffness of native muscle have been 
shown to enhance stem cell differentiation and myogenesis[150,151,182], with an ideal range of 8–17 
kPa[182]. The stiffness of the fibrin fibers has been optimized to mimic the mechanics of native 
muscle with an average Young’s Modulus of 11 kPa. In addition to providing an environment that 
mimics the alignment, structure, and mechanics of native muscle, the electrospun fibrin fibers are 
suturable and mechanically robust. The fibrin fibers also have the potential to be used as an off-
the-shelf material that can be stored long term and rehydrated prior to cell seeding and 
implantation. These capabilities as well as their ability to closely mimic the native muscle 
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environment make electrospun fibrin fibers a highly suitable candidate material for tissue 
engineered skeletal muscle. 
  When ASCs were seeded onto the electrospun fibrin fibers, they proliferated to cover the 
fiber surface and grow into the interior with good cell viability at a range of time points. The fiber 
surface topography encouraged ASC alignment with the fiber’s major axis. Alignment alone has 
been shown to stimulate increased ASC myogenic differentiation[148]. To further promote ASC 
myogenesis, 5’-azacytidine was added to the culture medium as a biochemical induction factor. 
Azacytidine, a DNA methyl transferase inhibitor, has been used previously to encourage both ASC 
as well as MSC myogenic differentiation by reversing gene silencing and potentially activating a 
subset of myogenic genes[183]. However, the yield of ASC myogenesis in vitro is reported to be as 
low as 0.1% with potential increases in ASC differentiation when they are co-cultured with 
myoblasts[184]. This is in keeping with the in vitro components of this study, where ASCs on 
electrospun fibers attained very low levels of myogenic characteristics after 2 months of culture 
with no visible differences between uninduced and induced ASCs. It is possible that the fiber 
alignment [148,149]  and stiffness [150,151,182] alone may be sufficient to promote the low levels of ASC 
myogenesis seen, which was not further improved by biochemical induction with 5-azacytidine. 
ASCs from two donors were used to demonstrate that results are not dependent on age or 
demographic.  
ASCs have much higher reported levels of muscle differentiation when implanted into a 
regenerating muscle environment in vivo than in vitro and have demonstrated incorporation into 
the regenerating muscle tissue[184]. Bacou et al found that cells from the stromal vascular fraction 
contributed up to 10% of regenerating muscle fibers in damaged TA muscles[185], and Di Rocco et 
al found that ASCs injected into ischemia-injured adductor muscles contributed up to 10-20% of 
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regenerating fibers[162]. A number of studies have assessed the muscle regenerative potential of 
ASCs injected in vivo[162], but implanting ASCs on a 3D scaffold to assess resulting skeletal muscle 
formation is still relatively unexplored. ASCs attached to PLGA microsphere carriers transplanted 
subcutaneously in nude mice formed new muscle tissue after 60 days[164], and NG2+ ASCs seeded 
onto hyaluronic acid scaffolds transplanted subcutaneously in nude mice expressed muscle 
markers after 30 days[175]. Animal models of VML vary greatly in the extent and mechanism of 
injury, muscle group, and location. VML models previously utilized for tissue engineered skeletal 
muscle include removal of 30% of the tibialis anterior[146], 50% of the lattissimus dorsi[186], and 
75% of the quadriceps muscles[54]. Regeneration in partial excision models likely relies in part on 
muscle stem/progenitor cell and vascular ingrowth from the remaining muscle tissue, as it has been 
shown that muscle progenitor cells can migrate to regenerate distal injuries[187]. Here, we provide 
a significantly more challenging VML model by excising the entire TA and EDL muscles and 
utilize this model to assess the muscle regenerative potential of ASCs. The robust VML model 
used in this study mimics some of the most severe patient cases with little hope for positive 
regenerative outcomes[36].  
In the current study, ASC-seeded fibers implanted in a VML defect had increased volume 
retention relative to acellular fibers with uninduced ASCs at 3 months exhibiting up to 4X higher 
volume retention than acellular fibers. Volume retention for fibers with induced ASCs was slightly 
lower, but the values for the two cell-seeded groups were not statistically different. This indicates 
that the addition of ASCs to the fibers preserves them from degradation. Both uninduced and 
induced ASCs showed low levels of fibrosis, similar ratios of human to mouse cells within the 
fibers at three months post-transplantation, and similar numbers of cells at 3 months that were 
eMHC+. However, fibers seeded with uninduced ASCs had significantly more regenerating 
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muscle cells positive for MHC when compared to acellular fibers, while fibers seeded with induced 
ASCs did not. Paired with the in vitro data, this suggests that 5-azacytidine may not be sufficiently 
potent to induce ASCs down a myogenic lineage and future studies should evaluate additional 
biological and biochemical factors that could work synergistically with the biophysical cues 
provided by the electrospun fibrin fibers. 
Despite low levels of muscle regeneration in all treatment groups and limited evidence of 
ASC myogenesis both in vitro and in vivo, there is some evidence that ASCs may improve 
regenerative outcomes for VML. In this study, acellular fibers had eMHC+ regenerating muscle 
cells at 3 months but no mature MHC+ muscle cells at either time point. Interestingly, ASC-seeded 
fibers had eMHC expression at 1 month and significantly earlier than that seen in acellular fibers, 
suggesting that the addition of ASCs hastened the muscle’s regenerative response. Additionally, 
unlike the acellular fibers, muscle cells within ASC-seeded fibers were MHC+ at both time points 
demonstrating the presence of mature muscle cells within the fiber interior. The source of 
regenerating muscle cells within the fibers is unclear. There were some cases where individual 
regenerating eMHC+ muscle cells contained Lamin AC+ nuclei but the majority of eMHC+ and 
MHC+ cells within the fibers did not have an ASC-derived nucleus. In addition, there laminin+ 
cells with Lamin AC+ nuclei were present in both induced and uninduced ASC samples. It is 
possible that implanted ASCs directly differentiated into muscle in vivo and/or fused with 
infiltrating host muscle cells. It is important to note that the eMHC, MHC, and laminin antibodies 
used stain both mouse and human proteins. It is also possible that implanted ASCs provided 
paracrine signaling to promote muscle progenitor cell infiltration from the host and subsequent 
regeneration. ASCs are known to provide a pro-regenerative environment and modulate the 
immune system[171,172] as well as secrete pro-angiogenic factors[180]. A large number of 
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regenerating muscle cells within the fibers were immediately adjacent to ASCs suggesting a 
correlation between ASC location and the presence of regenerating muscle. Our findings suggest 
that human ASCs promote moderate muscle reconstruction in VML models. Nonetheless, 
complete removal of the TA and EDL muscles is an aggressive VML injury model for testing the 
efficacy of this approach due to the lack of endogenous cell infiltration and potential paracrine 
signaling benefit.  It is likely that ASCs implanted in a VML defect involving partial removal of a 
single muscle would yield further improved regenerative outcomes. Further studies into ASC-
mediated muscle regeneration in VML models will be required to understand the mechanism by 
which ASCs promote regeneration within the harsh VML injury environment. 
 
3.5 Conclusions  
In this study, the muscle regenerative potential of ASCs combined with an electrospun 
fibrin fiber mimicking the structure, alignment, and mechanical properties of native skeletal 
muscle was assessed. The fibers promoted limited in vitro myogenic properties in both induced 
and uninduced ASCs but both groups failed to fully replicate myotube characteristics in vitro. 
When implanted in a severe VML defect model, the fibers integrated well with the native tissue, 
eliciting little scarring, promoting long-term survival of transplanted ASCs, and stimulating 
cellular and vascular ingrowth.  Although the number of eMHC+ and MHC+ cells in this model 
is modest up to 3 months, it should be noted that any amount of muscle regeneration is 
significant due to the severe VML model that was utilized. Interestingly, ex vivo differentiation 
of ASCs down the myogenic lineage via 5-azacytidine induction did not significantly improve in 
vivo muscle regeneration as was hypothesized. Implanted fibers with uninduced ASCs contained 
more muscle cells than acellular fibers at both 1 and 3 months, indicating that the addition of 
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uninduced ASCs on electrospun fibrin fibers may enhance muscle regeneration post-VML. In 
addition, several regenerating muscle cells had LaminAC+ nuclei indicating the possibility of 
direct contribution of ASCs to those regenerating cells. Taken together, this data illustrates that 
despite low in vitro myogenic potential, electrospun fibrin fibers combined with ASCs promote 




Chapter 4 Human Pluripotent Stem Cells: Assessment of 
Myogenic Potential In Vitro and In Vivo 
 
4.1 Introduction 
 Volumetric muscle loss (VML) occurs when large-scale damage to skeletal muscle 
overwhelms the natural repair mechanisms and leads to chronic functional deficits[146]. Current 
clinical treatment options for VML are limited by low success rates in restoring muscle function 
and at best provide aesthetic benefits and prevent further necrosis[36,146]. Tissue engineered grafts 
offer a potentially more effective regenerative medicine treatment option for VML that may 
alleviate the varied limitations of current treatments and lead to improved functional outcomes. A 
broad range of cell sources has been utilized to develop tissue engineered muscle grafts, including 
satellite cells or other muscle-derived precursor cells[21,33,56,69–73], mesenchymal stem cells[74,75], 
adipose-derived stem cells[76–78], and human pluripotent stem cells[79–81]. While satellite cells and 
myoblasts enable robust myogenic differentiation, they have limited proliferative capabilities and 
necessitate invasive, large biopsies from the patient[47,188]. Mesenchymal and adipose-derived stem 
cells are more easily isolated and have a higher proliferative capacity but often are quite limited in 
myogenic potential[77,188]. Human pluripotent stem cells (hPSCs) offer a translatable cell source 
that is sourced noninvasively from the patient, has unlimited self-renewal in culture, and can be 
differentiated into skeletal muscle[47,189]. 
 The myogenic differentiation capability of hPSCs has been widely established in 
monolayer cultures[80,190–192] and primarily utilizes either forced overexpression of a muscle gene 
or induction via small molecule signaling[189]. Despite extensive use in monolayer cultures, only 
two published studies thus far have described the development of an implantable hPSC-derived 
3D muscle construct and have evaluated its engraftment potential in non-VML animal 
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models[79,81]. In both studies, the implanted hPSC-derived constructs were induced towards 
myogenesis utilizing transduction and overexpression of Pax7 or MyoD. While genetic 
modification of iPSCs often results in higher levels of myogenesis it has been known to induce 
cancer-causing genetic abnormalities and has limited translational potential[47,189]. Our 
collaborators in the lab of Dr. Gabsang Lee have successfully developed a small-molecule based 
method to induce hPSC myogenesis that results in a robustly expandable population of myogenic 
precursor cells with the ability to engraft into injured skeletal muscle[80]. Our group has previously 
utilized electrospun fibrin microfiber bundles that mimic the native properties of skeletal muscle 
combined with C2C12 myoblasts to promote functional and histological regeneration post-VML 
[25]. In the current study we assess the in vitro and in vivo myogenic potential of small molecule-
induced hPSC-derived myoblasts (hPDMs) in a 3D electrospun fibrin construct. We test the 
hypothesis that the combination of hPDMs on electrospun fibrin fibers promotes in vitro 
myogenesis and in vivo engraftment utilizing several murine skeletal muscle defect models. We 
further test the hypothesis that the in vitro maturation time point of hPDM muscle constructs 
impacts its engraftment and regenerative potential following implantation. 
 
4.2 Methods 
Electrospinning Fibrin Scaffolds 
Fibrin scaffolds were electrospun in a sterile environment with sterile solutions as 
previously described [25,77,193]. Parallel syringes containing solutions of fibrinogen (Sigma) or 
sodium alginate (Sigma) were connected via a y-syringe and extruded by syringe pumps with an 
applied voltage of 3-5 kV applied to a 27G needle tip utilizing 1% fibrinogen with an extrusion 
rate of 4 ml/hr and 0.75% alginate with an extrusion rate of 1 ml/hr. Polyethylene oxide (average 
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Mv ~ 4 000 kDa, Sigma) was added to each solution at 0.2 wt% to increase viscosity during 
electrospinning. The electrospun hydrogel solutions were collected for 5.75 minutes on a rotating 
dish (~35rpm) containing 50 mM CaCl2 and 20 U/ml thrombin (Sigma) as crosslinking agents. 
Samples were allowed to crosslink and additional 3-5 min after electrospinning and were then 
wrapped around a 3.0 × 1.5 cm acrylonitrile-butadiene-styrene frame 4 times to yield a hydrogel 
microfiber bundle ~700 μm in diameter. Scaffolds were incubated overnight in 250 mM sodium 
citrate (Sigma) to dissolve the alginate and then transferred to DI water for storage up to 2 weeks.  
hPSC Myogenic Commitment and Expansion 
Human embryonic stem cells (H9 hESCs; WiCell) were cultured in Dr. Gabsang Lee’s 
lab as previously described [80]. Briefly, hESCs were cultured using a mouse embryonic 
fibroblast (MEFs; GlobalStem or AppliedStemCell) feeder layer at 12,000-15,000 cells/cm2. 
Expansion media contained DMEM/F12, 20% knockout serum replacement, 1 mM L-glutamine, 
100 mM MEM non-essential amino acids, 0.1 mM b-mercaptoethanol, and 10 ng/ml FGF2. 
Subsequent steps utilized N2 media containing DMEM/F12 powder, glucose, sodium 
bicarbonate, insulin, putrescine, progesterone, sodium selenite, and transferrin. For myogenic 
commitment, sterile filtered N2 media conditioned by MEFs for 24 hours was utilized. hESCs 
were seeded at a density of 1.5 x 105 cells/well of a 24 well plate coated with 1% Geltrex and fed 
with MEF-conditioned N2 media supplemented with 10 ng/ml FGF2 and 10 μM Y-27632 
(Cayman Chemical) for the first 24 hours of culture. For culture days 1-4, N2 media was 
supplemented with 3 μM CHIR99021 (Cayman Chemical) and media was changed every other 
day. For culture days 4-12, media was switched to N2 media containing 10 μM DAPT (Cayman 
Chemical). Following myogenic commitment, the cells were expanded for 5-6 passages in N2 
media containing 5% FBS prior to seeding in monolayers or on electrospun scaffolds. For 
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experiments utilizing Pax7-sorted hPDMs, hESCs were genetically manipulated prior to 
myogenic commitment using the CRISPR/Cas9 system to express a Pax7::GFP reporter as 
previously described[80]. Cells were then cultured following the myogenic commitment protocol 
described above in N2 media containing 5% FBS, 1% P/S, and 10 ng/ml FGF2. After 30 days of 
expansion, cells were sorted using fluorescence activated cell sorting (FACS) for the 
Pax7::GFP+ subpopulation. Pax7-sorted cells were then expanded for 5-6 passages prior to use 
in experiments. 
Cell Seeding on Scaffolds 
hPDMs were expanded as described above. For Geltrex-coated scaffolds, scaffolds were 
incubated in Geltrex dissolved in cold DMEM/F12 (1:100; Life Technologies) for 1 hour at 37 °C 
then 1 hour at RT. For fibronectin-coated scaffolds, scaffolds were incubated in 10 μg/ml 
fibronectin in 50 mM HEPES Buffer. In preparation for cell seeding, scaffolds were incubated in 
DMEM/F12 media for 20 min at RT. The scaffolds were then transferred to 6-well cell culture 
plates coated with 2% agarose type VII (Sigma) to minimize cell adhesion to the plate surface, 
which increases the seeding efficiency. A total seeding volume of 40 μl at 15,000 cells/μl was 
pipetted onto the scaffold surface in a series of 5 μl droplets (for a total seeding density of 600,000 
cells/scaffold).  
Various modifications to the regular seeding protocol were evaluated as follows. For the 
Geltrex Gel protocol, hPDMs were resuspended in liquid Geltrex at 15,000 cells/μl (for a total of 
600,000 cells/fiber) and quickly pipetted onto the scaffold surface prior to gelling. For the Injected 
Cells protocol, hPDMs were suspended in N2 media at 15,000 cells/μl (for a total of 600,000 
cells/fiber), loaded into a 1 ml syringe, and injected into the scaffold interior. For the 3D Printed 
Mold protocol, molds were designed to hold the electrospun scaffolds in a small volume of liquid 
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and 3D printed using acrylonitrile-butadiene-styrene. hPDMs were suspended in N2 media at 
15,000 cells/μl and scaffolds were incubated with 40 μl of cell solution per mold. For the Gel on 
Frame protocol, hPDMs were suspended in 32 μl of 1% fibrinogen at 15,000 cells/μl then mixed 
with 8 μl of 10 U/ml thrombin and immediately pipetted along a 3.0 x 1.5 cm acrylonitrile-
butadiene-styrene frame. For the bulk gel protocol, PDMS molds were created to hold a 40 μl 
volume and sterilized. hPDMs were suspended in 32 μl of 1% fibrinogen at 15,000 cells/μl then 
mixed with 8 μl of 10 U/ml thrombin and immediately pipetted into the PDMS molds to gel. For 
hybrid seeding, hPDMs were suspended in 20 μl of thrombin at 1.25 U/ml in N2 media containing 
40 mmol/L CaCl2. Fibrinogen was diluted in N2 media to 40 mg/ml and 20 μl of fibrinogen was 
mixed with 20 μl of thrombin and immediately pipetted onto the scaffold surface in 5 μl 
increments. All seeded scaffolds were incubated for 1 hour at 37°C with hydration levels 
maintained by addition of 15 μl of N2 media containing 5% FBS and 1% P/S halfway through. 
After the 1 hour incubation, 3 ml of N2 media containing 5% FBS, 1% P/S, and 30 μg/ml aprotinin 
(Affymetrix) was added to each well and care was taken to ensure the scaffolds had been 
submerged in the media. For induced samples, on day 3 or day 7 of culture myoblasts were 
transferred to low-serum Induction Medium: N2 media with 1% P/S and 30 μg/ml aprotinin and 
remained in Induction Medium for the extent of in vitro culture and media was changed every 
other day. For Pax7-sorted hPDMs, expansion and culture in monolayers and on fibers was in Pax7 
Media: N2 media supplemented with 5% FBS, 1% P/S, 10 ng/ml FGF2 (PeproTech), and 5 ng/ml 
FGF8 (PeproTech). 
Whole Mount Immunostaining 
Scaffolds were fixed in 4% formaldehyde at 4°C on a rocker at 80 rpm for 3 hours. 
Following 3 washes with PBS, scaffolds were blocked and permeabilized (Block/Perm Solution) 
122 
 
for 3 hours with 0.2% Triton X-100, 10% normal goat or donkey serum (Sigma). Scaffolds were 
then incubated with primary antibodies diluted in Block/Perm Solution overnight at 4°C on a 
rocker at 135 rpm, followed by three 1-hour washes with PBS. Primary antibodies included 
myogenin (5 μg/ml; DSHB), myosin heavy chain (5 μg/ml; DSHB), desmin (1:400; Abcam), α-
actinin (1:200; Abcam), titin (5 μg/ml; DSHB), and Pax7 (5 μg/ml; DSHB). Scaffolds were then 
incubated with secondary antibodies diluted in 10% normal goat or donkey serum and 0.1% Tween 
in PBS overnight at 4 °C on a rocker at 135 rpm, followed by three 1 hour washes with PBS. DAPI 
was incorporated in the second wash at a dilution of 1:2000. Secondary antibodies included 
DyLight 488-conjugated donkey anti-mouse (1:400; Jackson ImmunoResearch), Alexa Fluor 647-
conjugated donkey anti-rabbit (1:400; Jackson ImmunoResearch), or Cy3-conjugated donkey anti-
mouse (1:400; Jackson ImmunoResearch). Samples were then imaged with a Zeiss LSM 510 
confocal microscope.  
Animal Models 
Animal and surgical procedures were approved by the Institutional Animal Care and Use 
Committee at Johns Hopkins University School of Medicine. Female 2-4 month old NOD-scid 
IL2Rgnull (NSG) immunodeficient mice (Jackson Lab) were utilized to enable implantation of 
human cells. Mice were randomly assigned across all groups. In vitro constructs were prepared 
and cultured with hPDMs as described above. Muscle defects were created as previously 
described[25]. Mice were anesthetized with isofluorane, the TA muscle was exposed, and 
approximately 30-50% (VML defects) or 7-12% (sub-critical defects) of the muscle was removed. 
After bleeding ceased, scaffolds were placed in the defect site and ligated on both ends to the 
remaining TA muscle with non-absorbable sutures (6-0 Nylon, Express Medical Supplies). 
Surgical glue (Histoacryl, B. Braun) and sutures were used to close the skin. Rimadyl was injected 
123 
 
subcutaneously post-surgery for pain management (5 mg/kg). Mice were sacrificed at 1 or 2 weeks 
post-implantation by isoflurane overdose and cervical dislocation. Upon harvest, implanted 
scaffolds and surrounding TA muscle tissue were removed and cryopreserved. 
Histology 
Samples were sectioned on a cryostat (Leica) at a thickness of 10 μm for cross-sections 
and 70 μm for longitudinal sections. Masson’s Trichrome stains were imaged on a Zeiss Axio 
Imager upright microscope. For immunohistochemistry, slides were fixed in cold 4% 
formaldehyde for 10 min and rinsed with PBS three times for 15 min each, then blocked in 10% 
normal donkey or goat serum (Sigma) in PBS for 1 hour at RT. Slides were incubated with antigen-
specific primary antibodies in blocking solution overnight at 4°C. Primary antibodies included 
mouse anti-myosin heavy chain (5 μg/ml; DSHB), goat anti-mouse CD31 (1:100; R&D Systems), 
rabbi anti-LaminAC (1:500; Abcam), mouse anti-Pax7 (5 μg/ml; DSHB), and mouse anti-
embryonic myosin (5 μg/ml; DSHB). After three 5 min washes with PBS, slides were incubated 
with secondary antibodies and DAPI (1:2000) diluted in blocking solution for 1 hour at RT. 
Secondary antibodies included Cy3-conjugated donkey anti-mouse, Alexa Fluor 488-conjugated 
donkey anti-goat, DyLight 488-conjugated goat anti-mouse, or Alexa Fluor 647-conjugated 
donkey anti-rabbit (1:400; Jackson ImmunoResearch). Slides staining for phalloidin-TRITC (1:40; 
Sigma) or phalloidin-AF488 (1:40; Thermo Fisher) incorporated the stain into the secondary 
antibody stain. Slides were washed three times for 5 min then mounted with 50% glycerol and 
imaged on a Zeiss Axio Observer inverted fluorescence microscope or Zeiss Axio Observer 7. To 
quantify staining within the defect regions, tiled images covering the entire defect region were 




Statistical analysis was performed using GraphPad Prism 5 software. Statistical 
significance was determined by t test or one-way ANOVA with Dunnett or Bonferroni post-test. 




Unsorted hPSC-Derived Myoblasts Form Myotubes on Electrospun Fibers 
with Some Variability 
 Unsorted hPSC-derived myoblasts (hPDMs) committed to undergo myogenesis and 
expanded showed no difference in myogenic potential in monolayer culture between uninduced 
cells and those induced at day 3 of culture (Fig. 4.1A-C). When seeded on electrospun fibrin 
microfiber bundles and cultured for 10 days, hPDMs expressed the muscle markers myogenin 
and myosin heavy chain (MHC), forming MHC+ aligned and multinucleated myotubes in both 
uninduced and induced culture conditions. To further optimize hPDM seeding efficiency and 
myogenesis, fibers were coated with geltrex, fibronectin, a geltrex gel, or left uncoated. In all 
fiber coating groups, hPDMs were either uninduced or induced at day 3 or day 7 of culture (Fig. 
4.1E). Differences in MHC coverage were present between early and late induction time points 
for fibers in all coating groups, however fibers seeded with uninduced hPDMs had statistically 
similar amounts of MHC coverage to those induced at day 7 in most groups. MHC coverage for 
uncoated fibers was similar to other coating groups, leading to the selection of uncoated fibers 




Figure 4.1. Uninduced and induced unsorted hPDMs form myotubes on electrospun fibrin 
scaffolds. A) Timeline of hPSC myogenic induction, expansion, and seeding on electrospun 
fibers. B) Left: Brightfield imaging demonstrating cell morphology following monolayer 
expansion for 30 days and uninduced or induced replated monolayers. Right: Uninduced and 
induced monolayers immunostained for myosin heavy chain (MHC; green). C) Quantification of 
multinucleation and MHC coverage for uninduced and induced monolayers demonstrating no 
difference in myogenesis. D) Whole mount immunostaining for myogenin (red) and MHC 
(green) demonstrating myogenesis and myotube morphology for induced and uninduced hPSC-
derived myoblasts cultured on electrospun fibers for 10 days. E) Quantification of the MHC 
coverage on day 10 of culture comparing various fiber coatings and induction timelines. F) 
Quantification of MHC coverage and multinucleation of uncoated fibers seeded with hPSC-
derived myoblasts at day 10 of culture. **: p < 0.01; ***: p < 0.001 
 
Unsorted hPDM-Derived Muscle Constructs Demonstrate Survival but Little 
Regeneration Following Implantation in VML Defects 
 To evaluate the regenerative potential of unsorted hPDM constructs, uninduced and 
induced constructs were implanted in murine VML defects of the TA muscle for two weeks in 
immunodeficient mice. Although both induced and uninduced constructs had significant cell 
coverage in vitro, little MHC expression was seen at the time point of implantation further 
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demonstrating variability in myogenic potential between batches of unsorted hPDMs (Fig. 4.2A). 
Following implantation for 2 weeks, induced and uninduced constructs resulted in mild fibrosis 
within the defect region and maintained the defect volume (Fig. 4.2Bi). Human nuclei were 
visible within the defect region with no difference in the percent of human nuclei between 
groups (Fig. 4.2Bii,C). Although blood vessels infiltrated into implanted constructs, there was 
little evidence of MHC expression and muscle regeneration within the defect with no difference 
in MHC coverage between groups. 
 
Figure 4.2. Unsorted hPDM constructs demonstrate survival at 2 weeks post-VML with 
little regeneration. A) In vitro uninduced and induced constructs demonstrated little myosin 
heavy chain (MF20; green) expression at day 12 of culture. B) Masson’s trichrome staining (i) 
and immunostaining (ii) for myosin heavy chain (MHC; green), vasculature (CD31; right), and 
human nuclear protein (LaminAC; white). C) No difference was seen in the percent of human 
nuclei or MHC coverage between uninduced and induced constructs within the defect. 
Pax7-Sorted hPDMs Enable Improved In Vitro 3D Myogenesis  
 A purified population of Pax7-sorted hPDMs was investigated for its myogenic potential 
on electrospun fibrin fibers. hPSCs were initially tagged with a Pax7-driven green fluorescent 
protein (GFP) reporter gene, underwent the same myogenic commitment protocol, and were 
subsequently sorted using Fluorescence Activated Cell Sorting (FACS) for the GFP+ population. 
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Pax7-sorted hPDMs were then expanded for several passages and utilized for experiments (Fig. 
4.3A). Pax7-sorted hPDMs exhibited significantly more MHC expression and multinucleation 
compared to unsorted hPDMs when cultured in monolayer for 10 days (Fig. 4.3B,C). Pax7-
sorted hPDMs seeded onto electrospun fibrin fibers demonstrate a characteristic time-dependent 
expression profile of common muscle proteins (Fig. 4.4). Early proliferating hPDMs are positive 
for Pax7 at day 3 of culture which decreases in expression up to day 10. As the hPDMs mature 
and fuse into myotubes by day 10, they express increasing levels of desmin and MHC. Day 10 
hPDM-derived myotubes also express the mature muscle markers α-actinin and titin with 
characteristic striations. The level of multinucleation is low at day 3 and increases up to day 10 
as well.  
Figure 4.3. Pax7-Sorted hPDMs form more myotubes in monolayers than unsorted cells. A) 
Timeline of hPSC Pax::GFP reporter tagging, myogenic induction, expansion, sorting, and 
seeding on electrospun fibers. B) Pax7::GFP+ or unsorted hPSC-derived myoblast monolayers 
stained for myosin heavy chain (MF20; green) demonstrate increased presence of MHC+ 
myotubes for sorted cells. C) Quantification demonstrating increased multinucleation and MHC 




Figure 4.4. Pax7-Sorted hPDMs follow muscle protein expression timeline and form 
mature myotubes on 3D constructs. A) Pax7::GFP+ hPDMs seeded on electrospun fibers 
demonstrate expression of Pax7 (red) at day 3 of culture and myosin heavy chain (MF20; red), 
desmin (cyan), α-actinin (red), and titin (red) at da 10 of culture. Myotubes had visible striations 
at day 10 of culture. B) Expression of Pax7 decreased over time as cells matured while 
expression of desmin and MHC as well as the level of multinucleation increased over time. *: p 
< 0.05; **: p < 0.01; ***: p < 0.001 
 To improve seeding efficiency of hPDMs onto the fibers, a variety of seeding techniques 
were evaluated (Fig. 4.5A). Despite proliferation and myogenesis on the fibers, the regular 
seeding technique used previously resulted in significantly less cells one day post-seeding than 
seeding cells within a bulk fibrin gel. Despite increased cell retention, bulk gel seeding resulted 
in MHC and desmin positive myotubes at day 10 with a stunted and disorganized morphology 
(Fig. 4.5B). To utilize the benefits of bulk gel seeding while maintaining the pro-myogenic 
stiffness and alignment cues of electrospun fibrin fibers, a new hybrid seeding method was 
developed where hPDMs were suspended in a fibrin gel and seeded onto electrospun fibers in the 
gel prior to gel crosslinking. This resulted in significantly more cell retention at the electrospun 
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fiber surface at day 4 post-seeding compared to the regular seeding protocol used previously 
(Fig. 4.5C). 
 
Figure 4.5. Variability in seeding efficiency led to the development of a modified “hybrid” 
seeding method. A) Cell content day 1 post-seeded on electrospun fibers seeded with various 
protocol differed significantly. B) Immunostaining at day 10 of culture for myosin heavy chain 
(MF20; red) and desmin (cyan) demonstrated that despite increased seeding efficiency for bulk 
gel constructs, myotubes had increased alignment using the regular seeding protocol. C) 
Brightfield imaging demonstrating a difference in cell retention on the fiber exterior at day 4 of 
culture between the regular seeding protocol and a new hybrid protocol. ***: p < 0.001 
Pax7-Sorted hPDM-Derived Muscle Constructs Have Limited Survival and 
Regenerative Potential Following Implantation in Sub-Critical Defects 
 The engraftment and regenerative potential of day 10 Pax7-sorted hPDM-derived muscle 
constructs was evaluated in a sub-critical sized defect in immunodeficient mice at 1 and 2 weeks 
post-implantation. A sub-critical sized defect was utilized to decrease the inflammatory response 
to injury and promote cell survival. Pax7-sorted constructs maintained the defect volume but 
resulted in moderate fibrosis at both 1 and 2 weeks post-implantation (Fig. 4.6Ai). 
Immunostaining demonstrated the presence of blood vessel infiltration at both 1 and 2 weeks 
(Fig. 4.6Aii) but the presence of implanted human cells decreased significantly between 1 and 2 
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weeks post-implantation (Fig. 4.6B). Little MHC expression was present within the defect 
regions at both time points demonstrating the limited regenerative potential of hPDM-derived 
muscle constructs within this defect model. Despite the lack of muscle regeneration, longitudinal 
sectioning demonstrated the positive engraftment potential of hPDMs implanted for 1 week with 
dense human nuclei visible within the defect region (Fig. 4.6C). 
Figure 4.6. Pax7-sorted hPSC-derived muscle constructs demonstrate survival at 1 week 
but not 2 weeks in sub-critical defect. A) Masson’s trichrome staining (left) and 
immunostaining (right) for myosin heavy chain (MHC; green), vasculature (CD31; right), and 
human nuclear protein (LaminAC; white).  B) Pax7-sorted hPSC-derived muscle constructs 
implanted for 1 week contained significantly more human nuclei than those implanted for 2 
weeks with no difference in myogenesis. C) Longitudinal sectioning and immunostaining for 
phalloidin (F-actin; red) and human nuclear protein (LaminAC; white) at 1 week post-
implantation demonstrates dense human nuclei visible within the defect region. ***: p < 0.001 
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In Vitro Maturation Time Point of Pax7-Sorted hPDM-Derived Muscle 
Constructs May Impact In Vivo Engraftment and Regenerative Potential 
 Pax7-sorted hPDM-derived muscle constructs at either day 3 or day 10 of in vitro culture 
were implanted in sub-critical defects for 1 week to evaluate differences in engraftment and 
regenerative potential based on the in vitro maturation time point. Bulk fibrin gels seeded on the 
day of implantation were utilized as a near 100% seeding efficiency control. The in vitro day 3 
and day 10 constructs exhibited characteristic early (Pax7) and late (MHC) protein expression, 
respectively (Fig. 4.7A). Following implantation in a sub-critical defect for 1 week, bulk gels 
demonstrated significant construct resorption and a failure to maintain the defect volume. 
Implanted day 3 and day 10 fibers both maintained the defect volume with day 10 fibers 
resulting in a higher level of fibrosis (Fig. 4.7Bi). Immunostaining for Pax7 demonstrated the 
presence of human nuclei within the defect and satellite cells surrounding the defect regions for 
all groups (Fig. 4.7Bii). Myotube-like structures containing multiple human nuclei were visible 
in the defect regions of all groups with bulk gels and day 3 fibers resulting in more than day 10 
fibers (Fig. 4.7Biii). To further assess differences in the regenerative potential of Pax7-sorted 
hPDM-derived muscle constructs at different maturation time points, embryonic myosin 
(eMHC), a transient marker of muscle regeneration, was evaluated for co-expression with human 
nuclear LaminAC (Fig. 4.8). All three groups contained eMHC+ myofibers with human nuclei 
within and surrounding the defect region as well as blood vessel infiltration into the defect, 
demonstrating the ability of early- and late-stage hPDMs to form regenerating myofibers 




Figure 4.7. The in vitro maturation time point of Pax7-sorted hPSC-derived muscle 
constructs may impact survival and regenerative potential. A) In vitro constructs show 
expression of Pax7 (red) and some desmin (cyan) at day 3 of culture and significant expression 
of myosin heavy chain (MF20; red) and desmin at day 10 of culture. B) Differences in defect 
volume retention, fibrosis, and cell survival were visible via i) Masson’s trichrome staining, ii) 
immunostaining for phalloidin (F-actin; green), Pax7 (red), and human nuclear protein 
(LaminAC; white) in cross-sections, and iii) immunostaining for phalloidin, Pax7, and human 




Figure 4.8. Regenerating myofibers with human nuclei are present inside and surrounding 
the defect with blood vessel infiltration to defect. Immunostained cross-sections demonstrate 
expression of vasculature (CD31; green), regenerating myofibers (eMHC; red), and human 
nuclear protein (LaminAC; white) in A) bulk gels, B) day 3 fibers, and C) day 10 fibers 
implanted for one week. 
4.4 Discussion 
 The translational potential of tissue engineered muscle grafts relies on the use of a 
practical, expandable, and highly myogenic cell source. While hPSCs have been myogenically 
differentiated with significant success in monolayer cultures[80,190–192], the use of hPSCs to form 
an implantable 3D muscle construct has been described just twice before[79,81]. This discrepancy 
is likely due to difficulty in successfully translating monolayer culture protocols to a 3D tissue 
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engineered construct as well as the inherent variability posed by hPSC culture[194]. In both 
previously published hPSC-derived 3D muscle constructs, the implanted constructs utilized 
genetic modification to force overexpression of an early muscle gene and thereby induce hPSC 
myogenesis. One study assessed both genetic modification and small molecule induction 
protocols and selected the transgene-based protocol for subsequent experiments due to better 
myogenesis, scalability, and cost-effectiveness[79]. Although frequently resulting in higher levels 
of myogenesis, genetic modification  has limited translational potential[47,189]. To effectively 
develop a translational tissue engineered muscle graft, both the cell source and the myogenic 
induction protocol should be clinically feasible and safe. To that end, in the current study we 
have developed an implantable 3D hPSC-derived muscle construct utilizing small-molecule 
induction. Both prior studies evaluated the engraftment and myogenic potential of hPSC-derived 
3D muscle constructs in various non-VML models, which fail to assess the survival capability of 
hPSCs when implanted in the harsh post-injury environment. We have evaluated the survival, 
engraftment, and myogenesis of our hPSC-derived muscle constructs in both critical and sub-
critical muscle defects to advance understanding of hPSC survival in the unforgiving post-VML 
environment into which they would ultimately be implanted within patients. 
 Although unsorted hPDMs successfully formed MHC+ myotubes on electrospun fibers, 
there was significant variability between batches of expanded cells. Since hPSCs are an 
inherently heterogeneous cell population[194] it is likely that various non-myoblast cell 
populations remain present following the small-molecule myogenic induction. The process of 
seeding of hPDMs on electrospun fibers in addition to their expansion over the 10 day culture 
period may exacerbate differences in the heterogeneous population in several ways. First, a 
fibroblast-like subpopulation would have faster adhesion capabilities than myogenic precursors 
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and may adhere to the scaffold during seeding at a higher rate. The proportion of fibroblast-like 
cells to myogenic precursors in the starting population as well as inherent variability in the 
seeding process would thus lead to significant batch to batch variability in ultimate myogenic 
potential. It is also possible that hPDMs contain non-myoblasts subpopulations with an increased 
expansion rate and affinity for expansion on a soft hydrogel substrate compared to myogenic 
precursors. The observed variability myogenic potential between batches of unsorted hPDMs 
motivated the use of Pax7-sorted cells in subsequent experiments. 
 Sorting hPDMs for the Pax7::GFP+ subpopulation prior to expansion resulted in a higher 
myogenic potential in monolayer cultures and significant myogenesis on electrospun fibers. 
Some batch to batch variability was still observed following seeding onto 3D constructs which 
may be due to de-differentiation of some Pax7+ cells during expansion and subsequent 
variability in myogenic potential. Significantly, over 40% of cells remained Pax7+ at day 3 of 
culture on electrospun fibers. Pax7-sorted hPDM constructs matured over time demonstrating a 
decrease in Pax7 expression and subsequent increase in expression of mature muscle markers, 
multinucleation, and contractile proteins with visible sarcomeric striations. This is similar to the 
level of maturation seen in in vitro hPSC-derived 3D muscle constructs published previously.  
 Unsorted hPDM constructs were implanted in a murine VML defect to the TA muscle to 
evaluate cell survival in the harsh non-regenerative injury environment typical of VML. Similar 
levels of cell survival were seen 2 weeks post-implantation between induced and uninduced 
hPDM constructs. This result is not surprising given the similarity in DAPI coverage between the 
implanted in vitro induced and uninduced hPDM constructs. Although no muscle regeneration 
was seen, the implanted constructs of this batch had very little MHC coverage at the time point 
of implantation demonstrating the likely significant presence of a non-myogenic cells within the 
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hPDM population. To evaluate engraftment potential of Pax7-sorted hPDM constructs, a less 
damaging sub-critical muscle defect was utilized with approximately 75% less muscle removed 
than the previous VML defects. Interestingly, despite survival of unsorted hPDMs in the harsh 
VML environment up to 2 weeks post-implantation, the implanted Pax7-sorted hPDM constructs 
only survived up to 1 week post-implantation in a less severe defect model. This indicates a 
potential protective effect of the unsorted hPDMs. Previous reports have demonstrated that 
implantation of satellite cells along with non-muscle supporting cell types into a muscle defect 
results in improved regenerative potential compared to implantation of satellite cells alone[21]. It 
is possible that sorting hPDMs for the Pax7+ subpopulation negatively impacts their engraftment 
potential despite improving in vitro myogenic outcomes.  
Despite the presence of dense Pax7-sorted hPDMs and blood vessels within the defect 
region 1 week post-implantation, there remained little evidence of muscle regeneration due to the 
implanted muscle constructs. Previous experiments implanting hPDMs into cardiotoxin-injured 
muscle resulted in successful engraftment and fusion with host myofibers[80]. Due to measured 
differences in the expression of early and late muscle proteins during in vitro culture of hPDMs 
on electrospun fibers, we hypothesized that implantation of hPDM constructs with a higher 
proportion of satellite cells at day 3 of culture would more closely approximate the engraftment 
potential of recently expanded hPDMs seen previously. To account for differences in hPDM 
myogenic potential due to low seeding efficiency on electrospun fibers, hPDMs seeded within a 
bulk fibrin hydrogel on the day of implantation were included as a control. Following 1 week of 
implantation in sub-critical defects, hPDMs seeded on electrospun fibers at both time points 
demonstrated significantly improved defect volume retention compared to the implanted bulk 
gels. Promising preliminary data indicates the presence of myotube-like structures with human 
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nuclei within the defect regions of all implantation groups. It appears that day 3 hPDM 
constructs contained a higher proportion of myotube-like structures and further quantification is 
necessary to identify differences between treatment groups. In addition, eMHC+ regenerating 
myofibers containing human nuclear LaminAC were present within and surrounding the defect 
regions of all treatment groups. Quantification of eMHC+LaminAC+ co-expression will 
determine if there was a treatment group that promoted improved engraftment and in vivo 
myogenesis of implanted hPDMS. 
Future work on this study will include immunostaining for macrophage and neutrophil 
markers to determine if there is a correlation between hPDM survival and any immune response 
by the host. Despite the use of immunodeficient mice, preliminary data has shown a broad 
macrophage presence within and surrounding the defect region. It is likely that persistent 
inflammation in the injury environment negatively effects hPDM survival. In addition, flow 
cytometry will be used to determine the various non-muscle subpopulations present within 
unsorted and Pax7-sorted hPDMs that may contribute to differences in in vitro myogenic 
potential and survival following implantation. Further immunostaining and quantification of 
protein expression of the in vivo data will also be utilized to identify the various cell types 
present within the defect region of different treatment groups as there is a significant amount of 
DAPI staining not correlated with an immunostain utilized thus far. In conclusion, Pax7-sorted 
hPDM constructs have significant in vitro myogenic potential and survive one week post-
implantation in muscle defects with little regeneration. Further characterization and optimization 
of the Pax7-sorted hPDM constructs may improve its regenerative outcomes and enable the 




Chapter 5 Pre-Treatment of In Vitro Muscle Constructs to 
Promote Neuromuscular Regeneration Post-VML 
 
5.1 Introduction 
Volumetric muscle loss (VML) is a defect that overwhelms skeletal muscle’s natural repair 
mechanisms and leads to chronic functional deficits [146,195]. Current treatments are often 
unsuccessful in restoring muscle function and are limited by donor site morbidity, lack of donor 
tissue, and the need for highly skilled surgical teams [36]. It was recently demonstrated that VML 
causes significant motoneuron axotomy and lost interaction between neurons and the injured 
skeletal muscle, a probable cause for the heightened levels of lost muscle function seen post-VML 
[17]. Tissue engineered grafts have great potential to create clinical treatment options for 
regeneration of VML but previous approaches to regenerate the injured muscle remain limited in 
their ability to encourage neuromuscular regeneration within the healing tissue. Engineered muscle 
constructs that incorporate methods to encourage neural infiltration and the formation of functional 
NMJs post-VML provide promising avenues to restore interaction between the muscle and nerve.  
Prior strategies to promote neuromuscular regeneration post-VML have included 
neurotization [50,86], the use of rehabilitative exercise [21,46,84,121], and implantation of a pre-
innervated construct [196], and have resulted in some increased neural infiltration, force recovery, 
and neuromuscular junction (NMJ) formation within and around the defect site. Despite 
incremental neuromuscular regeneration, the nerve and NMJ densities within the defects remain 
low and the newly formed NMJs exhibit immature morphologies. In addition, there has been little 
effort to quantify neuromuscular regeneration across the entire defect area, instead relying on 
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subsets of the defect region at high magnifications that do not accurately represent variability in 
expression across the defect region. In native tissues, the mature NMJ contains densely clustered 
postsynaptic acetylcholine receptors (AChR) optimized for efficient signal transfer across the 
neuromuscular synapse and effective muscle contraction [117]. Agrin, a large heparan sulfate 
proteoglycan secreted by the nerve terminal, is vital for acetylcholine receptor (AChR) cluster 
stabilization during embryonic development [114] and has been utilized extensively to induce AChR 
clustering in cultured myotubes [130–138]. Muscle constructs containing agrin physically mixed into 
a fibrin hydrogel and seeded with C2C12 myoblasts were implanted subcutaneously in a non-VML 
defect near the peroneal nerve for 8 weeks and resulted in increased nerve infiltration, NMJ 
formation, and vascular infiltration [130], demonstrating the potential neuromuscular therapeutic 
benefits of scaffold-mediated agrin delivery in vivo. In this study, we resolved to test whether the 
delivery of soluble or chemically-tethered agrin could promote improved NMJ regeneration in the 
treatment of VML defects.  
Although release of bioactive molecules from engineered constructs has been utilized in 
VML treatment to promote vascular infiltration [24,33,88,106] and myogenesis [24,88,89], there have been 
no previously published constructs that have incorporated pharmacologic factors specific to 
neuromuscular regeneration for VML treatment. In addition, prior VML treatments with scaffold-
mediated delivery of bioactive molecules have utilized physical entrapment or passive adsorption 
to the scaffold prior to implantation, which rely on diffusion of the bioactive agent to the 
surrounding tissues [52]. In contrast, scaffolds incorporating immobilized bioactive agents offer the 
ability to control spatiotemporal presentation and local signaling to the regenerating tissue, avoid 
poor targeting efficiency, and extend factor bioactivity over time following implantation [197–199]. 
Our group has previously utilized electrospun fibrin microfiber bundles that mimic the native 
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properties of skeletal muscle combined with C2C12 myoblasts to promote functional and 
histological regeneration post-VML [25]. In the current study we have enhanced our in vitro muscle 
constructs to promote neuromuscular regeneration in VML defects through the delivery of agrin. 
Therefore, in this current study, we tested the hypothesis that immobilized agrin tethered to the 
surface of C2C12-seeded microfiber bundles would maintain its in vitro bioactivity and induce 
AChR clustering in myotubes cultured on the 3D constructs. In addition, we tested the ability of 
tethered agrin constructs implanted in a murine VML defect model to improve neuromuscular 
regeneration at 4 weeks compared to constructs pre-treated with soluble or zero agrin. 
 
5.2 Materials and Methods 
Electrospinning Fibrin Scaffolds 
Fibrin scaffolds were electrospun in a sterile environment with sterile solutions as 
previously described [25,77]. Parallel syringes containing solutions of fibrinogen (Sigma) or sodium 
alginate (Sigma) were connected via a y-syringe and extruded by syringe pumps with an applied 
voltage of 3-5 kV applied to a 27G needle tip utilizing 1% fibrinogen with an extrusion rate of 4 
ml/hr and 0.75% alginate with an extrusion rate of 1 ml/hr. Polyethylene oxide (average Mv ~ 4 
000 kDa, Sigma) was added to each solution at 0.2 wt% to increase viscosity during 
electrospinning. The electrospun hydrogel solutions were collected for 5.75 minutes on a rotating 
dish (~35rpm) containing 50 mM CaCl2 and 20 U/ml thrombin (Sigma) as crosslinking agents. 
Samples were allowed to crosslink and additional 3-5 min after electrospinning and were then 
wrapped around a 1.5 × 1.5 cm acrylonitrile-butadiene-styrene frame 4 times to yield a hydrogel 
microfiber bundle ~700 μm in diameter. Scaffolds were incubated overnight in 250 mM sodium 
citrate (Sigma) to dissolve the alginate and then transferred to DI water for storage up to 2 weeks.  
Protein Tethering to Scaffolds 
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Scaffolds with tethered proteins underwent the following tethering protocol one day prior 
to cell seeding. All incubation steps were performed at room temperature. Activation Buffer was 
prepared using 0.1M 4-Morpholineethanesulfonic acid (MES; Sigma) and 0.5M sodium chloride 
(Sigma) and adjusted to have pH 5-6. N-Ethyl-N′-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (EDC; Sigma) and N-hydroxysuccinimide (SNHS; ThermoFisher Scientific) were 
dissolved at 10 mg/ml in Activation Buffer immediately prior to use. Agrin (R&D Systems) or 
Cy3 was diluted to 2, 10, 50, or 100 μg/ml (0.08, 0.4, 2, 4 μg/fiber) in sterile PBS with pH 7.2-7.5. 
Scaffolds were incubated with Activation Buffer on a rocker at 100 rpm for two 30 min washes 
then transferred to EDC/SNHS Buffer on a rocker at 120 rpm for 15 min. Scaffolds were then 
transferred to custom small-volume molds designed to suspend the scaffolds within 40 μl of agrin 
or Cy3 on a rocker at 80 rpm for 3 hours. Scaffolds were then washed with DI water for two 20 
min washes and stored in fresh DI water overnight. 
Cell Culture and Seeding on Scaffolds 
C2C12 myoblasts were expanded in C2C12 Growth Medium: high-glucose DMEM 
(Invitrogen), 10% fetal bovine serum (FBS; Atlanta Biologicals), and 1% penicillin/streptomycin 
(P/S; Invitrogen) and used for experiments at passage 8. In preparation for cell seeding, scaffolds 
were incubated in high glucose DMEM for 20 min at 37 °C. The scaffolds were then transferred 
to 6-well cell culture plates coated with 2% agarose type VII (Sigma) to minimize cell adhesion to 
the plate surface, which increases the seeding efficiency. For all experiments, a total seeding 
volume of 40 μl at 7,500 cells/μl was pipetted onto the scaffold surface in a series of 5 μl droplets 
(for a total seeding density of 300,000 cells/scaffold). Scaffolds were incubated for 1 hour at 37°C 
with hydration levels maintained by addition of 15 μl of C2C12 Growth Medium at 30 minutes. 
After the 1-hour incubation, 3 ml of C2C12 Growth Medium containing 30 μg/ml aprotinin 
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(Affymetrix) was added to each well and care was taken to ensure the scaffolds had been 
submerged in the media. On day 3 of culture myoblasts were transferred to C2C12 Induction 
Medium: high-glucose DMEM, 2% horse serum (ThermoFisher Scientific), 1% P/S, 1% insulin-
tranferrin-selenium (ITS; Corning Cellgro), and 30 μg/ml aprotinin and media was changed every 
other day. Constructs with zero agrin or tethered agrin remained in C2C12 Induction Medium for 
the extent of in vitro culture. For soluble agrin constructs, recombinant rat agrin protein (agrin; 
R&D Systems) was added to C212 Induction Medium at 5 or 50 ng/ml at day 6 of culture and 
replenished at day 7 of culture. Zero agrin and tethered agrin constructs were used for experiments 
on day 7 of culture while soluble agrin constructs were used for experiments at day 8 of culture. 
Agrin Release Kinetics 
Scaffolds were electrospun and underwent agrin tethering with 50 μg/ml agrin as described 
above. Control scaffolds with untethered agrin were fabricated by incubating scaffolds in small-
volume molds containing 50 μg/ml agrin for 3 hours without the prior Activation Buffer and 
EDC/SNHS incubation steps. Immediately following the agrin incubation, all scaffolds were 
rinsed once in 1 ml of 1% BSA in PBS (Reagent Diluent Buffer; R&D Systems) which was 
collected and stored at -20°C. Scaffolds were then incubated in fresh buffer at 37°C. Excess 
residual agrin remaining within the small-volume molds following scaffold removal from the 
molds was also collected in buffer and stored at -20°C. At 1, 4, and 7 days post-tethering the buffer 
was removed, replaced with fresh buffer, and stored at -20°C. Control wells that served as a 100% 
release control contained 50 μg/ml agrin in 1 ml of buffer and were incubated at 37°C with 100 μl 
samples collected at days 1, 4, and 7. Agrin concentration for all samples was analyzed via ELISA 
(DuoSet ELISA for Rat Agrin, DY550; R&D Systems) with optical density determined using a 
microplate reader set to 450 nm. 
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In Vitro Mechanical Testing 
Scaffolds that were either untreated or pre-treated with EDC/SNHS buffer as described 
above were loaded into a custom bioreactor and stiffness analyzed as described previously [152,200]. 
Briefly, scaffolds were adjusted to zero strain, then stretched beyond 15% strain at ~1% strain/s as 
force sensors generated a stress-strain curve. Elastic modulus was calculated from a linear fit of 
the first 15% strain and corresponding stress. Diameter of the fibers was used to estimate the cross-
sectional area for stress calculation and was measured as an average of the diameter of two 
different regions of each fiber due to variability along the fiber length.   
Whole Mount Immunostaining 
Scaffolds were fixed in 4% formaldehyde at 4°C on a rocker at 80 rpm for 3 hours. 
Following 3 washes with PBS, scaffolds were blocked and permeabilized (Block/Perm Solution) 
for 3 hours with 0.2% Triton X-100, 10% normal goat serum (Sigma), and 2% bovine serum 
albumin (BSA; Sigma) in PBS. Scaffolds were then incubated with mouse anti-myosin heavy 
chain, fast (1:400; Sigma) diluted in Block/Perm Solution overnight at 4°C on a rocker at 135 rpm, 
followed by three 1-hour washes with PBS. Scaffolds were then incubated with DyLight 488-
conjugated goat anti-mouse (1:400; Jackson ImmunoResearch) and tetramethylrhodamine α-
bungarotoxin (1:50; Thermo Fisher) diluted in 10% normal goat serum, 2% BSA, and 0.1% Tween 
in PBS overnight at 4 °C on a rocker at 135 rpm, followed by three 1 hour washes with PBS. DAPI 
was incorporated in the second wash at a dilution of 1:2000. Samples were then imaged with a 
Zeiss LSM 510 confocal microscope. All in vitro staining was performed with n=3 samples per 
group and imaged with at least two 20x z-stack images per sample. To quantify AChR clusters, 
bungarotoxin stains were analyzed using Fiji software [201] with a size threshold of 3-225 μm2. 
Cluster density was determined as the total area of positive bungarotoxin staining divided by the 
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total area of MHC. Cluster spatial location was determined by quantifying the percent area 
coverage of each slice within a z-stack image using a size threshold of 3-225 μm2 and determining 
the distance above the scaffold with the Fiji Plot Z-axis Profile plugin. 
VML Defect Model 
Animal and surgical procedures were approved by the Institutional Animal Care and Use 
Committee at Johns Hopkins University School of Medicine. Unilateral VML defects in 17 two-
month-old female NOD-scid IL2Rgnull (NSG) immunodeficient mice (Jackson Lab) were utilized 
for in vivo testing of zero agrin (n=3 mice), soluble agrin (n=7 mice), and tethered agrin (n=7 
mice) constructs. Mice were randomly assigned across all groups. In vitro constructs were prepared 
and cultured with C2C12s as described above. VML defects were created as previously 
described[25]. Mice were anesthetized with isofluorane, the TA muscle was exposed, and 
approximately 30-50% of the muscle removed. After bleeding ceased, scaffolds were placed in the 
defect site and ligated on both ends to the remaining TA muscle with non-absorbable sutures (6-0 
Nylon, Express Medical Supplies). Surgical glue (Histoacryl, B. Braun) and sutures were used to 
close the skin. Rimadyl was injected subcutaneously post-surgery for pain management (5 mg/kg). 
Mice were sacrificed at 4 weeks post-implantation by isoflurane overdose and cervical dislocation. 
Upon harvest, implanted scaffolds and surrounding TA muscle tissue were removed and 
cryopreserved. 
In Vivo Functional Testing 
In vivo assessment of mouse TA muscle contractility was performed at 4 weeks as 
previously described [25,154]. Briefly, mice were anesthetized with isoflurane and the leg was 
stabilized in a custom-made apparatus. The foot was taped to a foot plate connected to a torque 
sensor and stepper motor and the ankle was positioned at 20° of plantarflexion, which has been 
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shown to be the optimum length to achieve maximum ankle dorsiflexor torque (in which the TA 
muscle accounts for the majority of ankle dorsiflexion). Electrodes were placed subcutaneously at 
the fibular head to stimulate the fibular nerve and induce dorsiflexion. Voltage and frequency were 
optimized for each leg during tetanic contractions (300 ms duration) and the maximal isometric 
torque was quantified per leg at each time point (n=7). Functional data for zero agrin (n=7) and 
untreated (n=6) groups is from previously published results [25]. 
Histology 
Samples were sectioned on a cryostat (Leica) at a thickness of 10 μm for cross-sections 
and 70 μm for longitudinal sections. Masson’s Trichrome stains were imaged on a Zeiss Axio 
Imager upright microscope. For immunohistochemistry, slides were fixed in cold 4% 
formaldehyde for 10 min and rinsed with PBS three times for 15 min each, then blocked in 10% 
normal donkey or goat serum (Sigma) in PBS for 1 hour at RT. For β tubulin III staining, slides 
were blocked in 10% normal donkey serum, 2% BSA, and 0.2% Triton X-100 in PBS for 3 hours 
at RT. For agrin staining, slides were fixed in a 1:1 mixture of ice-cold acetone and methanol for 
10 min, rinsed with PBS, then blocked in 5% normal donkey serum and 5% BSA in PBS for 1 
hour at RT. For YAP staining, slides were quenched in 50 mM ammonium chloride for 5 min at 
RT prior to blocking in 10% donkey serum and 1% BSA in PBS for 2 hours at RT. Slides were 
incubated with antigen-specific primary antibodies in blocking solution overnight at 4°C. Primary 
antibodies included mouse anti-embryonic myosin (5 μg/ml; DSHB), mouse anti-myosin heavy 
chain (fast-twitch) (1:400; Sigma Aldrich), goat anti-mouse CD31 (1:100; R&D Systems), rabbit 
anti-β tubulin III (1:200; Sigma), mouse anti-Pax7 (5 μg/ml; DSHB), rabbit anti-Ki67 (1:1000; 
Abcam), and rabbit anti-YAP (1:100; Cell Signaling Technology). After three 5 min washes with 
PBS, slides were incubated with Cy3-conjugated donkey anti-mouse, Alexa Fluor 488-conjugated 
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donkey anti-goat, DyLight 488-conjugated goat anti-mouse, or Alexa Fluor 647-conjugated 
donkey anti-rabbit (1:400; Jackson ImmunoResearch) and DAPI (1:2000) diluted in blocking 
solution for 1 hour at RT. Slides staining for α-bungarotoxin (1:50; Thermo Fisher) or phalloidin-
TRITC (1:40; Sigma) incorporated the stains into the secondary antibody stain. Slides were 
washed three times for 5 min then mounted with 50% glycerol and imaged on a Zeiss Axio 
Observer inverted fluorescence microscope or Zeiss Axio Observer 7. To quantify staining within 
the defect regions, tiled images covering the entire defect region were taken on a Zeiss Axio 
Observer 7 with a 20x objective. An AChR cluster was determined to be within an NMJ when the 
area of positive bungarotoxin staining was within 2 μm of an area with positive β-tubulin III 
staining. 
Statistics 
Statistical analysis was performed using GraphPad Prism 5 software. Statistical 
significance was determined by t test or one-way ANOVA with Dunnett or Bonferroni post-test. 




AChR Cluster 3D Spatial Distribution is Determined by Agrin Delivery 
Method 
Electrospun fibrin hydrogels designed to mimic the hierarchical structure and alignment of 
skeletal muscle were fabricated as previously described [25,77]. A protocol to chemically tether 
proteins to the electrospun fibrin scaffolds using the EDC zero-length crosslinker was initially 
developed and validated using a fluorescent Cy3 antibody which has a similar size to agrin (Fig. 
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5.1A). Agrin was chemically tethered to acellular scaffolds at 0.08-2 μg/scaffold prior to seeding 
with C2C12 myoblasts, after which C2C12-seeded constructs were cultured for 7 days (Fig. 5.2A). 
Tethered agrin constructs exhibited significantly higher mechanical stiffness than controls lacking 
the EDC crosslinker (Fig. 5.1B), likely due to increased crosslinking of the fibrin scaffold by EDC 
which is visible in scaffold cross-sections (Fig. 5.2B). Soluble agrin was tested in parallel and was 
delivered to muscle constructs at 10 or 100 ng/scaffold for 24 or 48 hours at days 6-8 of culture. 
Both soluble and tethered agrin induced some amount of AChR clustering in myotubes on 3D 
constructs at all concentrations, with differences in cluster density dependent on duration and 
concentration (Fig. 5.3A-C). To control for nonspecific adsorption of agrin to the scaffold, 
untethered control scaffolds were fabricated by incubation with agrin at 2 μg/scaffold without the 
addition of the EDC crosslinker. Despite evidence of some agrin binding, the bioactivity of 
scaffolds with untethered agrin was significantly lower than those with agrin tethered at the same 
concentration (Fig. 5.3C-E). Tethered agrin at 2 μg/scaffold and soluble agrin at 10 ng/scaffold 
for 48 hours had the highest cluster densities while still retaining normal myotube morphology and 
were selected for subsequent experiments. Few AChR clusters were visible in day 7 muscle 
constructs with no agrin, and both soluble and tethered agrin resulted in myotubes with 
significantly higher AChR cluster density, area, and length than zero agrin controls (Fig. 5.2C-F). 
Interestingly, tethered and soluble agrin resulted in significant differences in the spatial location 
of AChR clusters when analyzed in 3D using confocal imaging. Clusters induced by tethered agrin 
were primarily located about 10 μm from the scaffold surface while clusters induced by soluble 
agrin were visible throughout the myotube layer with two similar peaks in cluster density at about 
10 and 30 μm from the scaffold surface (Fig. 5.2G).  Localization of clusters to the scaffold side 
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of myotubes in the tethered agrin group was visible in immunostained cross-sections as well (Fig. 
5.2H). 
 
Figure 5.1. Protein tethering to scaffolds and mechanical testing. A) Fluorescence intensity 
over time for Cy3 tethered scaffolds at various concentrations. B) Mechanical testing 




Figure 5.2. Soluble and tethered agrin induce increased acetylcholine receptor clustering with 
spatial effects in 3D muscle constructs. A) Schematic illustrating agrin tethering and cell seeding on 
electrospun fibrin microfiber bundles. B) Masson’s Trichrome stain of cell-seeded scaffold cross-
sections demonstrating differences in crosslinking density in tethered agrin scaffolds. C) Aligned 
myotubes positive for myosin heavy chain (MHC; green) in all groups exhibit AChR clusters positive 
for α-bungarotoxin (αBTX; red) in agrin treatment groups. D) Density of AChR clusters is 
significantly increased in agrin treatment groups. E,F) The area and length of individual AChR 
clusters in agrin treatments groups was significantly higher than clusters in constructs with no agrin. 
G) The spatial location of AChR clusters differed significantly between groups: tethered agrin induced 
clusters close to the scaffold surface while soluble agrin induced AChR clusters independent of 
distance from the scaffold surface. H) Cross-section of cell-seeded tethered agrin scaffold 
immunostained for MHC and αBTX demonstrating the spatial location of AChR clusters at the 





Agrin Pre-Treatment did not Improve Muscle Function in VML Defects 
 At 4 weeks post-implantation in VML defects all treatment groups exhibited a healthy 
morphology with no signs of infection or graft rejection. Gross images revealed that defects treated 
with tethered agrin contained scaffolds that were significantly more visible within the tissue than 
other groups (Fig. 5.4A). Masson’s Trichrome staining of histologic sections demonstrated low 
levels of fibrosis and defect volume retention in all groups. Defects treated with soluble agrin 
contained dense muscle tissue similar to zero agrin controls (and previous observations [25]) while 
defects treated with tethered agrin resulted in dense muscle tissue containing distinct regions with 
persistent scaffold material and little visible regenerating muscle (Fig. 5.4B). Immunostaining for 
Figure 5.3. Tethering preserves in vitro bioactivity of agrin. A) Aligned myotubes positive for 
myosin heavy chain (MHC; green) exhibit AChR clusters positive for α-bungarotoxin (αBTX; red) in 
agrin treatment groups at differing concentrations and time points of application.  B,C) The spatial 
location of AChR clusters differed significantly between groups for both soluble and tethered agrin. 
D) AChR cluster density varied between tethered agrin concentrations. At the highest 2 μg 
concentration, tethered agrin resulted in significantly higher cluster density than untethered agrin. E) 
Cross-sections of cell-seeded scaffolds immunostained for agrin demonstrate the presence of agrin 
(red) through the scaffold interior in tethered agrin groups while zero agrin and untethered agrin have 
little to no positive agrin staining. *: p < 0.05; **: p < 0.01 
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agrin demonstrated visibly higher levels of agrin on all four implanted scaffolds in the tethered 
agrin treatment group when compared to soluble or zero agrin, demonstrating that tethering agrin 
to the scaffold surface causes persistent agrin presentation to surrounding tissues up to four weeks 
post-implantation (Fig. 5.5). Explanted muscles treated with tethered agrin had a higher wet weight 
and significantly higher defect cross-sectional area compared to soluble and zero agrin (Fig. 
5.4C,D). Despite these differences in histology and size for the tethered agrin group, there was no 
difference in either maximum torque or the force-frequency relationship between groups (Fig. 
5.4E,F).  
 
Figure 5.4. Muscle function following VML defects improved equally in no agrin and agrin-
treated groups. A) Gross morphology at scaffold implantation and 4 weeks post-implantation for 
zero, soluble, and tethered agrin constructs. B) Cross-sections of the explanted tibialis anterior 
muscle stained for Masson’s Trichrome demonstrate differences in defect area (yellow dashed 
line) and morphology between groups. C,D) Differences were present between groups in the 
harvested TA weight and defect size in cross-section. E,F) No difference in muscle function was 
seen between treatment groups. Green line: average max torque of age-matched uninjured TA 
muscle; Red line: average max torque of untreated VML defects at 4 weeks post-injury. All 




Agrin Pre-Treatment Increased NMJ Formation with Differences in NMJ 
Morphology 
 Immunostaining for myosin heavy chain (MHC) demonstrated densely packed myofibers 
in the defect regions for zero and soluble agrin while tethered agrin had dense MHC+ regions in 
addition to distinct areas lacking mature muscle (Fig. 5.6A). Tethered agrin treatment groups did 
contain higher total MHC area compared to zero agrin (Fig. 5.6B), although this is likely due to 
the increased defect size for tethered agrin as the myofiber density did not differ between tethered 
and zero agrin and was higher for soluble agrin compared to tethered agrin (Fig. 5.7). 
Figure 5.5. Agrin remains in VML defect up to 4 weeks post-implantation. A) Agrin was 
present within the defect region (white dashed line) at low levels in the zero and soluble agrin 
treatment groups. Defects treated with tethered agrin constructs contained persistent high levels 
of agrin visible as the four implanted scaffolds. B) High magnification images demonstrating 
differences in agrin distribution. 
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Neurofilament and acetylcholine receptor clusters were visible within the defects of all groups 
with tethered agrin treatment groups containing more total nerves than zero agrin (Fig. 5.6C). 
Neuromuscular junctions defined as positive αBTX staining within 2 μm of a nerve were 
quantified and soluble agrin treatment groups had statistically more AChR clusters within a NMJ 
than zero agrin (Fig. 5.6D). Tethered agrin samples also had a higher average percent of AChR 
clusters within a NMJ compared to zero agrin but with increased variability between samples.  
 
Figure 5.6. VML treatment with soluble and tethered agrin constructs increases NMJ 
formation in vivo. A) Cross-sections of explanted muscle stained for myosin heavy chain (MHC; 
green), neurofilament (β3T; cyan), and acetylcholine receptors (αBTX; red) with dense myotubes 
and NMJs within the defect area (white dashed line). B) Tethered agrin constructs resulted in 
more total myofibers within the defect region than other treatment groups. C) Tethered agrin 
constructs resulted in more total nerves in the defect region than other treatment groups. D) Both 
soluble and tethered agrin constructs resulted in higher percentages of AChR clusters within a 
NMJ than zero agrin. *: p < 0.05; **: p < 0.01 
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Due to the presence of some NMJs within the defect regions of all treatment groups, 
longitudinal sections were utilized to assess for differences in NMJ morphology within the defect 
that would otherwise not be visible in cross-section (Fig. 5.7A). NMJs for all VML treatment 
groups were smaller than those in native skeletal muscle and had a less mature morphology (Fig. 
5.7B). Despite differences in size and shape, visible overlap between the AChR clusters and 
neurofilament was visible in the soluble and tethered agrin groups but not zero agrin (Fig. 5.7C). 
NMJs visible within defects treated with tethered agrin constructs had an immature plaque 
morphology while the soluble agrin group contained some NMJs with a more complex rounded 
architecture. 
 
Persistent Agrin within Implanted Tethered Agrin Constructs Causes 
Localized Neurofilament Clustering  
Figure 5.7. Soluble agrin constructs result in NMJs with a more mature morphology than 
zero and tethered agrin constructs. A) Thick longitudinal sections of explanted muscles enable 
visualization of NMJ morphology. B) Immunostaining of NMJs within native muscle and the 
defect regions of all treatment groups demonstrate positive staining for pre-synaptic 
neurofilament (β3T; cyan), and post-synaptic acetylcholine receptors (αBTX; red) with 
differences in morphology between groups. Inset: high magnification images of NMJs. C) High 




Interesting patterns of protein expression were visible within the defect regions of the 
tethered agrin samples (Fig. 5.8). Overall, defect regions were highly positive for Pax7, CD31, 
and β3-tubulin compared to host muscle (Fig. 5.8A,B). Four regions of persistent undegraded 
scaffold were visible within the defect region that were primarily negative for mature muscle, as 
demonstrated above with Masson’s Trichrome and MY32 staining. Topographical differences in 
protein expression were visible within undegraded scaffold regions compared to between the 
scaffolds. Expression of Pax7 was fairly consistent across the defect region both within the four 
implanted scaffolds and between scaffolds (Fig. 5.8C,D) while blood vessel infiltration into the 
defect region was primarily between the implanted scaffolds (Fig. 5.8Aii,D). Overall, defect 
regions in tethered agrin groups contained higher total neurofilament as well as higher 
neurofilament density compared to other treatment groups.. Interestingly, undegraded scaffolds 
within the tethered agrin defect region were highly positive for the neurofilament stain β3-tubulin 
but not the areas between the scaffolds (Fig. 5.8Aiii,C,D). It is likely that persistent presentation 
of agrin within these undegraded scaffold regions contributed to the differences in protein 





Tethered Agrin Resulted in Increased Blood Vessels and Regenerating 
Myofibers 
 VML treatment with soluble and tethered agrin resulted in significant differences in a range 
of regenerative metrics. Total expression of embryonic myosin (eMHC), a marker of regenerating 
myofibers, was significantly higher in defects treated with tethered agrin compared to zero or 
soluble agrin (Fig. 5.9A,D) and the density of eMHC expression differed significantly between 
Figure 5.8. Satellite cell, vascular, and neural proteins were upregulated within and 
surrounding implanted tethered agrin constructs compared to host muscle. A) Low 
magnification image of TA cross-section treated with tethered agrin constructs and 
immunostained for (i) Pax7 (red), CD31 (green), and β3-tubulin (cyan), (ii) CD31 alone, or (iii) 
β3-tubulin alone. Dashed line: defect region; Solid lines: undegraded scaffold regions. Insets: 
three regions with corresponding high magnification images demonstrating variations in protein 
expression in host muscle (blue inset), at the host-defect border (red inset), and within the defect 
region but between implanted scaffolds (green inset). B) High magnification image of host muscle 
with low levels of Pax7, CD31, and β3T staining. C) High magnification image of the border 
between host muscle and an implanted tethered-agrin scaffold within the defect region. Increases 
in Pax7, CD31, and β3T expression are visible going into the defect region. D) High 
magnification image within the defect region but between implanted scaffolds. Pax7 and CD31 
remain upregulated between scaffolds but β3T expression is decreased.  
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both agrin treatment groups and the zero agrin control as well as between soluble and tethered 
agrin, with tethered agrin resulting in the highest overall eMHC density (Fig. 5.10). Soluble and 
tethered agrin constructs also resulted in increases in total blood vessels within the defect region 
compared to zero agrin (Fig. 5.9A,E). Tethered agrin resulted in higher total blood vessel content 
compared to soluble agrin but when normalized to the defect area, soluble agrin groups contained 
a higher blood vessel density than tethered agrin groups (Fig. 5.10). Total expression of the satellite 
cell marker Pax7 also increased due to tethered agrin constructs (Fig. 5.9B,F) and dense satellite 
cells were visible even within undegraded scaffold regions of tethered agrin groups that did not 
contain MHC+ myofibers (Fig. 5.9B). Total cell content within the defect region was also 
significantly higher due to tethered agrin compared to both other treatment groups (Fig 5.9C). 
These results indicate that persistent agrin presentation in tethered agrin treatment groups within 
regenerating VML defects causes significantly higher levels of eMHC+ regenerating myofibers 
compared to soluble and zero agrin treatment groups. Tethered agrin also increased total cell 
content, blood vessel infiltration, and satellite cell presence within VML defects. 
 Due to the striking increase in both total eMHC+ myofibers and eMHC+ myofiber density 
within defects treated with tethered agrin compared to other treatment groups, we next evaluated 
co-expression of eMHC and nuclear YAP, a transcriptional coactivator with nuclear expression in 
its active form (Fig. 5.11). Defects treated with tethered agrin constructs resulted in significantly 
higher total nuclear YAP expression compared to those treated with zero and soluble agrin (Fig. 
5.11A,B) while the density of nuclear YAP within defects was equal between groups (Fig. 5.12A). 
Both soluble and tethered agrin groups also had significantly higher total levels of cells co-
expressing eMHC and nuclear YAP compared to zero agrin (Fig. 5.11C). Due to the high levels 
of Pax7+ cells within defect regions of all groups, we also evaluated co-expression of Pax7 and 
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the proliferation marker Ki67 (Fig. 5.12B). Although tethered agrin constructs resulted in 
significantly more Ki67 compared to soluble agrin, there was no difference in the level of Pax7 
and Ki67 co-expression between groups. These data demonstrate that persistent agrin presentation 
within regenerating VML defects results in both higher total nuclear YAP expression and co-
expression of eMHC+ regenerating myofibers with nuclear YAP, as well as increased overall cell 
proliferation. 
 
Figure 5.9. Tethered agrin increases the presence of regenerating myofibers, blood vessels, 
and satellite cells within VML defects. A) Differences in expression within the defect site (white 
dashed line) between groups are visible via immunostaining for embryonic myosin (eMHC; red) 
and blood vessels (CD31; green). Inset: high magnification image. B) Immunostaining for satellite 
cells (Pax7; green) and filamentous actin (F-actin; red) demonstrated differences in satellite cell 
recruitment between treatment groups. C) Defects treated with tethered agrin contained more cells 
than zero or soluble agrin groups. D) Tethered agrin resulted in significantly more embryonic 
myosin positive cells within the defect region than zero or soluble agrin. E) Significant differences 
in total blood vessel coverage were seen between all treatment groups with tethered agrin inducing 
the highest amount of blood vessels within the defect region. F) Tethered agrin constructs resulted 
in higher satellite cell numbers within the defect region than zero or soluble agrin. *: p < 0.05; 





Figure 5.10. Further quantification of regenerative markers within VML defects treated with 
zero, soluble, or tethered agrin constructs. Significant differences were seen in the defect region 
between treatment groups in the density of total cells, blood vessels, regenerating myofibers, 





Figure 5.11. Co-expression of nuclear YAP and embryonic myosin within regenerating 
defects. A) In all treatment groups, some regenerating myofibers positive for embryonic myosin 
(eMHC; red) within the defect region also had nuclei positive for YAP (white). B) Total nuclear 
YAP (nYAP) was significantly higher in defects treated with tethered agrin constructs compared 
to other groups. C) Both soluble and tethered agrin constructs resulted in higher levels of eMHC+ 





Successful regeneration of VML defects includes the formation of mature NMJs that allow 
for efficient neural signal propagation and subsequent muscle contraction. Significant advances in 
the field of skeletal muscle tissue engineering have demonstrated varied levels of muscle tissue 
regeneration and functional recovery post-VML [16,21,71–73,22,33,56,66–70]  but remain limited in their 
ability to promote neuromuscular regeneration and few studies have been designed with this goal 
in mind. To date, there have been no previously published constructs that have incorporated 
pharmacologic factors specific to neuromuscular regeneration for VML treatment. Agrin has been 
Figure 5.12. Further quantification of YAP staining and analysis of Ki67 and Pax7 co-
expression. A) The density of nuclear YAP within defect regions did not differ between groups 
while the percent of eMHC+ myofibers containing YAP+ nuclei was significantly higher for 
soluble agrin compared to zero agrin. B) Defects treated with tethered agrin constructs contained 
significantly more Ki67+ nuclei compared to those treated with soluble agrin but the density of 
Ki67+ nuclei was higher for zero agrin compared to soluble agrin. All groups had very low co-
expression of Ki67 and Pax7 with no difference between groups in the total level of co-expression 
or the percent of co-expressing nuclei within the defect. *: p < 0.05 
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previously utilized to induce AChR clustering in cultured myotubes [130–138] and agrin-loaded 
muscle constructs have resulted in increased nerve infiltration and NMJ formation upon 
subcutaneous implantation in a non-VML model [130]. We thus identified agrin as a putative 
pharmacologic factor to induce neuromuscular regeneration post-VML and modified our 
previously developed electrospun muscle constructs [25,77] to incorporate agrin delivery within in 
vitro cultured muscle constructs as well as to the regenerating environment post-implantation. 
 Two methods of agrin delivery to 3D cultured myoblasts were examined for their 
neuromuscular potential in vitro and in vivo. Agrin provided in solution within cell culture media 
most closely mimics previous studies utilizing soluble agrin to induce AChR clustering in myotube 
monolayers via transient delivery to mature myotubes. Preliminary studies demonstrated that 
soluble agrin applied to immature C2C12 myoblast monolayers (day 2) did not cause AChR 
clustering while agrin applied to mature myotubes late in culture (day 8) was successful in inducing 
AChR clustering (data not shown). We thus applied agrin at a late time point (days 6-8) in the 
soluble agrin group. Chemically tethering agrin to electrospun fibrin scaffolds changes the cell 
microenvironment by enabling agrin signaling to cells throughout the duration of culture. In 
addition to inducing AChR clustering, in vitro agrin application to myotubes has been shown to 
increase contractile properties and dystrophin expression [134], myotube motility [202], and 
maturation of the excitation-contraction coupling machinery [203] further motivating prolonged 
agrin signaling via tethering to the scaffold surface. In addition, implanted constructs incorporating 
tethered agrin enable sustained local agrin signaling over time to the regenerating VML 
environment post-implantation with potential extended therapeutic benefit.  
Scaffold-mediated delivery of immobilized bioactive factors may be limited by the 
potential for decreased factor bioactivity by denaturing or deactivating the protein during the 
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tethering process [204]. The EDC crosslinking paradigm used in this study has been used previously 
to tether agrin to polymeric microparticles for application to in vitro cultured myotubes with 
preserved agrin bioactivity [132]. In the current study, the bioactivity of tethered agrin was 
maintained as well and resulted in significantly more AChR clustering than passively adsorbed 
agrin. The difference in the in vitro 3D spatial location of AChR clusters seen between soluble and 
tethered agrin delivery methods is similar to previous reports where spatial control of AChR 
clusters is controlled by localized agrin signaling [132] and further motivates the potential benefit 
of tethering agrin to the implanted scaffold to prolong agrin signaling in vivo such that AChR 
clusters are induced to form within the defect site. 
 The EDC tethering protocol resulted in increased crosslinking of microfiber bundles and a 
significantly higher mechanical stiffness than other treatment groups with implications for both in 
vitro myogenesis and regeneration upon implantation. In the current study, in vitro myotubes 
formed within tethered agrin constructs had no visible difference in morphology compared to 
myotubes in other groups. Following implantation in VML defects for four weeks, tethered agrin 
constructs resulted in regions with distinct undegraded scaffold clearly visible via histological 
staining and likely due to the increased crosslinking and mechanical stiffness. In addition, despite 
resulting in a higher regenerating defect cross-sectional area, tethered agrin constructs did not 
confer functional improvements compared to defects treated with zero or soluble agrin constructs. 
The lack of a functional difference between treatment groups is similar to a variety of previous 
studies demonstrating that VML treatment with acellular scaffolds provides functional 
improvements compared to untreated defects at similar levels to cell-seeded scaffolds, even 
without corresponding histological muscle regeneration [21,22,25,46,54,56,57]. In addition, a study 
comparing VML treatment with fibrin microthreads with adsorbed hepatocyte growth factor 
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(HGF) found no difference in maximum tetanic force with or without the loaded HGF [12,24]. In 
fact, a recent meta-analysis of various VML treatments found that while treatment resulted in 
improved muscle function compared to untreated VML, there was little difference in functional 
improvement between the various treatment options [205]. It is therefore unsurprising that VML 
treatment with myoblast-seeded constructs containing zero, soluble, or tethered agrin resulted in 
similar levels of functional improvement. Although the presence of agrin within the defect region 
four weeks post-implantation was highest for tethered agrin constructs, agrin was visible at low 
levels in the other two treatment groups as well. Agrin is endogenously expressed at neuromuscular 
junctions and some neural synapses [206,207] and immunostaining for agrin within the defect region 
may be identifying endogenous protein expression in addition to the implanted agrin constructs. 
 Improved neuromuscular regeneration was seen for VML treatment with both soluble and 
tethered agrin constructs compared to zero agrin constructs. The total nerve area and nerve density 
within defects treated with tethered agrin was higher than zero agrin, and soluble agrin constructs 
resulted in a higher percentage of AChR clusters within a NMJ compared to zero agrin. This is in 
keeping with a previous study where agrin-loaded muscle constructs were implanted 
subcutaneously and resulted in increased numbers of NMJs at 2, 4, and 8 weeks post-implantation 
[130]. Quantification of NMJ density and morphology post-VML has been primarily limited to thin 
histological cross-sections, which do not enable morphological analysis of the complete NMJ [208]. 
In the current study, when NMJs were viewed via longitudinal sectioning, differences in 
morphology were apparent between agrin treatment groups with soluble agrin constructs inducing 
a more mature NMJ morphology than tethered agrin constructs. It has been previously 
demonstrated in monolayer cultures that agrin preferentially induces AChR clusters with an 
immature plaque shape [137], possibly explaining the higher incidence of an immature, plaque-
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shaped NMJ morphology in VML defects exposed to sustained agrin presentation over time via 
tethered agrin constructs. 
 The sustained presentation of agrin combined with increased scaffold stiffness of tethered 
agrin constructs appears to have caused spatial differences in protein expression within the 
regenerating defect region. Soluble and tethered agrin constructs resulted in increased overall 
blood vessel infiltration, but blood vessels in zero and soluble agrin samples were uniform across 
the defect region while tethered agrin samples resulted in blood vessels primarily infiltrating 
between implanted scaffolds. This was likely due to increased stiffness of tethered agrin constructs 
and subsequent decreased ability for blood vessel penetration to the scaffold interior. In future 
studies we will assess the role of increased scaffold stiffness by utilizing EDC-treated scaffolds 
lacking agrin. Implanted tethered agrin constructs also contained high densities of neurofilament 
within the undegraded scaffold regions compared to regions between the implanted scaffolds and 
within host muscle tissue. Agrin treatment has been previously linked to increased nerve outgrowth 
[130] and neural proteolytic cleavage of agrin has been shown to induce formation of dendritic 
filopodia synaptic precursors [209]. The persistent agrin presence at four weeks post-implantation 
within tethered agrin scaffolds may have induced the high levels of neurofilament seen here. 
A high incidence of eMHC+ regenerating myofibers within the defect is perhaps the most 
striking result of implanted tethered agrin constructs. Embryonic myosin is a transient marker of 
regenerating skeletal muscle and we have demonstrated previously that C2C12-seeded electrospun 
fibrin scaffolds implanted in VML defects resulted in significant eMHC expression at 2 weeks but 
not 4 weeks post-implantation [25]. Here, both agrin groups resulted in a significant increase in 
eMHC expression within the defect region compared to zero agrin controls, with tethered agrin 
resulting in the highest amount of eMHC. It appears that agrin treatment induces a prolonged state 
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of eMHC expression within VML defects, with the sustained signaling of tethered agrin causing 
the highest level of eMHC. Agrin administration has recently been shown to suppress 
cardiomyocyte maturation and enable cardiac regeneration in adult mice with a link to increased 
nuclear YAP expression [210]. It is possible that the skeletal muscle constructs pre-treated with 
soluble and tethered agrin are causing a similar suppressed maturation state of the myofibers 
present within VML defect regions, resulting in sustained eMHC expression. Additionally, 
tethered agrin constructs resulted in increased total nuclear YAP expression and both agrin 
treatment groups resulted in increased myofibers with co-expression of eMHC and nuclear YAP. 
Agrin has recently been correlated with YAP activation and increased nuclear YAP expression in 
various tissues [207,211], and nuclear YAP expression has been linked to increased cell proliferation 
and decreased myoblast maturity [212,213]. The sustained agrin delivery provided by implanted 
tethered agrin constructs may thus promote the increased nuclear YAP, increased cell proliferation, 
and increased expression of eMHC found within regenerating VML defect regions here. While 
prolonged agrin signaling within the post-VML regenerating environment provides therapeutic 
benefit, optimization of the construct degradation timeline to match the rate of muscle regeneration 
would likely further improve the construct regenerative potential by enabling increased blood 
vessel and myofiber infiltration to the scaffold interior. Due to the increased fibrin crosslinking 
caused by EDC, utilization of a lower EDC concentration or alternative tethering chemistry could 
increase the construct degradation rate. As soluble agrin constructs provided improved blood 
vessel and myofiber density as well as increased NMJ maturity, pretreating muscle constructs with 
both soluble and tethered agrin could combine the benefits of both delivery approaches. In 
addition, defect regions in tethered agrin treatment groups were significantly larger than the other 
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groups, indicating possible overgrowth within the regenerating muscle in response to sustained 
agrin signaling and a potential need for regulating the temporal release of agrin in future studies. 
In conclusion, engineered muscle constructs pre-treated with agrin form dense AChR 
clusters in vitro and promote neuromuscular regeneration upon implantation in VML defects for 
four weeks. While all treatment groups resulted in improved muscle function, constructs pre-
treated with both soluble and tethered agrin caused increased neurofilament and blood vessel 
infiltration, NMJ formation, and the presence of eMHC+ regenerating myofibers compared to zero 
agrin controls. In addition, sustained in vivo agrin signaling in tethered agrin treatment groups 
caused heightened neurofilament and eMHC density compared to soluble agrin. Future studies 
should further investigate the role of agrin in the regenerating muscle environment post-VML over 









Chapter 6 Conclusions and Future Perspectives 
 
The data presented in this thesis demonstrate the regenerative potential of engineered 
muscle constructs following volumetric muscle loss. Electrospun fibrin scaffolds seeded with 
myoblasts enabled robust muscle regeneration post-VML, in vitro myogenesis of translatable cell 
sources, and neuromuscular regeneration post-VML when chemically modified for sustained 
agrin delivery to the regenerating tissue. This final chapter summarizes the most important 
conclusions, contributions, and future directions that have resulted from this work. 
6.1 Conclusions and Contributions 
Aim 1 Conclusions 
Chapter 2 describes the initial development of an engineered muscle construct utilizing an 
electrospun fibrin hydrogel scaffold and a mouse myoblast cell line. The electrospun scaffolds 
were designed to mimic the native stiffness and hierarchical structure of skeletal muscle. 
Engineered muscle constructs demonstrated spontaneous and electrically stimulated contraction in 
vitro and myotubes expressed mature muscle markers with characteristic striations. Following 
implantation for two or four weeks in murine VML defects, the engineered muscle constructs 
enabled functional recovery and robust regeneration of vascularized skeletal muscle tissue with 
little to no fibrosis at the graft-host interface. 
 The extent of muscle and vascular regeneration following VML injury when treated with 
C2C12-seeded electrospun scaffolds seen here is a significant improvement over previous 
treatment modalities, resulting in a high density of myofibers and perfusable vasculature within 
the defect. Despite the inability of acellular constructs to support muscle regeneration, both 
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myoblast-seeded and acellular scaffolds recovered the contractile function of injured muscle. This 
initially surprising result has since been demonstrated repeatedly by other labs and is thought to 
be due to scaffold mediated functional fibrosis, where the implanted scaffold provides a 
mechanical bridge to prevent prolonged overload injury to the remaining muscle after injury. In 
conclusion, the experiments comprising Aim 1 demonstrate the development of a novel construct 
system that enabled previously unprecedented levels of functional muscle and vascular 
regeneration. The body of work described in this aim resulted in one journal publication and three 
conference abstracts. 
 
Aim 2 Conclusions 
 The work described in Chapters 3 and 4 evaluated the ability of electrospun fibrin 
scaffolds to promote in vitro myogenesis and in vivo regeneration and engraftment of two 
translatable cell sources. Human adipose-derived stem cells expanded on electrospun scaffolds 
and formed elongated tube-like structures but had limited expression of muscle proteins in vitro 
even when induced with a DNA methyltransferase inhibitor shown previously to promote ASC 
myogenesis. Following implantation in an extensive VML model involving the complete 
removal of two entire muscles, implanted ASCs survived up to three months but myogenesis was 
low. After one month of implantation, there were slightly higher levels of regenerating and 
mature myofibers in defects treated with uninduced ASCs indicating a potential paracrine benefit 
of ASC implantation despite a lack of direct myogenesis. In rare instances, several myofibers 
containing a human nucleus were visible in the defect region demonstrating the feasibility of 
ASC contribution to muscle regeneration in vivo albeit at an extremely low level. Due to the 
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limited in vitro and in vivo myogenesis of ASCs, human pluripotent stem cells were next 
investigated as an alternative translatable cell source. 
 Both unsorted and Pax7-sorted hPSCs that underwent a small molecule myogenic 
commitment protocol successfully formed myotubes on electrospun scaffolds in vitro. Sorting 
the hPSCs for Pax7 resulted in improved myogenesis and constructs that exhibited a 
characteristic muscle protein expression timeline, sarcomeric striations, and multinucleation. 
Following implantation in critical or sub-critical defects, unsorted hPSC-derived muscle 
constructs enabled cell survival two weeks post-implantation while Pax7-sorted constructs only 
survived up to one week in vivo. Although there was little to no muscle regeneration present 
following implantation of unsorted hPSC-derived muscle constructs, Pax7-sorted constructs 
resulted in a significant amount of regenerating myofibers, many of which contained human 
nuclear protein. In addition, longitudinal views of the defect region contained myotube-like 
structures that were multinucleated with human nuclei. Preliminary data suggests that 
implantation of day 3 Pax7-sorted constructs improves regenerative outcomes compared to 
implantation of day 10 constructs. Further analysis and quantification will provide a broader 
understanding of the in vivo regenerative potential of Pax7-sorted constructs. In conclusion, the 
experiments comprising Aim 2 demonstrate the ability of electrospun fibrin scaffolds to promote 
in vitro myogenesis of translatable cell sources. ASCs were determined to have insufficient 
myogenic potential while hPSC-derived myoblasts sorted for the Pax7+ subpopulation 
demonstrated promising myogenic potential. The body of work described in this aim resulted in 
one journal publication and five conference abstracts. 
 
Aim 3 Conclusions 
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 Chapter 5 describes the pre-treatment of engineered muscle constructs with the 
proteoglycan agrin in order to promote neuromuscular regeneration. Incorporating both soluble 
and chemically tethered agrin into the in vitro muscle constructs promoted clustering of 
acetylcholine receptors, a necessary precursor to the formation of functional neuromuscular 
junctions. Tethering agrin to the scaffold surface changed the spatial location of AChR clusters 
compared to soluble agrin delivery, inducing clusters to form near the scaffold surface. 
Following four weeks of implantation in a VML defect, muscle constructs pre-treated with 
soluble or tethered agrin caused increased neuromuscular junctions, regenerating myofibers, 
vascular infiltration, neural infiltration, and nuclear yes-associated protein compared to 
constructs with no agrin. Sustained local agrin delivery to the regenerating environment post-
VML also increased the density of regenerating myofibers and neurofilament compared to 
constructs pre-treated with soluble agrin. 
 The improvements to neuromuscular regeneration caused by agrin pre-treatment are a 
significant improvement over previous attempts to promote neuromuscular regeneration post-
VML. Previous attempts to encourage neuromuscular regeneration are limited to the use of 
rehabilitative exercise or neurotization, and there have been no previous engineered muscle 
constructs designed to delivery bioactive factors for neuromuscular regeneration post-VML. The 
differences in regenerative potential between soluble and tethered agrin seen here also broaden 
understanding of the potential benefits of sustained release drug delivery platforms for 
regeneration post-VML. In conclusion, the experiments comprising Aim 3 demonstrate the 
remarkable neuromuscular regenerative capabilities of agrin when combined with our 
electrospun engineered muscle constructs. The body of work described in this aim resulted in 




6.2 Future Perspectives 
 This dissertation established the myogenic potential of electrospun fibrin scaffolds and 
the in vivo regenerative potential of engineered muscle constructs. While Chapter 2 demonstrates 
robust functional and histological regeneration of muscle post-VML, the engineered muscle 
constructs used were limited by a non-translational mouse myoblast cell line. In addition, despite 
extensive regeneration of the muscle and vasculature there was little neuromuscular regeneration 
within the defect region. Chapters 3 and 4 address the first of these limitations by evaluating the 
myogenic potential of two translational human stem cell sources on electrospun fibers both in 
vitro and in vivo. Chapter 5 addresses the promotion of neuromuscular regeneration through 
modifications to the engineered muscle construct to enable sustained local delivery of agrin. 
Although this body of work has resulted in significant progress toward the goal of a translational 
tissue engineered muscle graft, there remains a need for additional optimization and future 
experiments. 
 Further research is required on the utility of hPSC-derived myoblasts to regenerate VML 
defects. Although Pax7-sorted hPDMs resulted in significant in vitro myogenesis on 3D 
constructs, the cells only survived up to one week post-implantation. This poses a significant 
challenge towards the implementation of these cells for therapeutic use in animals and humans. It 
is possible that the host immune response to implanted hPDMs creates an environment in which 
the cells cannot survive past one week. Although the mice are immunodeficient and lack mature 
T and B cells, they retain some macrophage function as well as the primary immune response. It 
is unlikely that the mice are responding negatively purely based on implantation of human cells, 
however, due to the survival of implanted human ASCs up to 3 months in a significantly harsher 
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VML defect model. Differences in implanted hPDM survival were also observed between 
unsorted and Pax7-sorted populations, indicating that multiple factors contributed to the lack of 
survival seen here. Future experiments investigating the use of anti-fibrotic agents in 
combination with hPDM constructs may promote cell survival and muscle regeneration. In 
addition, preliminary differences in regenerative potential were seen between implantation of 
early versus late-stage hPDM constructs. Further investigation into the potential therapeutic 
benefits of early-stage hPDM constructs would broaden understanding of the therapeutic benefit 
of these cells. 
Although remarkable neuromuscular regeneration was achieved in the experiments 
described in Chapter 5, the regenerative potential of tethered agrin constructs is limited by 
diminished scaffold degradation following implantation. The EDC crosslinker used to tether 
agrin to the electrospun fibers resulted in increased crosslinking of the fibrin hydrogel and 
subsequent increased scaffold stiffness and decreased degradation in vivo. This resulted in 
pockets of undegraded scaffold lacking mature muscle within the defect region four weeks post-
implantation. Future experiments investigating lower crosslinker concentrations or alternative 
tethering mechanisms that enable a higher scaffold degradation rate would benefit the construct’s 
regenerative potential. Additionally, AChR clusters induced by agrin had a morphology that was 
primarily immature and plaque shaped. Utilization of additional proteins or AChR cluster-
inducing agents would benefit the maturation of NMJs forming within the treated VML defects. 
Rehabilitative exercise and neurotization have been shown to enhance neuromuscular 
regeneration post-VML. Future work should investigate the combinatorial effects of engineered 
muscle constructs pre-treated to promote AChR clustering in combination with rehabilitative 
exercise and neurotization.  
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Ultimately, the patients requiring VML treatment have often sustained their injury 
months if not years before receiving treatment. Currently, the vast majority of preclinical studies 
utilize VML models in which the animal undergoes VML injury and is immediately treated with 
an engineered muscle construct. This differs from the clinical environment, where extensive 
scarring and fibrosis of a VML injury sustained years prior must first be debrided prior to 
treatment. In addition, the engineered muscle grafts implanted into a fresh VML injury with its 
associated satellite cell recruitment and regenerative milieu can be expected to have a different 
regenerative potential than when implanted into a chronic VML injury. To enable clinical 
translation, future studies should evaluate the muscle, vascular, and neuromuscular regenerative 
potential of engineered muscle constructs implanted into chronic VML defects. 
Finally, immunodeficient animal models as well as small animal models have been 
utilized extensively in preclinical research of VML treatment. While immunodeficient animals 
enable implantation of muscle grafts composed of human cells, it is likely that the engineered 
muscle grafts would perform differently if implanted in animals with an intact immune system. 
The immune response to muscle injury plays a vital role in muscle regeneration and is often 
ignored when researching treatments for VML. For this reason, future studies should utilize 
engineered muscle grafts composed of autologous or allogeneic cells to enable the use of 
immune-competent animals. In addition, future work should focus on scale-up to larger size 
defects and larger animal models to test the limits of engineered muscle construct survival and 
regenerative potential. Numerous studies have investigated muscle regeneration in small defect 
models that don’t require an external vascular source and rely on oxygen diffusion and vascular 
infiltration from the host. In large VML defects, implanted muscle constructs would not survive 
in the harsh ischemic injury environment by relying on oxygen diffusion and the slow timeline of 
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host blood vessel infiltration alone. Future studies should address this limitation by incorporating 
an external vascular source or other angiogenic component to encourage blood vessel infiltration, 
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